Charles River Laboratories International (CRL) 10-K 16 Feb 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 25, 2021	Jan. 21, 2022	Jun. 26, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 25, 2021
Current Fiscal Year End Date	--12-25
Document Transition Report	false
Entity File Number	001-15943
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	06-1397316
Entity Address, Address Line One	251 Ballardvale Street
Entity Address, City or Town	Wilmington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01887
City Area Code	781
Local Phone Number	222-6000
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	CRL
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 18,338,961,840
Entity Common Stock, Shares Outstanding		50,486,047
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement for its 2022 Annual Meeting of Shareholders scheduled to be held on May 10, 2022, which will be filed with the Securities and Exchange Commission (SEC) not later than 120 days after December 25, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K. With the exception of the portions of the 2022 Proxy Statement expressly incorporated into this Annual Report on Form 10-K by reference, such document shall not be deemed filed as part of this Form 10-K.
Entity Central Index Key	0001100682
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false

Audit Information

Audit Information	12 Months Ended
	Dec. 25, 2021
Audit Information [Abstract]
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Boston, Massachusetts

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Total revenue	$ 3,540,160	$ 2,923,933	$ 2,621,226
Costs and expenses:
Selling, general and administrative	619,919	528,935	517,622
Amortization of intangible assets	124,857	111,877	89,538
Operating income	589,862	432,729	351,151
Other income (expense):
Interest income	652	834	1,522
Interest expense	(73,910)	(86,433)	(60,882)
Other (expense) income, net	(35,894)	99,984	12,293
Income before income taxes	480,710	447,114	304,084
Provision for income taxes	81,873	81,808	50,023
Net income	398,837	365,306	254,061
Less: Net income attributable to noncontrolling interests	7,855	1,002	2,042
Net income attributable to common shareholders	$ 390,982	$ 364,304	$ 252,019
Earnings per common share
Basic (in dollars per share)	$ 7.77	$ 7.35	$ 5.17
Diluted (in dollars per share)	$ 7.60	$ 7.20	$ 5.07
Weighted-average number of common shares outstanding:
Basic (in shares)	50,293	49,550	48,730
Diluted (in shares)	51,425	50,611	49,693
Service
Total revenue	$ 2,755,579	$ 2,296,156	$ 2,029,371
Costs and expenses:
Cost of services provided and products sold	1,837,487	1,533,230	1,371,699
Product
Total revenue	784,581	627,777	591,855
Costs and expenses:
Cost of services provided and products sold	$ 368,035	$ 317,162	$ 291,216

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 398,837	$ 365,306	$ 254,061
Other comprehensive income (loss):
Foreign currency translation adjustment and other	(29,493)	22,345	14,224
Pension and other post-retirement benefit plans (Note 12):
Prior service cost and (losses) gains arising during the period	(1,193)	15,747	(25,165)
Amortization of net loss, settlement losses, and prior service benefit included in total cost for pension and other post-retirement benefit plans	1,678	17,861	1,772
Comprehensive income, before income taxes	369,829	421,259	244,892
Less: Income tax (benefit) expense related to items of other comprehensive income (Note 10)	(3,965)	15,372	(3,633)
Comprehensive income, net of income taxes	373,794	405,887	248,525
Less: Comprehensive income related to noncontrolling interests, net of income taxes	8,678	2,438	1,822
Comprehensive income attributable to common shareholders, net of income taxes	$ 365,116	$ 403,449	$ 246,703

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Current assets:
Cash and cash equivalents	$ 241,214	$ 228,424
Trade receivables and contract assets, net of allowances for credit losses of $7,180 and $6,702, respectively	642,881	617,740
Inventories	199,146	185,695
Prepaid assets	93,543	96,712
Other current assets	97,311	72,560
Total current assets	1,274,095	1,201,131
Property, plant and equipment, net	1,291,068	1,124,358
Operating lease right-of-use assets, net	292,941	178,220
Goodwill	2,711,881	1,809,168
Client relationships and other intangible assets, net	1,061,192	787,599
Deferred tax assets	40,226	37,729
Other assets	352,889	352,626
Total assets	7,024,292	5,490,831
Current liabilities:
Current portion of long-term debt and finance leases	2,795	50,214
Accounts payable	198,130	122,475
Accrued compensation	246,119	206,823
Deferred revenue	219,703	207,942
Accrued liabilities	228,797	149,820
Other current liabilities	137,641	102,477
Total current liabilities	1,033,185	839,751
Long-term debt, net and finance leases	2,663,564	1,929,571
Operating lease right-of-use liabilities	252,972	155,595
Deferred tax liabilities	239,720	217,031
Other long-term liabilities	242,859	205,215
Total liabilities	4,432,300	3,347,163
Commitments and contingencies
Redeemable noncontrolling interests	53,010	25,499
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 50,480 shares issued and outstanding as of December 25, 2021 and 49,767 shares issued and outstanding as of December 26, 2020	505	498
Additional paid-in capital	1,718,304	1,627,564
Retained earnings	980,751	625,414
Treasury stock, at cost, 0 shares as of December 25, 2021 and December 26, 2020	0	0
Accumulated other comprehensive loss	(164,740)	(138,874)
Total equity attributable to common shareholders	2,534,820	2,114,602
Noncontrolling interest	4,162	3,567
Total equity	2,538,982	2,118,169
Total liabilities, redeemable noncontrolling interests and equity	7,024,292	5,490,831
Client relationships, net
Current assets:
Client relationships and other intangible assets, net	981,398	721,505
Other intangible assets, net
Current assets:
Client relationships and other intangible assets, net	$ 79,794	$ 66,094

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Statement of Financial Position [Abstract]
Trade receivables, allowance for credit losses	$ 7,180	$ 6,702
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	50,480,000	49,767,000
Common Stock, shares outstanding (in shares)	50,480,000	49,767,000
Treasury stock, shares (in shares)	0	0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Cash flows relating to operating activities
Net income	$ 398,837	$ 365,306	$ 254,061
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	265,540	234,924	198,095
Stock-based compensation	71,474	56,341	57,271
Loss on debt extinguishment and other financing costs	29,964	3,661	4,943
Deferred income taxes	(24,006)	(133)	(21,895)
Loss (gain) on venture capital and strategic equity investments, net	30,420	(100,861)	(20,706)
Gain on sale of businesses	(25,026)	0	0
Contingent consideration	(34,303)	(468)	0
Other, net	4,957	14,080	2,988
Changes in assets and liabilities:
Trade receivables and contract assets, net	(26,633)	(85,627)	(8,323)
Inventories	(25,159)	(18,379)	(21,399)
Accounts payable	44,901	748	29,775
Accrued compensation	44,304	40,481	3,394
Deferred revenue	(13,402)	28,647	(3,620)
Customer contract deposits	16,925	8,955	(10,898)
Other assets and liabilities, net	2,006	(1,100)	17,250
Net cash provided by operating activities	760,799	546,575	480,936
Cash flows relating to investing activities
Acquisition of businesses and assets, net of cash acquired	(1,293,095)	(418,628)	(515,701)
Capital expenditures	(228,772)	(166,560)	(140,514)
Purchases of investments and contributions to venture capital investments	(45,555)	(26,692)	(22,341)
Proceeds from sale of businesses, net	122,694	0	0
Proceeds from sale of investments	6,532	11,401	942
Other, net	264	(1,065)	(3,888)
Net cash used in investing activities	(1,437,932)	(601,544)	(681,502)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility	6,951,113	2,230,988	3,358,461
Proceeds from exercises of stock options	45,652	46,586	34,546
Payments on long-term debt, revolving credit facility, and finance lease obligations	(6,242,877)	(2,200,400)	(3,124,588)
Payment of debt extinguishment and financing costs	(38,255)	0	(6,593)
Purchase of treasury stock	(40,707)	(23,979)	(18,087)
Other, net	(2,328)	(5,947)	(11,802)
Net cash provided by financing activities	672,598	47,248	231,937
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	17,730	794	11,357
Net change in cash, cash equivalents, and restricted cash	13,195	(6,927)	42,728
Cash, cash equivalents, and restricted cash, beginning of period	233,119	240,046	197,318
Cash, cash equivalents, and restricted cash, end of period	246,314	233,119	240,046
Supplemental cash flow information:
Cash and cash equivalents	241,214	228,424	238,014
Restricted cash included in Other current assets	4,023	3,074	431
Restricted cash included in Other assets	1,077	1,621	1,601
Cash, cash equivalents, and restricted cash, end of period	246,314	233,119	240,046
Cash paid for income taxes	75,441	60,059	54,060
Cash paid for interest	70,775	72,461	67,813
Non-cash investing and financing activities:
Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities	72,043	25,614	21,447
Assets acquired under finance leases	$ 1,567	$ 1,571	$ 4,819

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total Equity Attributable to Common Shareholders	Noncontrolling Interest
Beginning balance (in shares) at Dec. 29, 2018		48,210				1
Beginning balance at Dec. 29, 2018	$ 1,319,778	$ 482	$ 1,447,512	$ 42,096	$ (172,703)	$ (55)	$ 1,317,332	$ 2,446
Increase (Decrease) in Stockholders' Equity
Net income	254,103			252,019			252,019	2,084
Other comprehensive income (loss)	(5,316)				(5,316)		(5,316)
Dividends declared to noncontrolling interest	(1,286)							(1,286)
Adjustment of redeemable noncontrolling interest to redemption value	(1,451)		(1,451)				(1,451)
Purchase of additional equity interest in and modification of Vital River redeemable noncontrolling interest	(1,870)		(1,870)				(1,870)
Issuance of stock under employee compensation plans (in shares)		866
Issuance of stock under employee compensation plans	34,686	$ 8	34,678				34,686
Acquisition of treasury shares (in shares)						139
Acquisition of treasury shares	$ (18,087)					$ (18,087)	(18,087)
Retirement of treasury shares (in shares)	(100)	(140)				(140)
Retirement of treasury shares	$ 0	$ (1)	(4,355)	(13,786)		$ 18,142
Stock-based compensation	57,271		57,271				57,271
Ending balance (in shares) at Dec. 28, 2019		48,936				0
Ending balance at Dec. 28, 2019	1,637,828	$ 489	1,531,785	280,329	(178,019)	$ 0	1,634,584	3,244
Increase (Decrease) in Stockholders' Equity
Net income	366,156			364,304			364,304	1,852
Other comprehensive income (loss)	39,145				39,145		39,145
Dividends declared to noncontrolling interest	(1,529)							(1,529)
Purchase of additional equity interest in and modification of Vital River redeemable noncontrolling interest	(2,379)		(2,379)				(2,379)
Issuance of stock under employee compensation plans (in shares)		977
Issuance of stock under employee compensation plans	46,586	$ 10	46,576				46,586
Acquisition of treasury shares (in shares)						146
Acquisition of treasury shares	$ (23,979)					$ (23,979)	(23,979)
Retirement of treasury shares (in shares)	(100)	(146)				(146)
Retirement of treasury shares	$ 0	$ (1)	(4,759)	(19,219)		$ 23,979
Stock-based compensation	56,341		56,341				56,341
Ending balance (in shares) at Dec. 26, 2020		49,767				0
Ending balance at Dec. 26, 2020	2,118,169	$ 498	1,627,564	625,414	(138,874)	$ 0	2,114,602	3,567
Increase (Decrease) in Stockholders' Equity
Net income	393,462						390,982	2,480
Other comprehensive income (loss)	(25,866)				(25,866)		(25,866)
Dividends declared to noncontrolling interest	(1,885)							(1,885)
Adjustment of redeemable noncontrolling interest to redemption value	(21,312)		(21,312)				(21,312)
Issuance of stock under employee compensation plans (in shares)		861
Issuance of stock under employee compensation plans	45,647	$ 8	45,639				45,647
Acquisition of treasury shares (in shares)						148
Acquisition of treasury shares	$ (40,707)					$ (40,707)	(40,707)
Retirement of treasury shares (in shares)	(100)	(148)				(148)
Retirement of treasury shares	$ 0	$ (1)	(5,061)	(35,645)		$ 40,707
Stock-based compensation	71,474		71,474				71,474
Ending balance (in shares) at Dec. 25, 2021		50,480				0
Ending balance at Dec. 25, 2021	$ 2,538,982	$ 505	$ 1,718,304	$ 980,751	$ (164,740)	$ 0	$ 2,534,820	$ 4,162

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical)	Feb. 29, 2020
Redeemable Noncontrolling Interest
Remaining ownership interest	10.00%

DESCRIPTION OF BUSINESS AND SUM

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 25, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business Charles River Laboratories International, Inc. (the Company), together with its subsidiaries, is a full service, non-clinical contract research organization (CRO). The Company has built upon its core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that enable the Company to support its clients from target identification through non-clinical development. The Company also provides a suite of products and services to support its clients’ manufacturing activities. Principles of Consolidation The Company’s consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. Segment Reporting The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Research and GMP-Compliant Cells businesses. R esearch Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services); and Research and GMP-Compliant Cells, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. The Company’s DSA reportable segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (GLP and non-GLP) safety assessment services. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO); Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens. Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States (U.S. GAAP) requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. On March 11, 2020, the World Health Organization declared the outbreak of a strain of novel coronavirus disease, COVID-19, a global pandemic. The COVID-19 pandemic is dynamic, and its ultimate scope, duration and effects are uncertain. This pandemic has and continues to result in, and any future epidemic or pandemic crises may potentially result in, direct and indirect adverse effects on the Company’s industry and customers, which in turn has (with respect to COVID-19) and may (with respect to future epidemics or crises) impact the Company’s business, results of operations and financial condition. Further, the COVID-19 pandemic may also affect the Company’s operating and financial results in a manner that is not presently known to the Company or that the Company currently does not expect to present significant risks to its operations or financial results. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s consolidated financial statements. Cash, Cash Equivalents, and Investments Cash equivalents include money market funds, time deposits and other investments with remaining maturities at the purchase date of three months or less. Time deposits with original maturities of greater than three months are reported as short-term investments. Trade Receivables and Contract Assets, Net The Company records trade receivables and contract assets, net of an allowance for credit losses. An allowance for credit losses is established based on historical collection information, a review of major client accounts receivable balances, current economic conditions in the geographies in which it operates, and the Company’s expectations of future economic conditions that may affect the collectability of the recorded amounts. Amounts determined to be uncollectible are charged or written off against the allowance. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, investments, trade receivables and contract assets. The Company places cash and cash equivalents and investments in various financial institutions with high credit rating and limits the amount of credit exposure to any one financial institution. Trade receivables and contract assets are primarily from clients in the pharmaceutical and biotechnology industries, as well as academic and government institutions. Concentrations of credit risk with respect to trade receivables and contract assets, which are typically unsecured, are limited due to the wide variety of customers using the Company’s products and services as well as their dispersion across many geographic areas. No single client accounted for more than 5% of revenue in fiscal years 2021, 2020, or 2019 or trade receivables as of December 25, 2021 or December 26, 2020. Fair Value Measurements The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company has certain financial assets and liabilities recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy: • Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access, • Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates, • Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows: • Cash equivalents - Valued at market prices determined through third-party pricing services; • Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates; • Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments; • Debt instruments - The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book values of the Company’s Senior Notes, which are fixed rate debt, are carried at amortized cost. Fair values of the Senior Notes are based on quoted market prices and on borrowing rates available to the Company; and • Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes and certain option pricing models . Inventories The Company’s inventories consist of raw materials, work in process and finished product related primarily to small models, large models, cell supply, microbial solutions products, and avian related eggs and flocks. Inventories are stated at the lower of cost or net realizable value. Inventory value is generally based on the standard cost method for all businesses except for the Avian business, which is based on an average cost. Standard costs are trued-up to reflect actual cost. For small models inventory, costs include direct materials such as feed and bedding, costs of personnel directly involved in the care of the models, and an allocation of facility overhead. For the large models inventory, costs are primarily the external cost paid to acquire the model along with allocated overhead costs. For cell supply inventory, costs include direct materials, costs of personnel directly involved in the processing of products sold, and an allocation of facility overhead. For the microbial solutions inventory, costs include direct materials, cost of personnel directly involved in the manufacturing and assembly of products sold, and an allocation of facility overhead. For the avian related inventory, costs include direct materials, such as animal feed, cost of personnel directly involved with the care of the eggs and flocks, and an allocation of facility overhead. Inventory costs are charged to cost of revenue in the period the products are sold to an external party. The Company analyzes its inventory levels on a quarterly basis and writes down inventory that is determined to be damaged, obsolete or otherwise unmarketable, with a corresponding charge to cost of products sold. Property, Plant and Equipment, Net Property, plant and equipment, net, including improvements that significantly add to productive capacity or extend useful life, are carried at cost and are subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment is expensed as incurred. In addition, the Company capitalizes certain internal use computer software development costs. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. The Company generally depreciates the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets as follow: Estimated (in years) Land Indefinite Buildings and building improvements 10 - 40 Machinery and equipment 3 - 20 Furniture and fixtures 5 - 10 Computer hardware and software 3 - 8 Vehicles 3 - 5 Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. Finance lease assets are amortized over the lease term, however, if ownership is transferred by the end of the finance lease, or there is a bargain purchase option, such finance lease assets are amortized over the useful life that would be assigned if such assets were owned. When the Company disposes of property, plant and equipment, it removes the associated cost and accumulated depreciation from the related accounts on its consolidated balance sheet and includes any resulting gain or loss recorded in Other (expense) income, net in the accompanying consolidated statements of income. Business Combinations The Company accounts for business combinations under the acquisition method of accounting. The Company allocates the amounts that it pays for each acquisition to the assets it acquires and liabilities it assumes based on their fair values at the dates of acquisition, including identifiable intangible assets, which typically represents a significant portion of the purchase price. The determination of the fair value of intangible assets requires the use of significant judgment using management’s best estimates of inputs and assumptions that a market participant would use. Significant judgments include (i) the fair value; and (ii) whether such intangible assets are amortizable or non-amortizable and, if the former, the period and the method by which the intangible asset will be amortized. The Company utilizes commonly accepted valuation techniques, such as the income, cost, and market approaches as appropriate, in establishing the fair value of intangible assets. Typically, key assumptions include projections of cash flows that arise from identifiable intangible assets of acquired businesses as well as discount rates based on an analysis of the weighted average cost of capital, adjusted for specific risks associated with the assets. In recent acquisitions, customer relationship intangible assets (also referred to as client relationships) are the most significant identifiable asset acquired. To determine the fair value of the acquired client relationships, the Company typically utilizes the multiple period excess earnings model (a commonly accepted valuation technique), which relies on the following key assumptions: projections of cash flows from the acquired entities, which includes future revenue growth rates, operating income margins, and customer attrition rates; as well as discount rates based on an analysis of the acquired entities’ weighted average cost of capital. Contingent Consideration The consideration for the Company’s acquisitions may include future payments that are contingent upon the occurrence of a particular event. The Company records an obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The Company revalues these contingent consideration obligations each reporting period. Changes in the fair value of the contingent consideration obligations are recognized in the Company’s consolidated statements of income as a component of selling, general and administrative expenses. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and changes in the assumed probabilities of successful achievement of certain financial targets. Discount rates in the Company’s valuation models represent a measure of the credit risk associated with settling the liability. The period over which the Company discounts its contingent obligations is typically based on when the contingent payments would be triggered. These fair value measurements are based on significant inputs not observable in the market. Goodwill and Intangible Assets Goodwill represents the difference between the purchase price and the fair value of assets acquired and liabilities assumed when accounted for using the acquisition method of accounting. Goodwill is not amortized, but reviewed for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company's reporting units below their carrying amounts. The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the carrying value of goodwill is not recoverable, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative test, the Company compares the fair value of its reporting units to their carrying values. If the carrying values of the net assets assigned to the reporting units exceed the fair values of the reporting units an impairment loss equal to the difference would be recorded. Definite-lived intangible assets, including client relationships, are amortized over the pattern in which the economic benefits of the intangible assets are utilized and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset, which requires the use of customer attrition rates and other assumptions. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the definite-lived intangible assets, the definite-lived intangible assets are written-down to their fair values. Valuation and Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell. Venture Capital Investments The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from less than 1% to approximately 12%. The Company accounts for the investments in limited partnerships (LPs), which are variable interest entities, under the equity method of accounting. For publicly-held investments in the LPs, the Company adjusts for changes in fair market value based on reported share holdings at the end of each fiscal quarter. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LPs’ economic performance. Under the equity method of accounting, the Company’s portion of the investment gains and losses, as reported in the fund’s financial statements on a quarterly lag each reporting period, is recorded in other (expense) income, net in the accompanying consolidated statements of income. In addition, the Company adjusts the carrying value of these investments to reflect its estimate of changes to fair value since the fund’s financial statements are based on information from the fund’s management team, market prices of known public holdings of the fund, and other information. Strategic Equity Investments The Company invests, with minority positions, directly in equity of predominantly privately-held companies that are reported either at fair value or under the equity method of accounting, as appropriate. Equity investments accounted for at fair value that do not have readily determinable fair values are generally recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same investee. Gains and losses from strategic equity investments are recorded in Other (expense) income, net in the accompanying consolidated statements of income. Life Insurance Contracts Investments in life insurance contracts are recorded at cash surrender value. The initial investment is remeasured based on fair value of underlying investments or contractual value each reporting period. Gains and losses from life insurance contracts are recorded in Other (expense) income, net in the accompanying consolidated statements of income. Investments in and redemptions of these life insurance contracts are reported as cash flows from investing activities in the consolidated statement of cash flows. The Company held 45 contracts at December 25, 2021 with a face value of $89.8 million and 44 contracts with a face value of $79.1 million at December 26, 2020. Leases At inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the following: (1) the right to obtain substantially all of the economic benefits from use of the identified asset, and (2) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and lease liabilities are recognized at lease commencement date based on the present value of the minimum future lease payments. The Company leases laboratory, production, and office space (real estate), as well as land, vehicles and certain equipment under non-cancellable operating and finance leases. The carrying value of the Company’s right-of-use lease assets is substantially concentrated in its real estate leases, while the volume of lease agreements is primarily concentrated in vehicles and equipment leases. The Company’s policy is to not record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements. Most real estate leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 5 years. Certain lease agreements contain options to purchase the leased property and options to terminate the lease. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be exercised or the option to terminate the lease will not be exercised, or is not at the Company’s option. The Company determines whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors. A portfolio approach is applied to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases. The Company subleases a limited number of lease arrangements. Sublease activity is not material to the consolidated financial statements. Stock-Based Compensation The Company may grant stock options, restricted stock, restricted stock units (RSUs), and performance share units (PSUs) to employees and stock options, restricted stock, and RSUs to non-employee directors under stock-based compensation plans. Stock-based compensation is recognized as an expense in the consolidated statements of income based on the grant date fair value, adjusted for forfeitures when they occur, over the requisite service period. For stock options, restricted stock and RSUs that vest based on service conditions, the Company uses the straight-line method to allocate compensation expense to reporting periods. Where awards are made with non-substantive vesting periods and a portion of the award continues to vest after the employee’s eligible retirement, the Company recognizes expense based on the period from the grant date to the date on which the employee is retirement eligible. The Company records the expense for PSU grants subject to performance and/or market conditions using the accelerated attribution method over the remaining service period when management determines that achievement of the performance-based milestone is probable. The fair value of stock options granted is calculated using the Black-Scholes option-pricing model and the fair value of PSUs is estimated using a lattice model with a Monte Carlo simulation, both of which require the use of subjective assumptions including volatility and expected term, among others. The expected volatility assumption is typically determined using the historical volatility of the Company’s common stock over the expected life of the stock-based award. The expected term is determined using historical option exercise activity. The fair value of restricted stock and RSUs is based on the market value of the Company’s common stock on the date of grant. Revenue Recognition Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the amount to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Generally, the Company does not extend payment terms beyond one year. Applying the practical expedient, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. The Company’s contracts do not generally contain significant financing components. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the impact on the existing transaction price and measure of progress for the performance obligation to which it relates is generally recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis. Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Depending on which better depicts the transfer of value to the customer, the Compa

ACQUISITIONS AND DIVESTITURES

ACQUISITIONS AND DIVESTITURES	12 Months Ended
	Dec. 25, 2021
Business Combination and Asset Acquisition [Abstract]
ACQUISITIONS AND DIVESTITURES	ACQUISITIONS AND DIVESTITURES Fiscal 2021 Acquisitions Vigene Biosciences, Inc. On June 28, 2021, the Company acquired Vigene Biosciences, Inc. (Vigene), a gene therapy contract development and manufacturing organization (CDMO), providing viral vector-based gene delivery solutions. The acquisition enables clients to seamlessly conduct analytical testing, process development, and manufacturing for advanced modalities with the same scientific partner. The preliminary purchase price of Vigene was $323.9 million, net of $2.7 million in cash. Included in the purchase price are contingent payments fair valued at $34.5 million, which was estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $57.5 million based on future performance). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s Manufacturing reportable segment. The preliminary purchase price allocation was as follows: June 28, 2021 (in thousands) Trade receivables $ 3,548 Other current assets (excluding cash) 1,657 Property, plant and equipment 7,649 Operating lease right-of-use asset, net 22,507 Goodwill 239,681 Definite-lived intangible assets 93,900 Other long-term assets 694 Deferred revenue (4,260) Current liabilities (6,319) Operating lease right-of-use liabilities (21,220) Deferred tax liabilities (13,958) Total purchase price allocation $ 323,879 The preliminary purchase price allocation is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 87,500 12 Backlog 2,900 1 Other intangible assets 3,500 4 Total definite-lived intangible assets $ 93,900 11 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s Manufacturing business from new customers introduced through Vigene and the assembled workforce of the acquired business. The goodwill attributable to Vigene is not deductible for tax purposes. The Company incurred transaction and integration costs in connection with the acquisition of $5.3 million during fiscal year 2021 , which were included in Selling, general and administrative expenses within t he consolidated statements of income. Pro forma financial information as well as the disclosure of actual revenue and operating income (loss) is presented as if it had occurred as of the beginning of the period immediately preceding the period of acquisition, which is December 29, 2019, after giving effect to certain adjustments. See the bottom of this section for combined pro forma disclosure. Retrogenix Limited On March 30, 2021, the Company acquired Retrogenix Limited (Retrogenix), an early-stage contract research organization providing specialized bioanalytical services utilizing its proprietary cell microarray technology. The acquisition of Retrogenix enhances the Company’s scientific expertise with additional large molecule and cell therapy discovery capabilities. The purchase price of Retrogenix was $53.9 million, net of $8.5 million in cash. Included in the purchase price are contingent payments fair valued at $6.9 million, which is the maximum potential payout, and was based on a probability-weighted approach. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. The preliminary purchase price allocation was as follows: March 30, 2021 (in thousands) Trade receivables $ 2,266 Other current assets (excluding cash) 209 Property, plant and equipment 400 Goodwill 34,489 Definite-lived intangible assets 22,126 Other long-term assets 1,385 Current liabilities (1,575) Deferred tax liabilities (4,174) Other long-term liabilities (1,205) Total purchase price allocation $ 53,921 The preliminary purchase price allocation is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. From the date of the acquisition through December 25, 2021, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 17,340 13 Developed technology 3,685 3 Other intangible assets 1,101 2 Total definite-lived intangible assets $ 22,126 11 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s DSA business from new customers introduced through Retrogenix and the assembled workforce of the acquired business. The goodwill attributable to Retrogenix is not deductible for tax purposes. The Company incurred transaction and integration costs in connection with the acquisition of $1.8 million during fiscal year 2021 , which were included in Selling, general and administrative expenses within t he consolidated statements of income. Pro forma financial information as well as the disclosure of actual revenue and operating income (loss) have not been included because Retrogenix’ s financial results are not significant when compared to the Company’s consolidated financial results. Cognate BioServices, Inc. On March 29, 2021, the Company acquired Cognate BioServices, Inc. (Cognate), a cell and gene therapy CDMO offering comprehensive manufacturing solutions for cell therapies, as well as for the production of plasmid DNA and other inputs in the CDMO value chain. The acquisition of Cognate establishes the Company as a scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from basic research and discovery through cGMP production. The preliminary purchase price of Cognate was $879.0 million, net of $70.5 million in cash, subject to certain post-closing adjustments and includes $15.7 million of consideration for an approximate 2% ownership interest not acquired, which will be redeemed in 2022 with the ultimate payout tied to performance in 2021. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility and recently issued Senior Notes. This business is reported as part of the Company’s Manufacturing reportable segment. The preliminary purchase price allocation was as follows: March 29, 2021 (in thousands) Trade receivables $ 18,566 Inventories 4,231 Other current assets (excluding cash) 9,816 Property, plant and equipment 52,082 Operating lease right-of-use assets, net 34,349 Goodwill 612,147 Definite-lived intangible assets 270,900 Other long-term assets 6,098 Deferred revenue (20,539) Current liabilities (44,974) Operating lease right-of-use liabilities (31,383) Deferred tax liabilities (31,847) Other long-term liabilities (414) Total purchase price allocation $ 879,032 The preliminary purchase price allocation is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts and obligations. From the date of the acquisition through December 25, 2021, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 257,200 13 Other intangible assets 4,800 2 Backlog 8,900 1 Total definite-lived intangible assets $ 270,900 13 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s Manufacturing business from new customers introduced through Cognate and the assembled workforce of the acquired business. The goodwill attributable to Cognate is not deductible for tax purposes. The Company incurred transaction and integration costs in connection with the acquisition of $27.1 million during fiscal year 2021 , which were included in Selling, general and administrative expenses within t he consolidated statements of income. Pro forma financial information as well as the disclosure of actual revenue and operating income (loss) is presented as if it had occurred as of the beginning of the period immediately preceding the period of acquisition, which is December 29, 2019, after giving effect to certain adjustments. See the bottom of this section for combined pro forma disclosure. Distributed Bio, Inc. On December 31, 2020, the Company acquired Distributed Bio, Inc. (Distributed Bio), a next-generation antibody discovery company with technologies specializing in enhancing the probability of success for delivering high-quality, readily formattable antibody fragments to support antibody and cell and gene therapy candidates to biopharmaceutical clients. The acquisition of Distributed Bio expands the Company’s capabilities with an innovative, large-molecule discovery platform, and creates an integrated, end-to-end platform for therapeutic antibody and cell and gene therapy discovery and development. The purchase price of Distributed Bio was $97.0 million, net of $0.8 million in cash. The total consideration includes $80.8 million cash paid, settlement of $3.0 million in convertible promissory notes previously issued by the Company during prior fiscal years, and $14.0 million of contingent consideration, which is estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $21.0 million based on future performance and milestone achievements over a one-year period). The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. The purchase price allocation was as follows: December 31, 2020 (in thousands) Trade receivables $ 2,722 Other current assets (excluding cash) 221 Property, plant and equipment 2,382 Goodwill 71,585 Definite-lived intangible assets 24,540 Other long-term assets 2,055 Current liabilities (2,823) Deferred tax liabilities (2,529) Other long-term liabilities (1,123) Total purchase price allocation $ 97,030 From the date of the acquisition through March 27, 2021, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation. The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 16,080 9 Developed technology 3,940 5 Other intangible assets 4,520 4 Total definite-lived intangible assets $ 24,540 7 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s DSA business from new customers introduced through Distributed Bio and the assembled workforce of the acquired business. The goodwill attributable to Distributed Bio is not deductible for tax purposes. The Company incurred transaction and integration costs in connection with the acquisition of $1.2 million during both fiscal years 2021 and 2020, which were included in Selling, general and administrative expenses within t he consolidated statements of income. Pro forma financial information as well as the disclosure of actual revenue and operating income (loss) have not been included because Distributed Bio 's financial results are not significant when compared to the Company’s consolidated financial results. Other Acquisition On March 3, 2021, the Company acquired certain assets from a distributor that supports the Company’s DSA reportable segment. The purchase price was $35.4 million, which includes $19.5 million in cash paid ($5.5 million of which was paid in fiscal 2020), and $15.9 million of contingent consideration, which is estimated using a Monte Carlo Simulation model (the maximum contingent contractual payments are up to $17.5 million based on future performance over a three-year period). The fair value of the net assets acquired included $17.3 million of goodwill, $15.2 million attributed to supplier relationships (to be amortized over a 4-year period), and $3.0 million of property, plant, and equipment. The business is reported as part of the Company’s DSA reportable segment. Pro forma information and transaction and integration costs have not been presented because such information is not material to the consolidated financial statements. Pro forma information The following selected unaudited pro forma consolidated results of operations are presented as if the Cognate and Vigene acquisitions had occurred as of the beginning of the period immediately preceding the period of acquisition, which is December 29, 2019, after giving effect to certain adjustments. For fiscal year 2021, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $24.5 million, additional interest expense on borrowing of $5.6 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments. For fiscal year 2020, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $24.2 million, additional interest expense on borrowing of $10.4 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments. Fiscal Year 2021 2020 (in thousands) (unaudited) Revenue $ 3,583,646 $ 3,068,161 Net income attributable to common shareholders 376,152 347,873 These unaudited pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the dates indicated or that may result in the future. No effect has been given for synergies, if any, that may be realized through the acquisitions. Cognate and Vigene have been included in the operating results of the Company since March 29, 2021 and June 28, 2021, respectively. Revenue and operating income for both acquisitions during fiscal year 2021 was $109.9 million and $2.5 million, respectively. Fiscal 2020 Acquisitions Cellero, LLC On August 6, 2020, the Company acquired Cellero, LLC (Cellero), a provider of cellular products for cell therapy developers and manufacturers worldwide. The addition of Cellero enhances the Company’s unique, comprehensive solutions for the high-growth cell therapy market, strengthening the ability to help accelerate clients’ critical programs from basic research and proof-of-concept to regulatory approval and commercialization. It also expands the Company’s access to high-quality, human-derived biomaterials with Cellero’s donor sites in the United States. The purchase price of Cellero was $36.9 million, net of $0.5 million in cash, which was funded through available cash. This business is reported as part of the Company’s RMS reportable segment. The purchase price allocation was as follows: August 6, 2020 (in thousands) Trade receivables $ 1,500 Inventories 551 Other current assets (excluding cash) 182 Property, plant and equipment 1,648 Goodwill 19,457 Definite-lived intangible assets 16,230 Other long-term assets 849 Current liabilities (1,360) Deferred tax liabilities (1,467) Other long-term liabilities (740) Total purchase price allocation $ 36,850 From the date of the acquisition through June 26, 2021, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation. The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 14,740 13 Other intangible assets 1,490 3 Total definite-lived intangible assets $ 16,230 12 The goodwill resulting from the transaction, $10.8 million of which is deductible for tax purposes due to a prior asset acquisition, is primarily attributable to the potential growth of the Company’s RMS business from new customers introduced to Cellero and the assembled workforce of the acquired business. The Company incurred transaction and integration costs in connection with the acquisition of $0.7 million and $2.7 million during fiscal years 2021 and 2020, respectively, which were included in Selling, general and administrative expenses within the consolidated statements of income. Pro forma financial information as well as the disclosure of actual revenue and operating income (loss) have not been included because Cellero's financial results are not significant when compared to the Company’s consolidated financial results. HemaCare Corporation On January 3, 2020, the Company acquired HemaCare Corporation (HemaCare), a business specializing in the production of human-derived cellular products for the cell therapy market. The acquisition of HemaCare expands the Company’s comprehensive portfolio of early-stage research and manufacturing support solutions to encompass the production and customization of high-quality, human derived cellular products to better support clients’ cell therapy programs. The purchase price of HemaCare was $376.7 million , net of $3.1 million in cash. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s RMS reportable segment. The purchase price allocation was as follows: January 3, 2020 (in thousands) Trade receivables $ 6,451 Inventories 8,468 Other current assets (excluding cash) 3,494 Property, plant and equipment 10,033 Goodwill 210,196 Definite-lived intangible assets 183,540 Other long-term assets 5,920 Current liabilities (5,188) Deferred tax liabilities (38,529) Other long-term liabilities (7,664) Total purchase price allocation $ 376,721 From the date of the acquisition through December 26, 2020, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation. The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 170,390 19 Trade name 7,330 10 Other intangible assets 5,820 3 Total definite-lived intangible assets $ 183,540 18 The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s RMS business from new customers introduced to HemaCare and the assembled workforce of the acquired business. The goodwill attributable to HemaCare is not deductible for tax purposes. The Company incurred transaction and integration costs in connection with the acquisition of $0.7 million , $6.1 million and $3.3 million during fiscal years 2021, 2020 and 2019, respectively , which were included in Selling, general and administrative expenses within the consolidated statements of income. Beginning on January 3, 2020, HemaCare has been included in the operating results of the Company. HemaCare revenue and operating loss during fiscal year 2020 was $43.0 million and $8.1 million, respectively. Fiscal 2019 Acquisitions Citoxlab On April 29, 2019, the Company acquired Citoxlab, a non-clinical CRO, specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. With operations in Europe and North America, the acquisition of Citoxlab further strengthens the Company’s position as a leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which enhances the Company’s ability to partner with clients across the drug discovery and development continuum. The purchase price of Citoxlab was $490.4 million, net of $36.7 million in cash, which was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. The purchase price allocation was as follows: April 29, 2019 (in thousands) Trade receivables $ 35,405 Inventories 5,282 Other current assets (excluding cash) 13,917 Property, plant and equipment 88,605 Goodwill 280,161 Definite-lived intangible assets 162,400 Other long-term assets 20,063 Deferred revenue (15,278) Current liabilities (46,081) Deferred tax liabilities (27,458) Other long-term liabilities (22,624) Redeemable noncontrolling interest (4,035) Total purchase price allocation $ 490,357 From the date of the acquisition through March 28, 2020, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation. The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 134,600 13 Developed technology 19,900 3 Backlog 7,900 1 Total definite-lived intangible assets $ 162,400 12 The goodwill resulting from the transaction, $7.2 million of which is deductible for tax purposes due to a prior asset acquisition, is primarily attributable to the potential growth of the Company’s DSA business from new customers introduced to Citoxlab and the assembled workforce of the acquired business. The Company incurred transaction and integration costs in connection with the acquisition of $2.3 million, $4.1 million and $20.7 million during fiscal years 2021, 2020 and 2019, respectively, which were included in Selling, general and administrative expenses within the consolidated statements of income. Other Acquisition On August 28, 2019, the Company acquired an 80% ownership interest in a supplier that supports the Company’s DSA reportable segment. The purchase price paid was approximately $23 million, net of a $4 million pre-existing relationship. The fair value of the net assets acquired included $13 million of goodwill, $12 million of other long-term assets, and $9 million for a 20% redeemable noncontrolling interest. The business is reported as part of the Company’s DSA reportable segment. Pro forma information and acquisition expenses have not been presented because such information is not material to the financial statements. Divestitures RMS Japan Divestiture On October 12, 2021, the Company sold its RMS Japan operations to The Jackson Laboratory for a preliminary purchase price of $73.5 million, which included $8.2 million in cash, $3.6 million pension over funding, and certain post-closing adjustments. The RMS Japan business was reported in the Company’s RMS reportable segment. The Company determined that the RMS Japan business was not optimized within the Company’s portfolio at its current scale, and that the capital could be better deployed in other long-term growth opportunities. During the three months ended December 25, 2021, the Company recorded a gain on the divestiture of the RMS Japan business of $22.7 million, net of costs to sell, a currency translation adjustment, and other adjustments related to certain ongoing arrangements with the buyer, which was included in Other (expense) income, net within the Company’s consolidated statements of income. The carrying amounts of the major classes of assets and liabilities associated with the divestiture of the business were as follows: October 12, 2021 (in thousands) Assets Current assets $ 26,524 Property, plant, and equipment, net 17,379 Goodwill 4,129 Other assets 3,695 Total assets $ 51,727 Liabilities Current liabilities $ 8,705 Long-term liabilities 94 Total liabilities $ 8,799 CDMO Sweden Divestiture On October 12, 2021, the Company sold its gene therapy CDMO site in Sweden to a private investor group for a preliminary purchase price of $59.6 million, net of $0.2 million in cash and other post-closing adjustments that may impact the purchase price. Included in the purchase price are contingent payments fair valued at $15.3 million, which were estimated using a probability weighted model (the maximum contingent contractual payments are up to $25.0 million based on future performance), as well as a purchase obligation of approximately $10 million between the parties. The Sweden CDMO business was acquired in March 2021 as part of the acquisition of Cognate and was reported in the Company’s Manufacturing reportable segment. The Company routinely evaluates the strategic fit and fundamental performance of our acquisitions integrated within our global infrastructure. As part of this assessment, the Company determined that this capital could be better deployed in other long-term growth opportunities. Due to the purchase price approximating the carrying value of the disposal group, no gain or loss was recorded during the three months ended December 25, 2021. The carrying amounts of the major classes of assets and liabilities associated with the divestiture of the business were as follows: October 12, 2021 (in thousands) Assets Current assets $ 8,187 Property, plant and equipment, net 14,339 Operating lease right-of-use assets, net 19,733 Goodwill 27,764 Intangible assets, net 14,089 Total assets $ 84,112 Liabilities Current liabilities $ 6,386 Operating lease right-of-use liabilities 18,221 Total liabilities $ 24,607

REVENUE FROM CONTRACTS WITH CUS

REVENUE FROM CONTRACTS WITH CUSTOMERS	12 Months Ended
	Dec. 25, 2021
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	REVENUE FROM CONTRACTS WITH CUSTOMERS Disaggregation of Revenue The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Timing of Revenue Recognition: 2021 2020 2019 (in thousands) RMS Services and products transferred over time $ 263,659 $ 240,480 $ 227,872 Services and products transferred at a point in time 426,778 330,672 309,217 Total RMS revenue 690,437 571,152 537,089 DSA Services and products transferred over time 2,103,415 1,836,519 1,618,281 Services and products transferred at a point in time 3,816 909 714 Total DSA revenue 2,107,231 1,837,428 1,618,995 Manufacturing Services and products transferred over time 335,745 174,254 142,896 Services and products transferred at a point in time 406,747 341,099 322,246 Total Manufacturing revenue 742,492 515,353 465,142 Total revenue $ 3,540,160 $ 2,923,933 $ 2,621,226 RMS The RMS business generates revenue through the commercial production and sale of research models, research and GMP-compliant cells (cell supply), and the provision of services related to the maintenance and monitoring of research models and management of clients’ research operations. Revenue from the sale of research models and cell supply is recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the shipping terms of a contract. Revenue generated from research models services is recognized over time and is typically based on a right-to-invoice measure of progress (output method) as invoiced amounts correspond directly to the value of the Company’s performance to date. DSA The DSA business provides a full suite of integrated drug discovery services directed at the identification, screening and selection of a lead compound for drug development and offers a full range of safety assessment services including bioanalysis, drug metabolism, pharmacokinetics, toxicology and pathology. DSA services revenue is generally recognized over time using the cost-to-cost or right to invoice measures of progress, primarily representing fixed fee service contracts and per unit service contracts, respectively. Manufacturing The Manufacturing business includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO); and Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens. Species identification service revenue is generally recognized at a point in time as identifications are completed by the Company. Biologics service revenue is generally recognized over time using the cost-to-cost measure of progress. Microbial Solutions and Avian product sales are generally recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Transaction Price Allocated to Future Performance Obligations The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of December 25, 2021. Excluded from the disclosure is the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less (ii) contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed and (iii) service revenue recognized in accordance with ASC 842, “Leases” (see additional disclosure for Other Performance Obligations). The Company has assessed future performance obligations with respect to the COVID-19 pandemic uncertainties and believes there is an insignificant impact on the ability to meet future performance obligations and the amount of revenue to be recognized. The following table include s estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of December 25, 2021: Revenue Expected to be Recognized in Future Periods Less than 1 Year 1 to 3 Years 4 to 5 Years Beyond 5 Years Total (in thousands) DSA $ 355,127 $ 338,685 $ 18,250 $ 1,683 $ 713,745 Manufacturing 2,728 — — — $ 2,728 Total $ 357,855 $ 338,685 $ 18,250 $ 1,683 $ 716,473 Contract Balances from Contracts with Customers The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), and contract liabilities (current and long-term deferred revenue and customer contract deposits) on the consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers: December 25, 2021 December 26, 2020 (in thousands) Balances from contracts with customers: Client receivables $ 489,452 $ 489,042 Contract assets (unbilled revenue) 160,609 135,400 Contract liabilities (current and long-term deferred revenue) 240,281 227,417 Contract liabilities (customer contract deposits) 59,512 42,244 When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. The Company excluded approximately $36 million and $16 million of unpaid advanced client billings from both client receivables and deferred revenue in the accompanying consolidated balance sheets as of December 25, 2021 and December 26, 2020, respectively. Advanced client payments of approximately $60 million and $42 million have been presented as customer contract deposits within other current liabilities in the accompanying consolidated balance sheets as of December 25, 2021 and December 26, 2020, respectively. Other changes in the co ntract asset and the con tract liability balances during fiscal years 2021 and 2020 were as follows: (i) Changes due to acquisitions and divestitures: See Note 2. “Acquisitions and Divestitures” for the Company’s recent acquisitions. (ii) Cumulative catch-up adjustments to revenue that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration is constrained), or a contract modification: During fiscal years 2021 and 2020, immaterial cumulative catch-up adjustments to revenue were recorded. (iii) A change in the time frame for a right to consideration to become unconditional (that is, for a contract asset to be recorded as a client receivable): Approximatel y 90% of unb illed revenue as of December 26, 2020, which was $135 million, was billed during fiscal year 2021. Approximately 90% of unbilled revenue as of December 28, 2019, which was $122 million, was billed during fiscal year 2020. (iv) A change in the time frame for a performance obligation to be satisfied (that is, for the recognition of revenue arising from a contract liability): Approximatel y 90% of contract liabilities as of December 26, 2020, which was $227 million, were recognized as revenue during fiscal year 2021. Approximately 90% of contract liabilities as of December 28, 2019, which was $193 million, were recognized as revenue during fiscal year 2020. Other Performance Obligations As part of the Company’s service offerings, primarily in the Manufacturing segment, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year. D uring fiscal year 2021 , the Company recognized lease revenue of $18.1 million , which is recorded within service revenue, which is transferred over time, within the consolidated statements of income. Due to the nature of these arrangements and timing of the contractual lease term, the remaining revenue to be recognized related to these lease performance obligations is not material to the consolidated financial statements.

SEGMENT AND GEOGRAPHIC INFORMAT

SEGMENT AND GEOGRAPHIC INFORMATION	12 Months Ended
	Dec. 25, 2021
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	SEGMENT AND GEOGRAPHIC INFORMATIONThe Company’s three reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). Asset information on a reportable segment basis is not disclosed as this information is not separately identified and internally reported to the Company’s Chief Operating Decision Maker. The following table presents revenue and other financial information by reportable segment: 2021 2020 2019 (in thousands) RMS Revenue $ 690,437 $ 571,152 $ 537,089 Operating income 166,814 102,706 133,912 Depreciation and amortization 39,123 37,080 19,197 Capital expenditures 61,188 29,487 26,989 DSA Revenue $ 2,107,231 $ 1,837,428 $ 1,618,995 Operating income 406,978 325,959 258,903 Depreciation and amortization 177,254 168,922 151,139 Capital expenditures 101,477 105,653 86,843 Manufacturing Revenue $ 742,492 $ 515,353 $ 465,142 Operating income 246,390 181,494 145,420 Depreciation and amortization 46,195 25,904 23,584 Capital expenditures 58,877 26,287 23,617 The following tables present reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts: Operating Income Depreciation and Amortization 2021 2020 2019 2021 2020 2019 (in thousands) Total reportable segments $ 820,182 $ 610,159 $ 538,235 $ 262,572 $ 231,906 $ 193,920 Unallocated corporate (230,320) (177,430) (187,084) 2,968 3,018 4,175 Total consolidated $ 589,862 $ 432,729 $ 351,151 $ 265,540 $ 234,924 $ 198,095 Capital Expenditures 2021 2020 2019 (in thousands) Total reportable segments $ 221,542 $ 161,427 $ 137,449 Unallocated corporate 7,230 5,133 3,065 Total consolidated $ 228,772 $ 166,560 $ 140,514 Revenue for each significant product or service offering is as follows: 2021 2020 2019 (in thousands) RMS $ 690,437 $ 571,152 $ 537,089 DSA 2,107,231 1,837,428 1,618,995 Manufacturing 742,492 515,353 465,142 Total revenue $ 3,540,160 $ 2,923,933 $ 2,621,226 A summary of unallocated corporat e expense co nsists of the following: 2021 2020 2019 (in thousands) Stock-based compensation $ 43,018 $ 34,111 $ 37,855 Compensation, benefits, and other employee-related expenses 92,459 73,814 73,893 External consulting and other service expenses 25,374 26,561 16,639 Information technology 18,450 18,912 16,080 Depreciation 2,968 3,018 4,175 Acquisition and integration 30,370 13,995 26,877 Other general unallocated corporate 17,681 7,019 11,565 Total unallocated corporate expense $ 230,320 $ 177,430 $ 187,084 Other general unallocated corporate expense consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations. Revenue and long-lived assets by geographic area are as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) 2021 Revenue $ 1,934,404 $ 1,036,465 $ 339,098 $ 222,902 $ 7,291 $ 3,540,160 Long-lived assets 755,400 323,405 145,274 64,864 2,125 1,291,068 2020 Revenue $ 1,627,149 $ 829,312 $ 306,259 $ 155,086 $ 6,127 $ 2,923,933 Long-lived assets 627,871 286,229 145,410 62,931 1,917 1,124,358 2019 Revenue $ 1,471,097 $ 726,421 $ 271,987 $ 146,218 $ 5,503 $ 2,621,226 Long-lived assets 602,654 253,665 127,495 60,213 101 1,044,128 Included in the Other category above are operations located in Brazil and Israel. Revenue represents sales originating in entities physically located in the identified geographic area. Long-lived assets consist of property, plant, and equipment, net.

SUPPLEMENTAL BALANCE SHEET INFO

SUPPLEMENTAL BALANCE SHEET INFORMATOIN	12 Months Ended
	Dec. 25, 2021
Supplemental Balance Sheet Information [Abstract]
SUPPLEMENTAL BALANCE SHEET INFORMATION	SUPPLEMENTAL BALANCE SHEET INFORMATION The composition of trade receivables and contract assets, net is as follows: December 25, 2021 December 26, 2020 (in thousands) Client receivables $ 489,452 $ 489,042 Unbilled revenue 160,609 135,400 Total 650,061 624,442 Less: Allowance for credit losses (7,180) (6,702) Trade receivables and contract assets, net $ 642,881 $ 617,740 Net provisions o f $1.7 million , $6.4 million , and $3.0 million were recorded to the allowance for credit losses in fiscal years 2021, 2020, and 2019, respectively. The composition of inventories is as follows: December 25, 2021 December 26, 2020 (in thousands) Raw materials and supplies $ 33,118 $ 28,317 Work in process 40,268 36,755 Finished products 125,760 120,623 Inventories $ 199,146 $ 185,695 The composition of other current assets is as follows: December 25, 2021 December 26, 2020 (in thousands) Prepaid income tax $ 84,725 $ 68,462 Short-term investments 1,063 1,024 Restricted cash 4,023 3,074 Other receivables 7,500 — Other current assets $ 97,311 $ 72,560 The composition of property, plant and equipment, net is as follows: December 25, 2021 December 26, 2020 (in thousands) Land $ 59,486 $ 61,031 Buildings (1) 987,544 1,059,641 Machinery and equipment (1) 760,353 661,124 Leasehold improvements 141,525 104,967 Furniture and fixtures 22,520 31,489 Computer hardware and software (1) 210,582 193,622 Vehicles (1) 6,897 6,152 Construction in progress 205,141 92,325 Total 2,394,048 2,210,351 Less: Accumulated depreciation (1,102,980) (1,085,993) Property, plant and equipment, net $ 1,291,068 $ 1,124,358 (1) These balances include assets under finance leases. See Note 16, “Leases.” Depreciation expense in fiscal years 2021, 2020 and 2019 was $140.7 million, $123.0 million and $108.6 million, respectively. The composition of other assets is as follows: December 25, 2021 December 26, 2020 (in thousands) Venture capital investments $ 149,640 $ 197,100 Strategic equity investments 51,712 24,704 Life insurance policies 51,048 43,827 Other long-term income tax assets 18,690 23,485 Restricted cash 1,077 1,621 Long-term pension assets 39,582 31,915 Other 41,140 29,974 Other assets $ 352,889 $ 352,626 The composition of other current liabilities is as follows: December 25, 2021 December 26, 2020 (in thousands) Current portion of operating lease right-of-use liabilities $ 33,267 $ 24,674 Accrued income taxes 26,161 24,884 Customer contract deposits 59,512 42,244 Other 18,701 10,675 Other current liabilities $ 137,641 $ 102,477 The composition of other long-term liabilities is as follows: December 25, 2021 December 26, 2020 (in thousands) U.S. Transition Tax $ 43,057 $ 48,781 Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plans 104,944 96,492 Long-term deferred revenue 20,578 19,475 Other 74,280 40,467 Other long-term liabilities $ 242,859 $ 205,215

VENTURE CAPITAL INVESTMENTS AND

VENTURE CAPITAL INVESTMENTS AND STRATEGIC EQUITY INVESTMENTS	12 Months Ended
	Dec. 25, 2021
Marketable Securities and Equity-Method Affiliates [Abstract]
VENTURE CAPITAL INVESTMENTS AND STRATEGIC EQUITY INVESTMENTS	VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS Venture capital investments were $149.6 million and $197.1 million as of December 25, 2021 and December 26, 2020, respectively. The Company’s total commitment to the venture capital funds as of December 25, 2021 was $165.3 million, of which the Company funded $113.3 million through that date. During fiscal years 2021, 2020, and 2019, the Company received distributions totaling $40.2 million, $27.6 million, and $11.4 million, respectively. During fiscal years 2021, 2020, and 2019, the Company recognized gains and losses related to the venture capital investments of $24.2 million loss, $100.4 million gain and $20.7 million gain, respectively. Losses in fiscal year 2021 predominantly resulted from decreases in fair value from publicly-held investment s. Gains in fiscal year 2020 predominantly resulted from increases in fair value from publicly-held investments, which included initial public offerings of certain portfolio companies . As of December 25, 2021 and December 26, 2020, the Company’s consolidated retained earnings included $27.1 million and $76.8 million, respectively, of the undistributed earnings related to these investments, net of tax. The Company also invests, with minority positions, directly in equity of predominantly privately-held companies. Strategic equity investments were $51.7 million and $24.7 million as of December 25, 2021 and December 26, 2020, respectively. Subsequent to December 25, 2021, the Company committed an additional $25 million to an existing strategic equity investment. During fiscal years 2021, 2020, and 2019, the Company recognized net gains and losses related to the Strategic equity investments of $6.2 million loss, $0.5 million gain, and $0.1 million gain, respectively.

FAIR VALUE

FAIR VALUE	12 Months Ended
	Dec. 25, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE Assets and liabilities measured at fair value on a recurring basis are summarized below: December 25, 2021 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 893 $ — $ 893 Other assets: Life insurance policies — 42,918 — 42,918 Total assets measured at fair value $ — $ 43,811 $ — $ 43,811 Other liabilities measured at fair value: Contingent consideration — — 11,794 11,794 Other long-term liabilities measured at fair value: Contingent consideration — — 25,450 25,450 Total liabilities measured at fair value $ — $ — $ 37,244 $ 37,244 December 26, 2020 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 2,273 $ — $ 2,273 Other assets: Life insurance policies — 35,770 — 35,770 Total assets measured at fair value $ — $ 38,043 $ — $ 38,043 Other current liabilities measured at fair value: Contingent consideration — — 2,328 2,328 Total liabilities measured at fair value $ — $ — $ 2,328 $ 2,328 During fiscal years 2021 and 2020, there were no transfers between fair value levels. Contingent Consideration The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions. Fiscal Year 2021 2020 (in thousands) Beginning balance $ 2,328 $ 712 Additions 71,559 2,131 Payments (2,889) (230) Total gains or losses (realized/unrealized): Foreign currency translation (368) 183 Adjustment of previously recorded contingent liability (33,386) (468) Ending balance $ 37,244 $ 2,328 During fiscal year 2021, the majority of the contingent consideration liabilities recognized were in connection with the Company’s recent acquisitions of Distributed Bio, Retrogenix, Vigene, and assets of a distributor. The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The unobservable inputs used in the fair value measurements include the probabilities of successful achievement of certain financial targets, forecasted results or targets, volatility, and discount rates. The total maximum payments due is approximately $110 million, of which the fair value as of December 25, 2021 is approximately $37.2 million. The weighted average probability of achieving the maximum target is approximately 34%. The average volatility and weighted average cost of capital are approximately 36% and 14%, respectively. Increases or decreases in these assumptions may result in a higher or lower fair value measurement, respectively. In the later part of fiscal year 2021, certain financial targets stipulated in the contingent consideration agreements were not achieved, which resulted in a decrease of the contingent consideration, primarily related to the Vigene and Distributed Bio acquisitions. Debt Instruments The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy. The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s Senior Notes is summarized below: December 25, 2021 December 26, 2020 Book Value Fair Value Book Value Fair Value 5.5% Senior Notes due 2026 $ — $ — $ 500,000 $ 523,100 4.25% Senior Notes due 2028 500,000 521,250 500,000 523,750 3.75% Senior Notes due 2029 500,000 506,700 — — 4.0% Senior Notes due 2031 500,000 507,500 — —

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Dec. 25, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill The following table provides a rollforward of the Company’s goodwill: Adjustments to Goodwill Adjustments to Goodwill December 28, 2019 Acquisitions Foreign Exchange December 26, 2020 Acquisitions Divestitures Foreign Exchange December 25, 2021 (in thousands) RMS $ 56,586 $ 229,654 $ 1,519 $ 287,759 $ — $ (4,129) $ (106) $ 283,524 DSA 2,350,223 (629) 33,536 2,383,130 123,091 — (28,715) 2,477,506 Manufacturing 138,756 — 4,523 143,279 851,828 (27,764) (11,492) 955,851 Gross carrying amount 2,545,565 229,025 39,578 2,814,168 974,919 (31,893) (40,313) 3,716,881 Accumulated impairment loss - DSA (1,005,000) — — (1,005,000) — — — (1,005,000) Goodwill $ 1,540,565 $ 1,809,168 $ 2,711,881 Based on the Company’s quantitative goodwill impairment test, which was performed in the fourth quarter for each of the fiscal years 2021, 2020 and 2019, the fair value of each reporting unit exceeded the reporting unit’s book value and, therefore, goodwill was not impaired. The increase in goodwill during fiscal year 2021 related primarily to the acquisitions of Cognate and Vigene in the Manufacturing reportable segment and Distributed Bio and Retrogenix in the DSA reportable segment. The decreases in the RMS and Manufacturing reportable segments was a result of the sales of RMS Japan and CDMO Sweden, respectively. The increase in goodwill during fiscal year 2020 related primarily to the acquisitions of HemaCare and Cellero in the RMS reportable segment. Intangible Assets, Net The following table displays intangible assets, net by major class: December 25, 2021 December 26, 2020 Gross Accumulated Net Gross Accumulated Net (in thousands) Backlog $ 12,577 $ (9,517) $ 3,060 $ 29,233 $ (29,233) $ — Technology 135,764 (95,454) 40,310 130,907 (81,305) 49,602 Trademarks and trade names 13,086 (3,448) 9,638 15,870 (5,648) 10,222 Other 35,231 (8,445) 26,786 20,903 (14,633) 6,270 Other intangible assets 196,658 (116,864) 79,794 196,913 (130,819) 66,094 Client relationships 1,475,757 (494,359) 981,398 1,137,331 (415,826) 721,505 Intangible assets $ 1,672,415 $ (611,223) $ 1,061,192 $ 1,334,244 $ (546,645) $ 787,599 The increase in intangible assets, net during fiscal year 2021 related primarily to the acquisitions of Cognate, Distributed Bio, Retrogenix, and Vigene . Amortization expense of definite-lived intangible assets, including client relationships, for fiscal years 2021, 2020 and 2019 was $124.9 million, $111.9 million and $89.5 million, respectively. As of December 25, 2021, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows: Fiscal Year Amortization Expense (in thousands) 2022 $ 143,202 2023 131,385 2024 118,295 2025 110,830 2026 103,485

LONG-TERM DEBT AND FINANCE LEAS

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS	12 Months Ended
	Dec. 25, 2021
Debt Disclosure [Abstract]
LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS	LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS Long-term debt, net and finance leases consists of the following: December 25, 2021 December 26, 2020 (in thousands) Term loans $ — $ 146,875 Revolving facility 1,161,431 814,752 5.5% Senior Notes due 2026 — 500,000 4.25% Senior Notes due 2028 500,000 500,000 3.75% Senior Notes due 2029 500,000 — 4.0% Senior Notes due 2031 500,000 — Other debt 368 3,457 Finance leases (Note 16) 27,223 29,047 Total debt and finance leases 2,689,022 1,994,131 Less: Current portion of long-term debt 101 47,196 Current portion of finance leases (Note 16) 2,694 3,018 Current portion of long-term debt and finance leases 2,795 50,214 Long-term debt and finance leases 2,686,227 1,943,917 Debt discount and debt issuance costs (22,663) (14,346) Long-term debt, net and finance leases $ 2,663,564 $ 1,929,571 As of December 25, 2021 and December 26, 2020, the weighted average interest rate on the Company’s debt was 2.78% and 3.11%, respectively. Term Loans and Revolving Facility (Credit Facility) As of and during the three months ended March 27, 2021 , the Company had a Credit Facility consisting of a $750 million term loan and a $2.05 billion multi-currency revolving facility. The term loan facility matured in 19 quarterly installments with the last installment due March 26, 2023. During the three months ended March 27, 2021, the Company prepaid the remaining amount of the term loan, or $146.9 million, with proceeds from an unregistered private offering (see 2029 and 2031 Senior Notes below). The revolving facility had a maturity date of March 26, 2023, and required no scheduled payment before that date. Approximately $0.2 million of deferred financing costs were expensed upon prepayment of the term loan. During the three months ended June 26, 2021, the Company amended and restated the Credit Facility increasing the capacity of the revolving credit facility and extending the maturity date to April 2026, with no required scheduled payment before that date. The amended and restated Credit Facility provides for a $3.0 billion multi-currency revolving facility. No additional term loan was borrowed. Amendments were made in connection with the prospective discontinuation of LIBOR and other changes in law since the execution of the Company’s existing credit agreement and other amendments were made to certain other covenants and terms. The interest rates applicable to the amended and restated revolving facility are equal to (A) for revolving loans denominated in U.S. dollars, at the Company’s option, either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted LIBOR rate plus 1.0%) or the adjusted LIBOR rate , (B) for revolving loans denominated in euros, the adjusted EURIBOR rate and (C) for revolving loans denominated in sterling, the daily simple SONIA rate, in each case, plus an interest rate margin based upon the Company’s leverage ratio. The Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business and negative and affirmative covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.50 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated EBITDA for any period of four consecutive fiscal quarters, of no more than 4.25 to 1.0. As of December 25, 2021, the Company wa s compliant wi th all financial covenants under the Credit Facility. The obligations of the Company under the Credit Facility are collateralized by substantially all of the assets of the Company. During fiscal years 2021 and 2020, the Company had multiple U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Company’s Credit Facility, which were $400 million each. This resulted in foreign currency losses recognized in Other (expense) income, n et of $31.8 million during fiscal 2021 and foreign currency gains of $11.9 million during fiscal year 2020 related to the remeasurement of the underlying debt. The Company entered into foreign exchange forward contracts to limit its foreign currency exposures related to these borrowings and recognized gains of $34.1 million and losses of $9.3 million during fiscal years 2021 and 2020, respectively , within Interest expense. As of December 25, 2021, the Company did not have any outstanding borrowings in a currency different than its respective functional currency. See Note 14, “Foreign Currency Contracts”, for further discussion. Base Indenture for Senior Notes The Company periodically enters into indentures in order to issue senior notes and is subject to certain affirmative and negative covenants. The Company has the following Senior Notes in the current and prior fiscal periods. 2026 Senior Notes In fiscal year 2018, the Company issued $500 million of 5.5% Senior Notes due in 2026 (2026 Senior Notes) in an unregistered offering. Interest on the 2026 Senior Notes was payable semi-annually on April 1 and October 1. During the three months ended March 27, 2021, the Company prepaid the $500 million 2026 Seniors Notes along with $21 million of related debt extinguishment costs and $13 million of accrued interest using proceeds from additional senior notes issued on the same day (see 2029 and 2031 Senior Notes). The payment of the 2026 Senior Notes was accounted for as a debt extinguishment. Approximately $21 million of debt extinguishment costs and $5 million of deferred financing costs write-offs were recorded in Interest expense during the three months ended March 27, 2021. 2028 Senior Notes In fiscal year 2019, the Company issued $500 million of 4.25% Senior Notes due in 2028 (2028 Senior Notes) in an unregistered offering. Interest on the 2028 Senior Notes is payable semi-annually on May 1 and November 1. 2029 Senior Notes and 2031 Senior Notes In fiscal year 2021, the Company issued $1 billion of debt split between $500 million of 3.75% Senior Notes due in 2029 (2029 Senior Notes), and $500 million of 4.00% Senior Notes due in 2031 (2031 Senior Notes), in an unregistered offering. Interest on the 2029 and 2031 Senior Notes is payable semi-annually on March 15 and September 15. Approximately $10 million of deferred financing costs were capitalized as part of this debt issuance. Proceeds from the 2029 and 2031 Senior Notes were used as follows: prepay the $500 million 2026 Senior Notes, $21 million of debt extinguishment costs, and $13 million of accrued interest; prepay the $146.9 million remaining term loan; pay down $135 million of the revolving facility; and pay for a portion of the Cognate acquisition, which occurred on March 29, 2021. Principal Maturities Principal maturities of existing debt, giving effect to the amended and restated Credit Agreement, for the periods set forth in the table below, are as follows: Principal (in thousands) 2022 $ 101 2023 — 2024 268 2025 — 2026 1,161,430 Thereafter 1,500,000 Total $ 2,661,799 Letters of Credit As of December 25, 2021 and December 26, 2020, the Company had $17.7 million and $16.0 million, respectively, in outstanding letters of credit.

EQUITY AND NONCONTROLLING INTER

EQUITY AND NONCONTROLLING INTERESTS	12 Months Ended
	Dec. 25, 2021
Equity [Abstract]
EQUITY AND NONCONTROLLING INTERESTS	EQUITY AND NONCONTROLLING INTERESTS Earnings Per Share The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Fiscal Year 2021 2020 2019 (in thousands) Numerator: Net income $ 398,837 $ 365,306 $ 254,061 Less: Net income attributable to noncontrolling interests 7,855 1,002 2,042 Net income attributable to common shareholders $ 390,982 $ 364,304 $ 252,019 Denominator: Weighted-average shares outstanding—Basic 50,293 49,550 48,730 Effect of dilutive securities: Stock options, restricted stock units and performance share units 1,132 1,061 963 Weighted-average shares outstanding—Diluted 51,425 50,611 49,693 Options to purchas e 0.2 million shares, 0.2 million shares, and 0.4 million shares for fiscal years 2021, 2020, and 2019, respectively, as well as a non -significant number of restricted stock units (RSUs) and performance share units (PSUs), were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Basic weighted-average shares outstanding for fiscal years 2021, 2020, and 2019 excluded the impa ct of 0.7 million sha res, 0.9 million shares and 1.0 million shares, respectively, of non-vested RSUs and PSUs. Treasury Shares The Company’s Board of Directors has authorized a $1.3 billion stock repurchase program. Under its authorized stock repurchase program, the Company did not repurchase any shares in fiscal years 2021, 2020, and 2019. As of December 25, 2021, the Company had $129.1 million remaining on the authorized stock repurchase program. The Company’s stock-based compensation plans permit the netting of common stock upon vesting of RSUs and PSUs in order to satisfy individual statutory tax withholding requirements. The Company acquired 0.1 million shares for $40.7 million, 0.1 million shares for $24.0 million, and 0.1 million shares for $18.1 million in fiscal years 2021, 2020, and 2019, respectively, from such netting. In fiscal years 2021, 2020 and 2019, the Company’s Board of Directors approved the cancellation and return to the Company’s authorized and unissued capital stock of 0.1 million treasury shares totaling $40.7 million, 0.1 million treasury shares totaling $24.0 million, and 0.1 million treasury shares totaling $18.1 million, re spectively, reducing treasury stock on the Company’s consolidated balance sheet. The Company allocated the excess of the repurchase price over the par value of shares acquired to reduce both retained earnings and additional paid-in capital for $35.6 million and $5.1 million, respectively, in fiscal year 2021, $19.2 million and $4.8 million, respectively, in fisc al year 2020 and $13.8 million and $4.3 million, respectively, in fiscal year 2019. Accumulated Other Comprehensive Income (Loss) Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment and Other Pension and Other Post-Retirement Benefit Plans Total (in thousands) December 28, 2019 $ (87,578) $ (90,441) $ (178,019) Other comprehensive income before reclassifications (1) 20,909 15,747 36,656 Amounts reclassified from accumulated other comprehensive income — 17,861 17,861 Net current period other comprehensive income 20,909 33,608 54,517 Income tax expense 7,215 8,157 15,372 December 26, 2020 (73,884) (64,990) (138,874) Other comprehensive loss before reclassifications (1) (30,316) (1,193) (31,509) Amounts reclassified from accumulated other comprehensive income — 1,678 1,678 Net current period other comprehensive loss (30,316) 485 (29,831) Income tax (benefit) expense (6,027) 2,062 (3,965) December 25, 2021 $ (98,173) $ (66,567) $ (164,740) (1) The impact of the foreign currency translation adjustment to other comprehensive income (loss) before reclassifications was primarily due to the effect of changes in foreign currency exchange rates of the Japanese Yen, Euro, British Pound, Canadian Dollar, Chinese Yuan Renminbi, and Hungarian Forint and to a lesser extent due to the impact of changes in the Brazilian Real. Nonredeemable Noncontrolling Interest The Company has an investment in an entity whose financial results are consolidated in the Company’s financial statements, as it has the ability to exercise control over this entity. The interest of the noncontrolling party in this entity has been recorded as noncontrolling interest within Equity in the accompanying consolidated balance sheets. The activity within the nonredeemable noncontrolling interest during fiscal years 2021, 2020, and 2019 was not significant. Redeemable Noncontrolling Interests The Company holds a 92% ownership interest in Vital River, a commercial provider of research models and related services in China as of December 25, 2021 . In 2019, the Company purchased an additional 5% equity interest in Vital River for $7.9 million. The Company recorded a $0.8 million gain in equity equal to the excess fair value of the 5% equity interest over the purchase price. Concurrent with the transaction, the pre-existing agreement was further amended to provide the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 8% equity interest (redeemable noncontrolling interest) at a contractually defined redemption value, subject to a redemption floor, which represents a derivative embedded within the equity instrument. These rights are exercisable beginning in 2022. In 2019, the Company recorded a charge of $2.2 million in Selling, general and administrative expenses within the consolidated statements of income, equal to the excess fair value of the hybrid instrument (equity interest with embedded derivative) over the fair value of the 8% equity interest. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the contractually defined redemption value ($23.0 million as of December 25, 2021) and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 8% interest, the noncontrolling interest is classified in the mezzanine section of the consolidated balance sheets, which is presented above the equity section and below liabilities. The amount that the Company could be required to pay to purchase the remaining 8% equity interest is not limited. As part of the Citoxlab acquisition in 2019, the Company acquired an approximate 90% equity interest in a subsidiary that was fully consolidated under the voting interest model, which included an approximate 10% redeemable noncontrolling interest. In February 2020, the Company purchased the remaining approximate 10% noncontrolling interest for approximately $4 million and assumption of a contingent consideration liability of approximately $2 million payable to the former shareholders. See Note 7. “Fair Value”. In 2019, the Company acquired an 80% equity interest in a subsidiary that is fully consolidated under the voting interest model, which includes a 20% redeemable noncontrolling interest. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 20% equity interest at its appraised value ($30.0 million as of December 25, 2021). These rights are exercisable beginning in 2022. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the appraised value and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest or a predetermined floor value. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 20% interest, the noncontrolling interest is classified in the mezzanine section of the consolidated balance sheets, which is presented above the equity section and below liabilities. The amount that the Company could be required to pay to purchase the remaining 20% equity interest is not limited. The following table provi des a rollforward of the activity related to the Company’s redeemable noncontrolling interests: Fiscal Year 2021 2020 (in thousands) Beginning balance $ 25,499 $ 28,647 Adjustment of noncontrolling interests to redemption value 21,312 — Purchase of a 10% redeemable noncontrolling interest — (3,732) Net income (loss) attributable to noncontrolling interests 5,375 (852) Foreign currency translation 824 1,436 Ending balance $ 53,010 $ 25,499

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 25, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The components of income from continuing operations before income taxes and the related provision for income taxes are presented below: Fiscal Year 2021 2020 2019 (in thousands) Income before income taxes: U.S. $ 129,598 $ 226,935 $ 108,326 Non-U.S. 351,112 220,179 195,758 Total income before income taxes $ 480,710 $ 447,114 $ 304,084 Income tax provision (benefit): Current: Federal $ 32,728 $ 38,192 $ 18,101 Foreign 60,197 35,410 43,489 State 9,257 6,623 9,915 Total current 102,182 80,225 71,505 Deferred: Federal (27,486) 386 (3,226) Foreign 13,891 5,583 (17,111) State (6,714) (4,386) (1,145) Total deferred (20,309) 1,583 (21,482) Total provision for income taxes $ 81,873 $ 81,808 $ 50,023 Included in the fiscal year 2019 income tax expense of $50.0 million is a $20.6 million tax benefit for the recognition of $315.5 million of historical foreign net operating loss deferred tax assets, partially offset by a $294.9 million valuation allowance. Prior to 2019, these deferred tax assets were not recognized as the Company believed the ability to utilize the net operating losses was remote. As a result of both changes to U.S. tax law and European tax legislation, the Company made changes in 2019 to its financing structure, resulting in the ability to utilize a portion of the net operating losses previously considered remote in nature. Reconciliations of the statutory U.S. federal income tax rate to effective tax rates are as follows: Fiscal Year 2021 2020 2019 U.S. statutory income tax rate 21.0 % 21.0 % 21.0 % Foreign tax rate differences 0.1 1.2 2.7 State income taxes, net of federal tax benefit 0.8 0.4 2.6 Non-deductible compensation 1.2 1.0 1.7 Research tax credits and enhanced deductions (5.0) (3.4) (4.4) Stock-based compensation (4.3) (2.7) (2.2) Enacted tax rate changes 3.0 0.7 (0.4) Tax on unremitted earnings 1.8 1.3 1.7 Impact of tax uncertainties 0.7 (0.2) (2.6) Impact of acquisitions and restructuring (1.6) 0.5 2.7 Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA) — (0.1) (6.8) Other (0.7) (1.4) 0.5 Effective income tax rate 17.0 % 18.3 % 16.5 % The components of deferred tax assets and liabilities are as follows: December 25, 2021 December 26, 2020 (in thousands) Deferred tax assets: Compensation $ 28,900 $ 32,118 Accruals and reserves 23,760 17,970 Net operating loss and credit carryforwards 410,156 406,085 Operating lease liability 65,592 43,646 Other 8,323 4,253 Valuation allowance (315,645) (334,845) Total deferred tax assets 221,086 169,227 Deferred tax liabilities: Goodwill and other intangibles (280,081) (202,430) Depreciation related (35,514) (33,277) Venture capital investments (16,018) (32,848) Tax on unremitted earnings (21,060) (27,707) Right-of-use assets (64,257) (43,557) Other (3,650) (8,710) Total deferred tax liabilities (420,580) (348,529) Net deferred taxes $ (199,494) $ (179,302) The Company has recognized its deferred tax assets on the belief that it is more likely than not that they will be realized. The only exceptions relate to deferred tax assets primarily for net operating losses in Luxembourg, Sweden, certain capital losses, and fixed assets in the U.K. A reconciliation of the Company’s beginning and ending valuation allowance are as follows: Fiscal Year 2021 2020 2019 Beginning balance $ 334,845 $ 309,962 $ 9,788 Additions (reductions) charged to income tax provision, net 1,023 (2,707) 299,197 Additions due to acquisitions 7,747 — 924 Reductions due to divestitures, restructuring (4,706) — — Currency translation and other (23,264) 27,590 53 Ending balance $ 315,645 $ 334,845 $ 309,962 As of December 25, 2021, the Company had tax-effected deferred tax assets for net operating loss carryforwards of $368.5 million, as compared to $369.0 million as of December 26, 2020. Of this amount, $24.9 million are definite-lived and begin to expire in 2022, and the remainder of $343.6 million can be carried forward indefinitely. The Company has deferred tax assets for tax credit carryforwards of $41.7 million. Of this amount, $40.4 million are definite-lived and begin to expire after 2038, the remainder of $1.3 million can be carried forward indefinitely. Additionally, the Company records a benefit to operating income for research and development and other credits in Quebec, France, the Netherlands, and the U.K. related to its DSA facilities. Additionally, the Company records a benefit to operating income for research and development and other credits in Quebec, France, the Netherlands, and the U.K. related to its DSA facilities. A reconciliation of the Company’s beginning and ending unrecognized income tax benefits is as follows: Fiscal Year 2021 2020 2019 (in thousands) Beginning balance $ 24,970 $ 19,665 $ 18,827 Additions to tax positions for current year 9,544 7,044 3,691 Additions to tax positions for prior years 2,476 4,589 5,234 Reductions to tax positions for prior years (1,330) (127) (1,033) Settlements (1,870) (5,859) (274) Expiration of statute of limitations (1,198) (342) (6,780) Ending balance $ 32,592 $ 24,970 $ 19,665 The $7.6 million increase in unrecognized income tax benefits during fiscal year 2021 as compared to the corresponding period in 2020 is primarily attributable to tax positions associated with our international financing structure, an additional year of Canadian Scientific Research and Experimental Development (SR&ED) credit, and acquired uncertain tax positions. The amount of unrecognized income tax benefits that, if recognized, would favorably impact the effective tax rate was $30.0 million as of December 25, 2021 and $22.6 million as of December 26, 2020. The $7.4 million increase is primarily due to the same items noted above. It is reasonably possible as of December 25, 2021 that the liability for unrecognized tax benefits for the uncertain tax position will decrease by approximately $10 million over the next twelve-month period. The Company continues to recognize interest and penalties related to unrecognized income tax benefits in income tax expense. The total amount of cumulative accrued interest related to unrecognized income tax benefits as of December 25, 2021 and December 26, 2020 was $1.7 million and $2.4 million, respectively. Interest expense recorded as a component of income taxes was immaterial for all periods. There were no accrued penalties related to unrecognized income tax benefits as of December 25, 2021 or as of December 26, 2020. The Company conducts business in a number of tax jurisdictions. As a resu lt, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., the U.K., China, France, Germany, and Canada . With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 20 18. The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., Canada, Germany, and France . The Company does not anticipate resolution of these audits will have a material impact on its consolidated financial statements.

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS	12 Months Ended
	Dec. 25, 2021
Retirement Benefits [Abstract]
EMPLOYEE BENEFIT PLANS	EMPLOYEE BENEFIT PLANS Pension Plans The Charles River Laboratories, Inc. Pension Plan (U.S. Pension Plan) was a qualified, non-contributory defined benefit plan that covered certain U.S. employees. Effective 2002, the U.S. Pension Plan was amended to exclude new participants from joining and in 2008 the accrual of benefits was frozen. In January 2019, the Company commenced the process to terminate this plan and received regulatory approval in April 2020. In October 2020, the Company settled all remaining benefits directly with vested participants through either lump sum payouts or the purchase of a group annuity contract from a qualified insurance company to administer all future payments. Prior to the settlement, the U.S. Pension Plan was underfunded with a benefit obligation of $93.8 million and plan assets of $93.0 million. In the fourth quarter of fiscal year 2020, the Company made a contribution of $0.8 million to fully fund this plan to cover the lump sum payments, purchase the group annuity contract, and settle remaining termination costs. Upon settlement of the pension liability, the Company recognized a non-cash settlement charge of $10.3 million related to pension losses, reclassified from accumulated other comprehensive loss on the consolidated balance sheet, to other expense in the consolidated statements of income. The Charles River Pension Plan (U.K. Pension Plan) is a defined contribution and defined benefit pension plan covering certain U.K. employees. Benefits are based on participants’ final pensionable salary and years of service. Participants’ rights vest immediately. Effective December 31, 2002, the plan was amended to exclude new participants from joining the defined benefit section of the plan and a defined contribution section was established for new entrants. Contributions under the defined contribution plan are determined as a percentage of gross salary. In the fourth quarter of 2015, the U.K. Pension Plan was amended such that the members of the defined benefit section of the plan ceased to accrue additional benefits; however, their benefits continue to be adjusted for changes in their final pensionable salary or a specified inflation index, as applicable. During fiscal 2021, the Company made contributions of $8.3 million to the U.K. Pension Plan. As of fiscal 2021 year-end, this plan was in a funded status of $39.6 million. In addition, the Company has several defined benefit plans in certain other countries in which it maintains an operating presence, including Canada, France, Germany, Italy and Netherlands. On October 12, 2021, the Company sold RMS Japan, which included the related pension plan in Japan. All pension related assets and liabilities were assumed by the buyer. Refer to Note 2. “Acquisitions and Divestitures” for more details on this divestiture. The net periodic benefit cost (income) associated with these plans for fiscal years 2021, 2020 and 2019 totaled $0.5 million, $1.6 million and $1.5 million, respectively. Charles River Laboratories Deferred Compensation Plan and Executive Supplemental Life Insurance Retirement Plan The Company maintains a non-qualified deferred compensation plan, known as the Charles River Laboratories Deferred Compensation Plan (DCP), which allows a select group of eligible employees to defer a portion of their compensation. At the present time, no contributions are credited to the DCP, except as set forth below. Participants must specify the distribution date for deferred amounts at the time of deferral, in accordance with applicable IRS regulations. Generally, amounts may be paid in lump sum or installments upon retirement or termination of employment, or later if the employee terminates employment after age 55 and before age 65. Amounts may also be distributed during employment, subject to a minimum deferral requirement of three years. The Company provides certain active employees an annual contribution into their DCP account of 10% of the employee’s base salary plus the lesser of their target annual bonus or actual annual bonus. In addition to the DCP, certain officers and key employees also participate, or in the past participated, in the Company’s Executive Supplemental Life Insurance Retirement Plan (ESLIRP), which is a non-funded, non-qualified arrangement. Annual benefits under this plan will equal a percentage of the highest five $8.1 million . Upon settlement of this pension liability, the Company recognized a non-cash settlement charge of $2.1 million related to pension losses, reclassified from accumulated other comprehensive loss on the consolidated balance sheet, to other expense in the consolidated statements of income. The net periodic benefit cost associated with these plans for fiscal years 2021, 2020 and 2019 totaled $4.3 million, $5.7 million and $2.5 million, respectively. The Company has invested in several corporate-owned key-person life insurance policies with the intention of using these investments to fund the ESLIRP and the DCP. Participants have no interest in any such investments. As of December 25, 2021 and December 26, 2020, the cash surrender value of these life insurance policies were $51.0 million and $43.8 million, respectively. The following table provides a reconciliation of benefit obligations and plan assets of the Company’s pension, DCP and ESLIRP plans: December 25, 2021 December 26, 2020 (in thousands) Change in projected benefit obligations: Benefit obligation at beginning of year $ 367,468 $ 447,409 Service cost 3,455 3,609 Interest cost 5,492 8,849 Other — 429 Benefit payments (7,564) (8,913) Settlements (82) (101,979) Transfer out due to divestiture (11,956) — Actuarial loss 18,107 9,816 Administrative expenses paid — (808) Effect of foreign exchange (2,321) 9,056 Benefit obligation at end of year $ 372,599 $ 367,468 Change in fair value of plan assets: Fair value of plan assets at beginning of year $ 324,752 $ 357,181 Actual return on plan assets 24,151 36,551 Employer contributions 11,221 34,092 Settlements (82) (101,979) Transfer out due to divestiture (15,918) — Benefit payments (7,564) (8,913) Administrative expenses paid — (808) Effect of foreign exchange (929) 8,628 Fair value of plan assets at end of year $ 335,631 $ 324,752 Net balance sheet liability $ 36,968 $ 42,716 Amounts recognized in balance sheet: Noncurrent assets $ 39,621 $ 31,916 Current liabilities 1,876 1,713 Noncurrent liabilities 74,713 72,919 Actuarial losses are driven mainly by liability losses as a result of changes in economic assumptions, in particular higher inflation related assumptions, offset by liability gains due to higher discount rates and changes in mortality assumptions. Amounts recognized in accumulated other comprehensive loss related to the Company’s pension, DCP and ESLIRP plans are as follows: Fiscal Year 2021 2020 (in thousands) Net actuarial loss $ 82,746 $ 82,914 Net prior service cost (credit) (1,091) (1,593) Net amount recognized $ 81,655 $ 81,321 The accumulated benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with accumulated benefit obligations in excess of plan assets are as follows: December 25, 2021 December 26, 2020 (in thousands) Accumulated benefit obligation $ 75,133 $ 72,940 Fair value of plan assets 12,663 11,543 The projected benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with projected benefit obligations in excess of plan assets are as follows: December 25, 2021 December 26, 2020 (in thousands) Projected benefit obligation $ 96,089 $ 93,192 Fair value of plan assets 19,500 18,560 Components of total benefit cost for the Company’s pension, DCP and ESLIRP plans are as follows: Fiscal Year 2021 2020 2019 (in thousands) Service cost $ 3,455 $ 3,609 $ 2,833 Interest cost 5,492 8,849 11,583 Expected return on plan assets (8,058) (11,348) (13,005) Amortization of prior service credit (531) (489) (489) Amortization of net loss 4,528 6,239 2,250 Other — 417 850 Net periodic benefit cost 4,886 7,277 4,022 Settlement (2,320) 12,385 — Total benefit cost $ 2,566 $ 19,662 $ 4,022 Assumptions Weighted-average assumptions used to determine projected benefit obligations are as follows: December 25, 2021 December 26, 2020 Discount rate 1.8 % 1.5 % Rate of compensation increase 3.7 % 3.0 % The discount rate reflects the rate the Company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. A 25- basis point change across all discount rates changes the projected benefit obligation by approximately $17 million for all Company plans. Weighted-average assumptions used to determine net periodic benefit cost are as follows: December 25, 2021 December 26, 2020 December 28, 2019 Discount rate 1.5 % 2.1 % 3.2 % Expected long-term return on plan assets 2.5 % 3.4 % 4.3 % Rate of compensation increase 3.0 % 3.0 % 3.2 % A 0.5% decrease in the expected rate of return would increase annual pension expense by $1.7 million. In fiscal years 2021 and 2020, new mortality improvement scales were issued in the U.S. and the United Kingdom (U.K.) reflecting a decline in longevity projection from previous releases the Company adopted, which decreased the Company’s benefit obligations by $0.5 million and $7.8 million as of December 25, 2021 and December 26, 2020, respectively. Plan Assets The Company invests its pension assets with the objective of achieving a total long-term rate of return sufficient to fund future pension obligations and to minimize future pension contributions. The Company is willing to tolerate a commensurate level of risk to achieve this objective. The Company controls its risk by maintaining a diversified portfolio of asset classes. Plan assets did not include any of the Company’s common stock as of December 25, 2021 or December 26, 2020. The weighted-average target asset allocations are 20.7% to equity securities, 13.8% to fixed income securities and 65.5% to other securities. The fair value of the Company’s pension plan assets by asset category are as follows: December 25, 2021 December 26, 2020 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total (in thousands) Cash and cash equivalents $ 8,142 $ 4,549 $ — $ 12,691 $ 20,163 $ 1,466 $ — $ 21,629 Equity securities (1) — 60,872 — 60,872 8,633 54,832 — 63,465 Debt securities (2) — 140,082 — 140,082 — 99,188 — 99,188 Mutual funds (3) 7,071 69,269 — 76,340 7,018 65,189 — 72,207 Other (4) — 44,568 1,078 45,646 508 66,439 1,316 68,263 Total $ 15,213 $ 319,340 $ 1,078 $ 335,631 $ 36,322 $ 287,114 $ 1,316 $ 324,752 (1) This category comprises equity investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end. (2) This category comprises debt investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end. Holdings primarily include investment-grade corporate bonds and treasuries at various durations. (3) This category comprises mutual funds valued at the net asset value of shares held by non-U.S. pension plans at year end and translated into U.S. dollars using a foreign currency exchange rate at year end. (4) This category mainly comprises fixed income securities tied to various U.K. government bond yields held by non-US pension plans valued at the net asset value of shares held at year-end and translated into U.S. dollars using a foreign currency exchange rate at year end. The activity within the Level 3 pension plan assets was not significant during the periods presented. During fiscal year 2021, the Company contributed $9.1 million to the pension plans and expects to contribute approximately $0.2 million in fiscal year 2022. During fiscal year 2021, the Company paid $2.1 million directly to certain participants outside of plan assets. Expected benefit payments are estimated using the same assumptions used in determining the Company’s benefit obligation as of December 25, 2021. Benefit payments will depend on future employment and compensation levels, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the aggregate for fiscal years 2027 through 2031, are as follows. Fiscal Year Pension Plans (in thousands) 2022 $ 7,317 2023 6,865 2024 7,475 2025 7,870 2026 53,330 2027-2031 45,604 Post-Retirement Health and Life Insurance Plans The Company’s Canadian location offers post-retirement life insurance benefits to its employees and post-retirement medical and dental insurance coverage to certain executives. The plan is non-contributory and unfunded. As of December 25, 2021 and December 26, 2020, the accumulated benefit obligation related to the plan was $1.0 million and $1.3 million, respectively. The amounts included in other accumulated comprehensive income as well as expenses related to the plan were not significant for fiscal years 2021, 2020 and 2019. Charles River Laboratories Employee Savings Plan The Charles River Laboratories Employee Savings Plan is a defined contribution plan in the form of a qualified 401(k) plan in which substantially all U.S. employees are eligible to participate upon employment. The plan contains a provision whereby the Company matches a percentage of employee contributions. During fiscal years 2021, 2020 and 2019, the costs associated with this defined contribution plan totaled $24.0 million, $14.6 million and $19.1 million, respectively.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 25, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The Company has stock-based compensation plans under which employees and non-employee directors may be granted stock-based awards such as stock options, restricted stock, restricted stock units (RSUs), and performance share units (PSUs). During fiscal years 2021, 2020 and 2019, the primary share-based awards and their general terms and conditions are as follows: • Stock options, which entitle the holder to purchase a specified number of shares of common stock at an exercise price equal to the closing market price of common stock on the date of grant; typically vest over 4 years; and typically expire 5 or 10 years from date of grant. • RSUs, which represent an unsecured promise to grant at no cost a set number of shares of common stock upon the completion of the vesting schedule, and typically vest over 2 to 4 years. With respect to RSUs, recipients are not entitled to cash dividends and have no voting rights on the stock during the vesting period. • PSUs, which entitle the holder to receive at no cost, a specified number of shares of common stock within a range of shares from zero to a specified maximum and typically vest over 3 years. Payout of this award is contingent upon achievement of certain performance and market conditions. In May 2016, the Company’s shareholders approved the 2016 Incentive Plan (2016 Plan). The 2016 Plan provided no further awards to be granted under preexisting stock option and incentive plans; provided, however, that any shares that have been forfeited or canceled in accordance with the terms of the applicable award under a preexisting plan may be subsequently awarded in accordance with the terms of the preexisting plan. The 2016 Plan allows a maximum of 6.1 million shares to be awarded, of which restricted stock grants, RSUs, and performance-based stock awards count as 2.3 shares and stock options count as 1.0 share. Any stock options and other share-based awards that were granted under prior plans and were outstanding in May 2016 continue in accordance with the terms of the respective plans. In May 2018, the Company’s shareholders approved the 2018 Incentive Plan, which was amended in 2020 (2018 Plan). The 2018 Plan provided no further awards to be granted under preexisting stock option and incentive plans; provided, however, that any shares that have been forfeited or canceled in accordance with the terms of the applicable award under a preexisting plan may be subsequently awarded in accordance with the terms of the preexisting plan. The 2018 Plan allows a maximum of 8.9 million shares to be awarded, of which restricted stock grants, RSUs, and performance-based stock awards count as 2.3 shares and stock options count as 1.0 share. Any stock options and other share-based awards that were granted under prior plans and were outstanding in May 2018 continue in accordance with the terms of the respective plans. As of December 25, 2021, approximately 6.2 million shares were authorized for future grants under the Company’s share-based compensation plans. The Company settles employee share-based compensation awards with newly issued shares. The following table provides stock-based compensation by the financial statement line item in which it is reflected: Fiscal Year 2021 2020 2019 (in thousands) Cost of revenue $ 13,087 $ 10,636 $ 9,038 Selling, general and administrative 58,387 45,705 48,233 Stock-based compensation, before income taxes 71,474 56,341 57,271 Provision for income taxes (10,299) (8,130) (9,465) Stock-based compensation, net of income taxes $ 61,175 $ 48,211 $ 47,806 No stock-based compensation related costs were capitalized in fiscal years 2021, 2020 and 2019. Stock Options The following table summarizes stock option activity under the Company’s stock-based compensation plans: Number of shares Weighted Average Weighted Average Aggregate (in thousands) (in years) (in thousands) Options outstanding as of December 26, 2020 1,216 $ 129.34 Options granted 160 $ 337.13 Options exercised (431) $ 105.80 Options canceled (28) $ 177.46 Options outstanding as of December 25, 2021 917 $ 175.24 4.7 $ 177,834 Options exercisable as of December 25, 2021 286 $ 127.69 2.6 $ 69,111 Options expected to vest as of December 25, 2021 631 $ 196.81 5.6 $ 108,723 The fair value of stock options granted was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Fiscal Year 2021 2020 2019 Expected life (in years) 6.0 6.0 3.6 Expected volatility 32 % 30 % 27 % Risk-free interest rate 1.0 % 0.4 % 2.4 % Expected dividend yield 0 % 0 % 0 % The weighted-average grant date fair value of stock options granted was $108.61, $53.37 and $33.97 for fiscal years 2021, 2020 and 2019, respectively. As of December 25, 2021, the unrecognized compensation cost related to unvested stock options expected to vest was $21.4 million. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.2 years. The total intr insic value of options exercised during fiscal years 2021, 2020 and 2019 was $94.4 million, $48.6 million and $27.0 million, respectively, with intrinsic value defined as the difference between the market price on the date of exercise and the exercise price. Restricted Stock Units The following table summarizes the restricted stock units activity for fiscal year 2021: Restricted Stock Units Weighted Average Grant Date Fair Value (in thousands) December 26, 2020 466 $ 144.03 Granted 103 $ 340.42 Vested (173) $ 131.93 Canceled (23) $ 194.61 December 25, 2021 373 $ 197.45 As of December 25, 2021, the unrecognized compensation cost related to shares of unvested RSUs expected to vest was $46.0 million, which is expected to be recognized over an estimated weighted-average amortization period of 2.4 years. The total f air value of RSU grants that vested during fiscal years 2021, 2020 and 2019 was $22.8 million, $20.0 million and $16.5 million, respectively. Performance Based Stock Award Program The Company issues PSUs to certain corporate officers. The number of shares of common stock issued for each PSU is adjusted based on a performance condition linked to the Company’s financial performance. Certain awards are further adjusted based on a market condition, which is calculated based on the Company’s stock performance relative to a peer group over the three-year vesting period. The fair value of the market condition is reflected in the fair value of the award at grant date. The Company utilizes a Monte Carlo simulation valuation model to value these awards. Information pertaining to the Company’s PSUs and the related estimated weighted-average assumptions used to calculate their fair value were as follows: Fiscal Year 2021 2020 2019 (shares in thousands) PSUs granted 64 98 160 Weighted average grant date fair value $ 407.76 $ 209.67 $ 164.47 Key assumptions: Expected volatility 37 % 35 % 25 % Risk-free interest rate 0.2 % 0.2 % 2.4 % Expected dividend yield 0 % 0 % 0 % Total shareholder return of 20-trading day average stock price on grant date 39.9 % 21.7 % 17.7 % The maxim um number of common shares to be issued upon vesting of PSUs is 0.1 million. For fiscal years 2021, 2020 and 2019, the Company recognized stock-based compensation related to PSUs of $31.8 million, $22.7 million and $25.3 million, respectively. The total fair value of PSUs that vested during fiscal years 2021, 2020 and 2019 was $26.0 million, $20.9 million and $20.2 million, respectively. In fiscal years 2021, 2020 and 2019, the Company also issued approximately 5,000, 9,000 and 15,000 PSUs using a weighted-average grant date fair value per share of $477.52, $179.66 and $144.67, respectively. These PSUs vest upon the achievement of financial targets and other performance measures.

FOREIGN CURRENCY CONTRACTS

FOREIGN CURRENCY CONTRACTS	12 Months Ended
	Dec. 25, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
FOREIGN CURRENCY CONTRACTS	FOREIGN CURRENCY CONTRACTS Cross Currency Loans The Company periodically enters into foreign exchange forward contracts to limit its foreign currency exposure related to U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Company’s Credit Facility. These contracts are not designated as hedging instruments. Any gains or losses on these forward contracts are recognized immediately within Interest expense in the consolidated statements of income. The Company had no such open forward contracts as of December 25, 2021 or December 26, 2020. The following table summarizes the effect of the foreign exchange forward contracts entered into to limit the Company’s foreign currency exposure related to U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility on the Company’s consolidated statements of income: Fiscal Year 2021 2020 2019 Location of gain (loss) Financial statement caption amount Amount of gain (loss) Financial statement caption amount Amount of gain (loss) Financial statement caption amount Amount of gain (loss) (in thousands) Interest expense $ 73,910 $ 34,131 $ 86,433 $ (9,325) $ 60,882 $ 18,672 Intercompany Loans The Company periodically enters into foreign exchange forward contracts to limit its foreign currency exposure related to certain intercompany loans. These contracts are not designated as hedging instruments. Any gains or losses on forward contracts associated with intercompany loans are recognized immediately in Other (expense) income, net and are largely offset by the remeasurement of the underlying intercompany loans. The Company entered into foreign currency forward contracts related to certain intercompany loans during fiscal years 2021 and 2020. The Company had one open forward contracts as of December 25, 2021, with a duration of three months and was recorded at fair value in the Company’s accompanying consolidated balance sheet. The Company did not have any such open contracts as of December 26, 2020. The notional amount and fair value of the open contract is summarized as follows: December 25, 2021 Notional Amount Fair Value Balance Sheet Location (in thousands) $ 39,211 $ (141) Other current liabilities The Company had settled foreign currency forward contract related to certain intercompany loans during fiscal years 2021, 2020 and 2019 , and recognized losses in Other (expense) income, net in the consolidated statement of income. The following table summarizes the effect of the foreign exchange forward contracts in connection with certain intercompany loans on the Company’s consolidated statements of income: Fiscal Year 2021 2020 2019 Location of gain (loss) Financial statement caption amount Amount of gain (loss) Financial statement caption amount Amount of gain (loss) Financial statement caption amount Amount of gain (loss) (in thousands) Other (expense) income, net $ (35,894) $ (1,599) $ 99,984 $ (892) $ 12,293 $ (121)

RESTRUCTURING AND ASSET IMPAIRM

RESTRUCTURING AND ASSET IMPAIRMENTS	12 Months Ended
	Dec. 25, 2021
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND ASSET IMPAIRMENTS	RESTRUCTURING AND ASSET IMPAIRMENTS Global Restructuring Initiatives In recent fiscal years, the Company has undertaken productivity improvement initiatives within all reportable segments at various locations across the U.S., Canada, Europe, and China. This includes workforce right-sizing and scalability initiatives, resulting in severance and transition costs; and cost related to the consolidation of facilities, resulting in asset impairment and accelerated depreciation charges. The Company does not have any significant remaining lease obligations for facilities associated with restructuring activities. The following table presents a summary of restructuring costs related to these initiatives within the consolidated statements of income: Severance and Transition Costs Asset Impairments and Other Costs Total (in thousands) December 25, 2021 Cost of services provided and products sold (excluding amortization of intangible assets) $ 1,898 $ 934 $ 2,832 Selling, general and administrative 2,819 1,205 4,024 Total $ 4,717 $ 2,139 $ 6,856 December 26, 2020 Cost of services provided and products sold (excluding amortization of intangible assets) $ 4,453 $ 920 $ 5,373 Selling, general and administrative 3,137 4,084 7,221 Total $ 7,590 $ 5,004 $ 12,594 December 28, 2019 Cost of services provided and products sold (excluding amortization of intangible assets) $ 4,348 $ 2,367 $ 6,715 Selling, general and administrative 7,106 18 7,124 Total $ 11,454 $ 2,385 $ 13,839 The following table presents restructuring costs by reportable segment for these productivity improvement initiatives: Fiscal Year 2021 2020 2019 (in thousands) RMS $ 7 $ 845 $ 3,110 DSA 3,114 8,605 7,307 Manufacturing 3,663 2,733 3,032 Unallocated corporate 72 411 390 Total $ 6,856 $ 12,594 $ 13,839 Rollforward of Restructuring Activities The following table provides a rollforward for all of the Company’s severance and transition costs and certain lease related costs related to all restructuring activities: Fiscal Year 2021 2020 2019 (in thousands) Beginning balance $ 5,818 $ 6,406 $ 2,921 Expense (excluding non-cash charges) 5,695 9,284 12,674 Payments / utilization (5,604) (9,918) (9,206) Other non-cash adjustments (1,831) — — Foreign currency adjustments (67) 46 17 Ending balance $ 4,011 $ 5,818 $ 6,406

LEASES

LEASES	12 Months Ended
	Dec. 25, 2021
Leases [Abstract]
LEASES	LEASES Operating and Finance Leases Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows: Fiscal Year December 25, 2021 December 26, 2020 (in thousands) Operating leases Operating lease right-of-use assets, net $ 292,941 $ 178,220 Other current liabilities $ 33,267 $ 24,674 Operating lease right-of-use liabilities 252,972 155,595 Total operating lease liabilities $ 286,239 $ 180,269 Finance leases Property, plant and equipment, net $ 29,437 $ 31,614 Current portion of long-term debt and finance leases $ 2,694 $ 3,018 Long-term debt, net and finance leases 24,529 26,029 Total finance lease liabilities $ 27,223 $ 29,047 The components of operating and finance lease costs were as follows: Fiscal Year December 25, 2021 December 26, 2020 December 28, 2019 (in thousands) Operating lease costs $ 45,728 $ 32,965 $ 30,885 Finance lease costs: Amortization of right-of-use assets 3,337 3,723 4,007 Interest on lease liabilities 1,280 1,306 1,349 Short-term lease costs 2,441 2,349 1,056 Variable lease costs 4,623 5,122 3,161 Sublease income (2,008) (1,673) (994) Total lease costs $ 55,401 $ 43,792 $ 39,464 Other information related to leases was as follows: Supplemental Cash Flow Information Fiscal Year December 25, 2021 December 26, 2020 December 28, 2019 (in thousands) Cash flows included in the measurement of lease liabilities: Operating cash flows from operating leases $ 42,576 $ 29,961 $ 27,153 Operating cash flows from finance leases 1,282 1,306 1,406 Finance cash flows from finance leases 3,202 4,350 3,766 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 142,764 $ 63,499 $ 24,382 Right-of-use lease assets obtained in exchange for new finance lease liabilities 1,567 1,571 4,819 Lease Term and Discount Rate As of As of As of December 25, 2021 December 26, 2020 December 28, 2019 Weighted-average remaining lease term (in years) Operating lease 9.0 8.5 8.2 Finance lease 11.7 12.4 13.0 Weighted-average discount rate Operating lease 3.6 % 4.5 % 4.4 % Finance lease 4.4 % 4.1 % 4.6 % At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate, which is based on the information available at the lease commencement date and represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. As of December 25, 2021, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows: Operating Leases Finance Leases (in thousands) 2022 $ 43,420 $ 3,865 2023 40,959 3,524 2024 39,080 3,288 2025 37,177 2,955 2026 32,072 2,460 Thereafter 146,151 19,157 Total minimum future lease payments 338,859 35,249 Less: Imputed interest 52,620 8,026 Total lease liabilities $ 286,239 $ 27,223 Total minimum future lease payments (predominantly operating leases) of approximately $111 million for leases that have not commenced as of December 25, 2021, as the Company does not yet control the underlying assets, are not included in the consolidated financial statements. These leases are expected to commence between fiscal years 2022 and 2024 with lease terms of approximately 6 to 15 years.
LEASES	LEASES Operating and Finance Leases Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows: Fiscal Year December 25, 2021 December 26, 2020 (in thousands) Operating leases Operating lease right-of-use assets, net $ 292,941 $ 178,220 Other current liabilities $ 33,267 $ 24,674 Operating lease right-of-use liabilities 252,972 155,595 Total operating lease liabilities $ 286,239 $ 180,269 Finance leases Property, plant and equipment, net $ 29,437 $ 31,614 Current portion of long-term debt and finance leases $ 2,694 $ 3,018 Long-term debt, net and finance leases 24,529 26,029 Total finance lease liabilities $ 27,223 $ 29,047 The components of operating and finance lease costs were as follows: Fiscal Year December 25, 2021 December 26, 2020 December 28, 2019 (in thousands) Operating lease costs $ 45,728 $ 32,965 $ 30,885 Finance lease costs: Amortization of right-of-use assets 3,337 3,723 4,007 Interest on lease liabilities 1,280 1,306 1,349 Short-term lease costs 2,441 2,349 1,056 Variable lease costs 4,623 5,122 3,161 Sublease income (2,008) (1,673) (994) Total lease costs $ 55,401 $ 43,792 $ 39,464 Other information related to leases was as follows: Supplemental Cash Flow Information Fiscal Year December 25, 2021 December 26, 2020 December 28, 2019 (in thousands) Cash flows included in the measurement of lease liabilities: Operating cash flows from operating leases $ 42,576 $ 29,961 $ 27,153 Operating cash flows from finance leases 1,282 1,306 1,406 Finance cash flows from finance leases 3,202 4,350 3,766 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 142,764 $ 63,499 $ 24,382 Right-of-use lease assets obtained in exchange for new finance lease liabilities 1,567 1,571 4,819 Lease Term and Discount Rate As of As of As of December 25, 2021 December 26, 2020 December 28, 2019 Weighted-average remaining lease term (in years) Operating lease 9.0 8.5 8.2 Finance lease 11.7 12.4 13.0 Weighted-average discount rate Operating lease 3.6 % 4.5 % 4.4 % Finance lease 4.4 % 4.1 % 4.6 % At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate, which is based on the information available at the lease commencement date and represents a rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. As of December 25, 2021, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows: Operating Leases Finance Leases (in thousands) 2022 $ 43,420 $ 3,865 2023 40,959 3,524 2024 39,080 3,288 2025 37,177 2,955 2026 32,072 2,460 Thereafter 146,151 19,157 Total minimum future lease payments 338,859 35,249 Less: Imputed interest 52,620 8,026 Total lease liabilities $ 286,239 $ 27,223 Total minimum future lease payments (predominantly operating leases) of approximately $111 million for leases that have not commenced as of December 25, 2021, as the Company does not yet control the underlying assets, are not included in the consolidated financial statements. These leases are expected to commence between fiscal years 2022 and 2024 with lease terms of approximately 6 to 15 years.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 25, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Insurance The Company maintains certain insurance policies that maintain large deductibles up to approximately $2 million, some with or without stop-loss limits, depending on market availability. Insurance policies at certain locations are based on a percentage of the insured assets, for which deductibles for certain property may exceed $15.0 million in the event of a catastrophic event. In addition, the Company purchased representation and warranty insurance in support of some acquisitions, in which deductibles could reach $6.6 million. Litigation Various lawsuits, claims and proceedings of a nature considered normal to its business are pending against the Company. While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing matters would have a material adverse effect on the Company’s business or financial condition. Guarantees The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Purchase Obligations The Company enters into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. These unconditional purchase obligations exclude agreements that are cancellable at any time without penalty. The aggregate amount of the Company’s unconditional purchase obligations totaled approximately $260 million as of December 25, 2021 and the majority of these obligations are expected to be settled during 2022.

DESCRIPTION OF BUSINESS AND S_2

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 25, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation The Company’s consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.
Segment Reporting	Segment Reporting The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Research and GMP-Compliant Cells businesses. R esearch Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; Insourcing Solutions (IS), which provides colony management of its clients’ research operations (including recruitment, training, staffing, and management services); and Research and GMP-Compliant Cells, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. The Company’s DSA reportable segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (GLP and non-GLP) safety assessment services. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States (U.S. GAAP) requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Cash and Cash Equivalents	Cash, Cash Equivalents, and Investments Cash equivalents include money market funds, time deposits and other investments with remaining maturities at the purchase date of three months or less. Time deposits with original maturities of greater than three months are reported as short-term investments.
Trade Receivables and Contract Assets, Net	Trade Receivables and Contract Assets, Net The Company records trade receivables and contract assets, net of an allowance for credit losses. An allowance for credit losses is established based on historical collection information, a review of major client accounts receivable balances, current economic conditions in the geographies in which it operates, and the Company’s expectations of future economic conditions that may affect the collectability of the recorded amounts. Amounts determined to be uncollectible are charged or written off against the allowance.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, investments, trade receivables and contract assets. The Company places cash and cash equivalents and investments in various financial institutions with high credit rating and limits the amount of credit exposure to any one financial institution. Trade receivables and contract assets are primarily from clients in the pharmaceutical and biotechnology industries, as well as academic and government institutions. Concentrations of credit risk with respect to trade receivables and contract assets, which are typically unsecured, are limited due to the wide variety of customers using the Company’s products and services as well as their dispersion across many geographic areas. No single client accounted for more than 5% of revenue in fiscal years 2021, 2020, or 2019 or trade receivables as of December 25, 2021 or December 26, 2020.
Fair Value Measurements	Fair Value Measurements The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company has certain financial assets and liabilities recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy: • Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access, • Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates, • Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows: • Cash equivalents - Valued at market prices determined through third-party pricing services; • Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates; • Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments; • Debt instruments - The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book values of the Company’s Senior Notes, which are fixed rate debt, are carried at amortized cost. Fair values of the Senior Notes are based on quoted market prices and on borrowing rates available to the Company; and • Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes and certain option pricing models .
Inventories	Inventories The Company’s inventories consist of raw materials, work in process and finished product related primarily to small models, large models, cell supply, microbial solutions products, and avian related eggs and flocks. Inventories are stated at the lower of cost or net realizable value. Inventory value is generally based on the standard cost method for all businesses except for the Avian business, which is based on an average cost. Standard costs are trued-up to reflect actual cost. For small models inventory, costs include direct materials such as feed and bedding, costs of personnel directly involved in the care of the models, and an allocation of facility overhead. For the large models inventory, costs are primarily the external cost paid to acquire the model along with allocated overhead costs. For cell supply inventory, costs include direct materials, costs of personnel directly involved in the processing of products sold, and an allocation of facility overhead. For the microbial solutions inventory, costs include direct materials, cost of personnel directly involved in the manufacturing and assembly of products sold, and an allocation of facility overhead. For the avian related inventory, costs include direct materials, such as animal feed, cost of personnel directly involved with the care of the eggs and flocks, and an allocation of facility overhead. Inventory costs are charged to cost of revenue in the period the products are sold to an external party. The Company analyzes its inventory levels on a quarterly basis and writes down inventory that is determined to be damaged, obsolete or otherwise unmarketable, with a corresponding charge to cost of products sold.
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment, net, including improvements that significantly add to productive capacity or extend useful life, are carried at cost and are subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment is expensed as incurred. In addition, the Company capitalizes certain internal use computer software development costs. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. The Company generally depreciates the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets as follow: Estimated (in years) Land Indefinite Buildings and building improvements 10 - 40 Machinery and equipment 3 - 20 Furniture and fixtures 5 - 10 Computer hardware and software 3 - 8 Vehicles 3 - 5 Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. Finance lease assets are amortized over the lease term, however, if ownership is transferred by the end of the finance lease, or there is a bargain purchase option, such finance lease assets are amortized over the useful life that would be assigned if such assets were owned. When the Company disposes of property, plant and equipment, it removes the associated cost and accumulated depreciation from the related accounts on its consolidated balance sheet and includes any resulting gain or loss recorded in Other (expense) income, net in the accompanying consolidated statements of income.
Business Combinations	Business Combinations The Company accounts for business combinations under the acquisition method of accounting. The Company allocates the amounts that it pays for each acquisition to the assets it acquires and liabilities it assumes based on their fair values at the dates of acquisition, including identifiable intangible assets, which typically represents a significant portion of the purchase price. The determination of the fair value of intangible assets requires the use of significant judgment using management’s best estimates of inputs and assumptions that a market participant would use. Significant judgments include (i) the fair value; and (ii) whether such intangible assets are amortizable or non-amortizable and, if the former, the period and the method by which the intangible asset will be amortized. The Company utilizes commonly accepted valuation techniques, such as the income, cost, and market approaches as appropriate, in establishing the fair value of intangible assets. Typically, key assumptions include projections of cash flows that arise from identifiable intangible assets of acquired businesses as well as discount rates based on an analysis of the weighted average cost of capital, adjusted for specific risks associated with the assets. In recent acquisitions, customer relationship intangible assets (also referred to as client relationships) are the most significant identifiable asset acquired. To determine the fair value of the acquired client relationships, the Company typically utilizes the multiple period excess earnings model (a commonly accepted valuation technique), which relies on the following key assumptions: projections of cash flows from the acquired entities, which includes future revenue growth rates, operating income margins, and customer attrition rates; as well as discount rates based on an analysis of the acquired entities’ weighted average cost of capital. Contingent Consideration The consideration for the Company’s acquisitions may include future payments that are contingent upon the occurrence of a particular event. The Company records an obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, that incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The Company revalues these contingent consideration obligations each reporting period. Changes in the fair value of the contingent consideration obligations are recognized in the Company’s consolidated statements of income as a component of selling, general and administrative expenses. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and changes in the assumed probabilities of successful achievement of certain financial targets. Discount rates in the Company’s valuation models represent a measure of the credit risk associated with settling the liability. The period over which the Company discounts its contingent obligations is typically based on when the contingent payments would be triggered. These fair value measurements are based on significant inputs not observable in the market.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the difference between the purchase price and the fair value of assets acquired and liabilities assumed when accounted for using the acquisition method of accounting. Goodwill is not amortized, but reviewed for impairment on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company's reporting units below their carrying amounts. The Company has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test. If the Company elects this option and believes, as a result of the qualitative assessment, that it is more-likely-than-not that the carrying value of goodwill is not recoverable, the quantitative impairment test is required; otherwise, no further testing is required. Alternatively, the Company may elect to not first assess qualitative factors and immediately perform the quantitative impairment test. In the quantitative test, the Company compares the fair value of its reporting units to their carrying values. If the carrying values of the net assets assigned to the reporting units exceed the fair values of the reporting units an impairment loss equal to the difference would be recorded. Definite-lived intangible assets, including client relationships, are amortized over the pattern in which the economic benefits of the intangible assets are utilized and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset, which requires the use of customer attrition rates and other assumptions. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the definite-lived intangible assets, the definite-lived intangible assets are written-down to their fair values.
Valuation and Impairment of Long-Lived Assets	Valuation and Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.
Venture Capital Investments	Venture Capital Investments The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from less than 1% to approximately 12%. The Company accounts for the investments in limited partnerships (LPs), which are variable interest entities, under the equity method of accounting. For publicly-held investments in the LPs, the Company adjusts for changes in fair market value based on reported share holdings at the end of each fiscal quarter. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LPs’ economic performance. Under the equity method of accounting, the Company’s portion of the investment gains and losses, as reported in the fund’s financial statements on a quarterly lag each reporting period, is recorded in other (expense) income, net in the accompanying consolidated statements of income. In addition, the Company adjusts the carrying value of these investments to reflect its estimate of changes to fair value since the fund’s financial statements are based on information from the fund’s management team, market prices of known public holdings of the fund, and other information.
Strategic Equity Investments	Strategic Equity Investments The Company invests, with minority positions, directly in equity of predominantly privately-held companies that are reported either at fair value or under the equity method of accounting, as appropriate. Equity investments accounted for at fair value that do not have readily determinable fair values are generally recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same investee. Gains and losses from strategic equity investments are recorded in Other (expense) income, net in the accompanying consolidated statements of income.
Life Insurance Contracts	Life Insurance Contracts Investments in life insurance contracts are recorded at cash surrender value. The initial investment is remeasured based on fair value of underlying investments or contractual value each reporting period. Gains and losses from life insurance contracts are recorded in Other (expense) income, net in the accompanying
Leases	Leases At inception of a contract, the Company determines if a contract meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the following: (1) the right to obtain substantially all of the economic benefits from use of the identified asset, and (2) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and lease liabilities are recognized at lease commencement date based on the present value of the minimum future lease payments. The Company leases laboratory, production, and office space (real estate), as well as land, vehicles and certain equipment under non-cancellable operating and finance leases. The carrying value of the Company’s right-of-use lease assets is substantially concentrated in its real estate leases, while the volume of lease agreements is primarily concentrated in vehicles and equipment leases. The Company’s policy is to not record leases with an original term of twelve months or less on the consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term. Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease components are not measured as part of the right-of-use asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single lease component and are recognized as part of a right-of-use asset and liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements. Most real estate leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 5 years. Certain lease agreements contain options to purchase the leased property and options to terminate the lease. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be exercised or the option to terminate the lease will not be exercised, or is not at the Company’s option. The Company determines whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors. A portfolio approach is applied to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases. The Company subleases a limited number of lease arrangements. Sublease activity is not material to the consolidated financial statements.
Stock-Based Compensation	Stock-Based Compensation The Company may grant stock options, restricted stock, restricted stock units (RSUs), and performance share units (PSUs) to employees and stock options, restricted stock, and RSUs to non-employee directors under stock-based compensation plans. Stock-based compensation is recognized as an expense in the consolidated statements of income based on the grant date fair value, adjusted for forfeitures when they occur, over the requisite service period. For stock options, restricted stock and RSUs that vest based on service conditions, the Company uses the straight-line method to allocate compensation expense to reporting periods. Where awards are made with non-substantive vesting periods and a portion of the award continues to vest after the employee’s eligible retirement, the Company recognizes expense based on the period from the grant date to the date on which the employee is retirement eligible. The Company records the expense for PSU grants subject to performance and/or market conditions using the accelerated attribution method over the remaining service period when management determines that achievement of the performance-based milestone is probable. The fair value of stock options granted is calculated using the Black-Scholes option-pricing model and the fair value of PSUs is estimated using a lattice model with a Monte Carlo simulation, both of which require the use of subjective assumptions including volatility and expected term, among others. The expected volatility assumption is typically determined using the historical volatility of the Company’s common stock over the expected life of the stock-based award. The expected term is determined using historical option exercise activity. The fair value of restricted stock and RSUs is based on the market value of the Company’s common stock on the date of grant.
Revenue Recognition	Revenue Recognition Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the amount to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Generally, the Company does not extend payment terms beyond one year. Applying the practical expedient, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. The Company’s contracts do not generally contain significant financing components. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
Income Taxes	Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements carrying amounts and their respective tax basis. The Company measures deferred tax assets and liabilities using the enacted tax rates in effect when the temporary differences are expected to be settled. The Company evaluates the realizability of its deferred tax assets and establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The Company evaluates uncertain tax positions on a quarterly basis and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in-process audit activities and changes in facts or circumstances related to a tax position. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.
Foreign Currency Contracts and Translation of Foreign Currencies	Foreign Currency Contracts Foreign currency contracts are recorded at fair value in the Company’s consolidated balance sheets and are not designated as hedging instruments. Any gains or losses on forward contracts associated with intercompany loans are recognized immediately in Other (expense) income, net and are largely offset by the remeasurement of the underlying intercompany loan. Any gains or losses on forward contracts associated with the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity under the Company’s Credit Facility are recognized immediately in Interest expense. Gains or losses incurred on the remeasurement of the Company’s U.S. dollar denominated loan borrowed by a non-U.S. entity with a different functional currency is recorded in Other (expense) income, net. Translation of Foreign Currencies For the Company’s subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive loss, a separate component of equity.
Pension and Other Post-Retirement Benefit Plans	Pension and Other Post-Retirement Benefit Plans The Company recognizes the funded status of its defined benefit pension and other post-retirement benefit plans as an asset or liability. This amount is defined as the difference between the fair value of plan assets and the benefit obligation. The Company measures plan assets and benefit obligations as of its fiscal year end. The key assumptions used to calculate benefit obligations and related pension costs include expected long-term rate of return on plan assets, withdrawal and mortality rates, expected rate of increase in employee compensation levels and a discount rate. Assumptions are determined based on the Company’s data and appropriate market indicators, and evaluated each year as of the plan’s measurement date. The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the Company considers the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. The rate of compensation increase reflects the expected annual salary increases for the plan participants based on historical experience and the current employee compensation strategy. The Company is required to recognize as a component of other comprehensive income, net of tax, the actuarial gains or losses and prior service costs or credits that arise but were not previously required to be recognized as components of net periodic benefit cost. Other comprehensive income is adjusted as these amounts are later recognized in income as components of net periodic benefit cost. The Company records the service cost component of the net periodic benefit cost within Cost of services provided and Selling, general, and administrative expenses and all other components of net periodic benefit cost within Other (expense) income, net in the consolidated statements of income. The Company recognizes pension settlement gains or losses in the period when all of the following settlement criteria are met: there is an irrevocable action, the Company is relieved of primary responsibility for a benefit obligation, and significant risks related to the obligation and the assets used to effect the settlement are eliminated.
Earnings Per Share	Earnings Per Share Basic earnings per share is calculated by dividing net income attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Except where the result would be anti-dilutive to income from continuing operations, diluted earnings per share is computed using the treasury stock method, assuming the exercise of stock options and the vesting of restricted stock awards, RSUs, or PSUs, as well as their related income tax effects.
Treasury Shares	Treasury Shares The Company periodically retires treasury shares acquired through share repurchases and returns those shares to the status of authorized but unissued. The Company accounts for treasury stock transactions under the cost method. For each reacquisition of common stock, the number of shares and the acquisition price for those shares is added to the existing treasury stock count and total value. Thus, the average cost per share is re-averaged each time shares are acquired. When treasury shares are retired, the Company allocates the excess of the repurchase price over the par value of shares acquired to both retained earnings and additional paid-in-capital. The portion allocated to additional paid-in-capital is determined by applying a percentage, determined by dividing the number of shares to be retired by the number of shares issued, to the balance of additional paid-in-capital as of the retirement date.
Newly Adopted and Newly Issued Accounting Pronouncements	Newly Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board (FASB) issued ASU 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”. ASU 2021-08 improves the accounting for acquired revenue contracts with customers in a business combination by addressing the diversity in practice and inconsistency related to the recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU require acquirers to recognize and measure contract assets and contract liabilities acquired in the business combination in accordance with Topic 606 as if it had originated the contracts. The Company’s adoption of this standard in fiscal year 2021 did not have a significant impact on the consolidated financial statements and related disclosures. In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU, including subsequently issued updates, offers temporary optional expedients and exceptions for applying U.S. GAAP to modifications to agreements such as loans, debt securities, derivatives, and borrowings which reference LIBOR or another reference rate that will partially discontinue after December 31, 2021 and fully cease by June 30, 2023. The expedients and exceptions provided by the standard do not apply to modifications made and hedging relationships entered into or evaluated after that, except for hedging relationships existing as of the phase-out date that an entity has elected certain optional expedients for and are retained through the end of the hedging relationship. The ASU is effective until the replacement for LIBOR is completed. The interest rate on the Company’s revolving credit facility, which was amended and restated in April 2021 (see Note 9. Long-Term Debt and Finance Lease Obligations) and matures in fiscal year 2026, is linked to LIBOR and alternative interest rates when LIBOR is discontinued. The Company’s adoption of this standard in fiscal year 2021 did not have a significant impact on the consolidated financial statements and related disclosures. In January 2020, the FASB issue d ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. The Company’s adoption of this standard in fiscal year 2021 did not have a significant impact on the consolidated financial statements and related disclosures. In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” ASU 2019-12 simplifies the accounting for income taxes by removing exceptions within the general principles of Topic 740 regarding the calculation of deferred tax liabilities, the incremental approach for intraperiod tax allocation, and calculating income taxes in an interim period. In addition, the ASU adds clarifications to the accounting for franchise tax (or similar tax), which is partially based on income, evaluating tax basis of goodwill recognized from a business combination, and reflecting the effect of any enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The Company’s adoption of this standard in fiscal year 2021 did not have a significant impact on the consolidated financial statements and related disclosures. Newly Issued Accounting Pronouncements

DESCRIPTION OF BUSINESS AND S_3

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 25, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Property, Plant, and Equipment Estimated Useful Lives	The Company generally depreciates the cost of its property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets as follow: Estimated (in years) Land Indefinite Buildings and building improvements 10 - 40 Machinery and equipment 3 - 20 Furniture and fixtures 5 - 10 Computer hardware and software 3 - 8 Vehicles 3 - 5

ACQUISITIONS AND DIVESTITURES (

ACQUISITIONS AND DIVESTITURES (Tables)	12 Months Ended
	Dec. 25, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Preliminary Purchase Price Allocation	The preliminary purchase price allocation was as follows: June 28, 2021 (in thousands) Trade receivables $ 3,548 Other current assets (excluding cash) 1,657 Property, plant and equipment 7,649 Operating lease right-of-use asset, net 22,507 Goodwill 239,681 Definite-lived intangible assets 93,900 Other long-term assets 694 Deferred revenue (4,260) Current liabilities (6,319) Operating lease right-of-use liabilities (21,220) Deferred tax liabilities (13,958) Total purchase price allocation $ 323,879 The preliminary purchase price allocation was as follows: March 30, 2021 (in thousands) Trade receivables $ 2,266 Other current assets (excluding cash) 209 Property, plant and equipment 400 Goodwill 34,489 Definite-lived intangible assets 22,126 Other long-term assets 1,385 Current liabilities (1,575) Deferred tax liabilities (4,174) Other long-term liabilities (1,205) Total purchase price allocation $ 53,921 The preliminary purchase price allocation was as follows: March 29, 2021 (in thousands) Trade receivables $ 18,566 Inventories 4,231 Other current assets (excluding cash) 9,816 Property, plant and equipment 52,082 Operating lease right-of-use assets, net 34,349 Goodwill 612,147 Definite-lived intangible assets 270,900 Other long-term assets 6,098 Deferred revenue (20,539) Current liabilities (44,974) Operating lease right-of-use liabilities (31,383) Deferred tax liabilities (31,847) Other long-term liabilities (414) Total purchase price allocation $ 879,032 The purchase price allocation was as follows: December 31, 2020 (in thousands) Trade receivables $ 2,722 Other current assets (excluding cash) 221 Property, plant and equipment 2,382 Goodwill 71,585 Definite-lived intangible assets 24,540 Other long-term assets 2,055 Current liabilities (2,823) Deferred tax liabilities (2,529) Other long-term liabilities (1,123) Total purchase price allocation $ 97,030 The purchase price allocation was as follows: August 6, 2020 (in thousands) Trade receivables $ 1,500 Inventories 551 Other current assets (excluding cash) 182 Property, plant and equipment 1,648 Goodwill 19,457 Definite-lived intangible assets 16,230 Other long-term assets 849 Current liabilities (1,360) Deferred tax liabilities (1,467) Other long-term liabilities (740) Total purchase price allocation $ 36,850 The purchase price allocation was as follows: January 3, 2020 (in thousands) Trade receivables $ 6,451 Inventories 8,468 Other current assets (excluding cash) 3,494 Property, plant and equipment 10,033 Goodwill 210,196 Definite-lived intangible assets 183,540 Other long-term assets 5,920 Current liabilities (5,188) Deferred tax liabilities (38,529) Other long-term liabilities (7,664) Total purchase price allocation $ 376,721 The purchase price allocation was as follows: April 29, 2019 (in thousands) Trade receivables $ 35,405 Inventories 5,282 Other current assets (excluding cash) 13,917 Property, plant and equipment 88,605 Goodwill 280,161 Definite-lived intangible assets 162,400 Other long-term assets 20,063 Deferred revenue (15,278) Current liabilities (46,081) Deferred tax liabilities (27,458) Other long-term liabilities (22,624) Redeemable noncontrolling interest (4,035) Total purchase price allocation $ 490,357
Schedule of Finite-Lived Intangible Assets Acquired	The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 87,500 12 Backlog 2,900 1 Other intangible assets 3,500 4 Total definite-lived intangible assets $ 93,900 11 The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 17,340 13 Developed technology 3,685 3 Other intangible assets 1,101 2 Total definite-lived intangible assets $ 22,126 11 The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 257,200 13 Other intangible assets 4,800 2 Backlog 8,900 1 Total definite-lived intangible assets $ 270,900 13 The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 16,080 9 Developed technology 3,940 5 Other intangible assets 4,520 4 Total definite-lived intangible assets $ 24,540 7 The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 14,740 13 Other intangible assets 1,490 3 Total definite-lived intangible assets $ 16,230 12 The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 170,390 19 Trade name 7,330 10 Other intangible assets 5,820 3 Total definite-lived intangible assets $ 183,540 18 The definite-lived intangible assets acquired were as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 134,600 13 Developed technology 19,900 3 Backlog 7,900 1 Total definite-lived intangible assets $ 162,400 12
Schedule of Pro Forma Information	Fiscal Year 2021 2020 (in thousands) (unaudited) Revenue $ 3,583,646 $ 3,068,161 Net income attributable to common shareholders 376,152 347,873
Schedule of Carrying Amounts of Assets and Liabilities	The carrying amounts of the major classes of assets and liabilities associated with the divestiture of the business were as follows: October 12, 2021 (in thousands) Assets Current assets $ 26,524 Property, plant, and equipment, net 17,379 Goodwill 4,129 Other assets 3,695 Total assets $ 51,727 Liabilities Current liabilities $ 8,705 Long-term liabilities 94 Total liabilities $ 8,799 October 12, 2021 (in thousands) Assets Current assets $ 8,187 Property, plant and equipment, net 14,339 Operating lease right-of-use assets, net 19,733 Goodwill 27,764 Intangible assets, net 14,089 Total assets $ 84,112 Liabilities Current liabilities $ 6,386 Operating lease right-of-use liabilities 18,221 Total liabilities $ 24,607

REVENUE FROM CONTRACTS WITH C_2

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	12 Months Ended
	Dec. 25, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Timing of Revenue Recognition: 2021 2020 2019 (in thousands) RMS Services and products transferred over time $ 263,659 $ 240,480 $ 227,872 Services and products transferred at a point in time 426,778 330,672 309,217 Total RMS revenue 690,437 571,152 537,089 DSA Services and products transferred over time 2,103,415 1,836,519 1,618,281 Services and products transferred at a point in time 3,816 909 714 Total DSA revenue 2,107,231 1,837,428 1,618,995 Manufacturing Services and products transferred over time 335,745 174,254 142,896 Services and products transferred at a point in time 406,747 341,099 322,246 Total Manufacturing revenue 742,492 515,353 465,142 Total revenue $ 3,540,160 $ 2,923,933 $ 2,621,226 Revenue for each significant product or service offering is as follows: 2021 2020 2019 (in thousands) RMS $ 690,437 $ 571,152 $ 537,089 DSA 2,107,231 1,837,428 1,618,995 Manufacturing 742,492 515,353 465,142 Total revenue $ 3,540,160 $ 2,923,933 $ 2,621,226
Schedule of Estimated Revenue Related to Performance Obligations	The following table include s estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of December 25, 2021: Revenue Expected to be Recognized in Future Periods Less than 1 Year 1 to 3 Years 4 to 5 Years Beyond 5 Years Total (in thousands) DSA $ 355,127 $ 338,685 $ 18,250 $ 1,683 $ 713,745 Manufacturing 2,728 — — — $ 2,728 Total $ 357,855 $ 338,685 $ 18,250 $ 1,683 $ 716,473
Schedule of Client Receivables, Contract Assets and Contract Liabilities	The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers: December 25, 2021 December 26, 2020 (in thousands) Balances from contracts with customers: Client receivables $ 489,452 $ 489,042 Contract assets (unbilled revenue) 160,609 135,400 Contract liabilities (current and long-term deferred revenue) 240,281 227,417 Contract liabilities (customer contract deposits) 59,512 42,244

SEGMENT AND GEOGRAPHIC INFORM_2

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	Dec. 25, 2021
Segment Reporting [Abstract]
Revenue and Other Financial Information by Reportable Segment	The following table presents revenue and other financial information by reportable segment: 2021 2020 2019 (in thousands) RMS Revenue $ 690,437 $ 571,152 $ 537,089 Operating income 166,814 102,706 133,912 Depreciation and amortization 39,123 37,080 19,197 Capital expenditures 61,188 29,487 26,989 DSA Revenue $ 2,107,231 $ 1,837,428 $ 1,618,995 Operating income 406,978 325,959 258,903 Depreciation and amortization 177,254 168,922 151,139 Capital expenditures 101,477 105,653 86,843 Manufacturing Revenue $ 742,492 $ 515,353 $ 465,142 Operating income 246,390 181,494 145,420 Depreciation and amortization 46,195 25,904 23,584 Capital expenditures 58,877 26,287 23,617
Reconciliation of Segment Operating Income and Capital Expenditures to Respective Consolidated Amounts	The following tables present reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts: Operating Income Depreciation and Amortization 2021 2020 2019 2021 2020 2019 (in thousands) Total reportable segments $ 820,182 $ 610,159 $ 538,235 $ 262,572 $ 231,906 $ 193,920 Unallocated corporate (230,320) (177,430) (187,084) 2,968 3,018 4,175 Total consolidated $ 589,862 $ 432,729 $ 351,151 $ 265,540 $ 234,924 $ 198,095 Capital Expenditures 2021 2020 2019 (in thousands) Total reportable segments $ 221,542 $ 161,427 $ 137,449 Unallocated corporate 7,230 5,133 3,065 Total consolidated $ 228,772 $ 166,560 $ 140,514
Revenue for Each Significant Product or Service Offering	The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Timing of Revenue Recognition: 2021 2020 2019 (in thousands) RMS Services and products transferred over time $ 263,659 $ 240,480 $ 227,872 Services and products transferred at a point in time 426,778 330,672 309,217 Total RMS revenue 690,437 571,152 537,089 DSA Services and products transferred over time 2,103,415 1,836,519 1,618,281 Services and products transferred at a point in time 3,816 909 714 Total DSA revenue 2,107,231 1,837,428 1,618,995 Manufacturing Services and products transferred over time 335,745 174,254 142,896 Services and products transferred at a point in time 406,747 341,099 322,246 Total Manufacturing revenue 742,492 515,353 465,142 Total revenue $ 3,540,160 $ 2,923,933 $ 2,621,226 Revenue for each significant product or service offering is as follows: 2021 2020 2019 (in thousands) RMS $ 690,437 $ 571,152 $ 537,089 DSA 2,107,231 1,837,428 1,618,995 Manufacturing 742,492 515,353 465,142 Total revenue $ 3,540,160 $ 2,923,933 $ 2,621,226
Summary of Unallocated Corporate Overhead	A summary of unallocated corporat e expense co nsists of the following: 2021 2020 2019 (in thousands) Stock-based compensation $ 43,018 $ 34,111 $ 37,855 Compensation, benefits, and other employee-related expenses 92,459 73,814 73,893 External consulting and other service expenses 25,374 26,561 16,639 Information technology 18,450 18,912 16,080 Depreciation 2,968 3,018 4,175 Acquisition and integration 30,370 13,995 26,877 Other general unallocated corporate 17,681 7,019 11,565 Total unallocated corporate expense $ 230,320 $ 177,430 $ 187,084
Revenue and Long-Lived Assets by Geographic Area	Revenue and long-lived assets by geographic area are as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) 2021 Revenue $ 1,934,404 $ 1,036,465 $ 339,098 $ 222,902 $ 7,291 $ 3,540,160 Long-lived assets 755,400 323,405 145,274 64,864 2,125 1,291,068 2020 Revenue $ 1,627,149 $ 829,312 $ 306,259 $ 155,086 $ 6,127 $ 2,923,933 Long-lived assets 627,871 286,229 145,410 62,931 1,917 1,124,358 2019 Revenue $ 1,471,097 $ 726,421 $ 271,987 $ 146,218 $ 5,503 $ 2,621,226 Long-lived assets 602,654 253,665 127,495 60,213 101 1,044,128

SUPPLEMENTAL BALANCE SHEET IN_2

SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)	12 Months Ended
	Dec. 25, 2021
Supplemental Balance Sheet Information [Abstract]
Composition of Trade Receivables, Net	The composition of trade receivables and contract assets, net is as follows: December 25, 2021 December 26, 2020 (in thousands) Client receivables $ 489,452 $ 489,042 Unbilled revenue 160,609 135,400 Total 650,061 624,442 Less: Allowance for credit losses (7,180) (6,702) Trade receivables and contract assets, net $ 642,881 $ 617,740
Composition of Inventories	The composition of inventories is as follows: December 25, 2021 December 26, 2020 (in thousands) Raw materials and supplies $ 33,118 $ 28,317 Work in process 40,268 36,755 Finished products 125,760 120,623 Inventories $ 199,146 $ 185,695
Composition of Other Current Assets	The composition of other current assets is as follows: December 25, 2021 December 26, 2020 (in thousands) Prepaid income tax $ 84,725 $ 68,462 Short-term investments 1,063 1,024 Restricted cash 4,023 3,074 Other receivables 7,500 — Other current assets $ 97,311 $ 72,560
Composition of Property, Plant and Equipment, Net	The composition of property, plant and equipment, net is as follows: December 25, 2021 December 26, 2020 (in thousands) Land $ 59,486 $ 61,031 Buildings (1) 987,544 1,059,641 Machinery and equipment (1) 760,353 661,124 Leasehold improvements 141,525 104,967 Furniture and fixtures 22,520 31,489 Computer hardware and software (1) 210,582 193,622 Vehicles (1) 6,897 6,152 Construction in progress 205,141 92,325 Total 2,394,048 2,210,351 Less: Accumulated depreciation (1,102,980) (1,085,993) Property, plant and equipment, net $ 1,291,068 $ 1,124,358 (1) These balances include assets under finance leases. See Note 16, “Leases.”
Composition of Other Assets	The composition of other assets is as follows: December 25, 2021 December 26, 2020 (in thousands) Venture capital investments $ 149,640 $ 197,100 Strategic equity investments 51,712 24,704 Life insurance policies 51,048 43,827 Other long-term income tax assets 18,690 23,485 Restricted cash 1,077 1,621 Long-term pension assets 39,582 31,915 Other 41,140 29,974 Other assets $ 352,889 $ 352,626
Composition of Other Current Liabilities	The composition of other current liabilities is as follows: December 25, 2021 December 26, 2020 (in thousands) Current portion of operating lease right-of-use liabilities $ 33,267 $ 24,674 Accrued income taxes 26,161 24,884 Customer contract deposits 59,512 42,244 Other 18,701 10,675 Other current liabilities $ 137,641 $ 102,477
Schedule of Other Long-Term Liabilities	The composition of other long-term liabilities is as follows: December 25, 2021 December 26, 2020 (in thousands) U.S. Transition Tax $ 43,057 $ 48,781 Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plans 104,944 96,492 Long-term deferred revenue 20,578 19,475 Other 74,280 40,467 Other long-term liabilities $ 242,859 $ 205,215

FAIR VALUE (Tables)

FAIR VALUE (Tables)	12 Months Ended
	Dec. 25, 2021
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value on a recurring basis are summarized below: December 25, 2021 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 893 $ — $ 893 Other assets: Life insurance policies — 42,918 — 42,918 Total assets measured at fair value $ — $ 43,811 $ — $ 43,811 Other liabilities measured at fair value: Contingent consideration — — 11,794 11,794 Other long-term liabilities measured at fair value: Contingent consideration — — 25,450 25,450 Total liabilities measured at fair value $ — $ — $ 37,244 $ 37,244 December 26, 2020 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ — $ 2,273 $ — $ 2,273 Other assets: Life insurance policies — 35,770 — 35,770 Total assets measured at fair value $ — $ 38,043 $ — $ 38,043 Other current liabilities measured at fair value: Contingent consideration — — 2,328 2,328 Total liabilities measured at fair value $ — $ — $ 2,328 $ 2,328
Rollforward of Contingent Consideration	The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions. Fiscal Year 2021 2020 (in thousands) Beginning balance $ 2,328 $ 712 Additions 71,559 2,131 Payments (2,889) (230) Total gains or losses (realized/unrealized): Foreign currency translation (368) 183 Adjustment of previously recorded contingent liability (33,386) (468) Ending balance $ 37,244 $ 2,328
Schedule of Book and Fair Values of Debt	The book value and fair value of the Company’s Senior Notes is summarized below: December 25, 2021 December 26, 2020 Book Value Fair Value Book Value Fair Value 5.5% Senior Notes due 2026 $ — $ — $ 500,000 $ 523,100 4.25% Senior Notes due 2028 500,000 521,250 500,000 523,750 3.75% Senior Notes due 2029 500,000 506,700 — — 4.0% Senior Notes due 2031 500,000 507,500 — —

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 25, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Rollforward of Goodwill	The following table provides a rollforward of the Company’s goodwill: Adjustments to Goodwill Adjustments to Goodwill December 28, 2019 Acquisitions Foreign Exchange December 26, 2020 Acquisitions Divestitures Foreign Exchange December 25, 2021 (in thousands) RMS $ 56,586 $ 229,654 $ 1,519 $ 287,759 $ — $ (4,129) $ (106) $ 283,524 DSA 2,350,223 (629) 33,536 2,383,130 123,091 — (28,715) 2,477,506 Manufacturing 138,756 — 4,523 143,279 851,828 (27,764) (11,492) 955,851 Gross carrying amount 2,545,565 229,025 39,578 2,814,168 974,919 (31,893) (40,313) 3,716,881 Accumulated impairment loss - DSA (1,005,000) — — (1,005,000) — — — (1,005,000) Goodwill $ 1,540,565 $ 1,809,168 $ 2,711,881
Schedule of Intangible Assets, Net by Class	The following table displays intangible assets, net by major class: December 25, 2021 December 26, 2020 Gross Accumulated Net Gross Accumulated Net (in thousands) Backlog $ 12,577 $ (9,517) $ 3,060 $ 29,233 $ (29,233) $ — Technology 135,764 (95,454) 40,310 130,907 (81,305) 49,602 Trademarks and trade names 13,086 (3,448) 9,638 15,870 (5,648) 10,222 Other 35,231 (8,445) 26,786 20,903 (14,633) 6,270 Other intangible assets 196,658 (116,864) 79,794 196,913 (130,819) 66,094 Client relationships 1,475,757 (494,359) 981,398 1,137,331 (415,826) 721,505 Intangible assets $ 1,672,415 $ (611,223) $ 1,061,192 $ 1,334,244 $ (546,645) $ 787,599
Schedule of Estimated Amortization Expense	As of December 25, 2021, estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows: Fiscal Year Amortization Expense (in thousands) 2022 $ 143,202 2023 131,385 2024 118,295 2025 110,830 2026 103,485

LONG-TERM DEBT AND FINANCE LE_2

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS (Tables)	12 Months Ended
	Dec. 25, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt, Net	Long-term debt, net and finance leases consists of the following: December 25, 2021 December 26, 2020 (in thousands) Term loans $ — $ 146,875 Revolving facility 1,161,431 814,752 5.5% Senior Notes due 2026 — 500,000 4.25% Senior Notes due 2028 500,000 500,000 3.75% Senior Notes due 2029 500,000 — 4.0% Senior Notes due 2031 500,000 — Other debt 368 3,457 Finance leases (Note 16) 27,223 29,047 Total debt and finance leases 2,689,022 1,994,131 Less: Current portion of long-term debt 101 47,196 Current portion of finance leases (Note 16) 2,694 3,018 Current portion of long-term debt and finance leases 2,795 50,214 Long-term debt and finance leases 2,686,227 1,943,917 Debt discount and debt issuance costs (22,663) (14,346) Long-term debt, net and finance leases $ 2,663,564 $ 1,929,571
Schedule of Principal Maturities of Existing Debt	Principal maturities of existing debt, giving effect to the amended and restated Credit Agreement, for the periods set forth in the table below, are as follows: Principal (in thousands) 2022 $ 101 2023 — 2024 268 2025 — 2026 1,161,430 Thereafter 1,500,000 Total $ 2,661,799

EQUITY AND NONCONTROLLING INT_2

EQUITY AND NONCONTROLLING INTERESTS (Tables)	12 Months Ended
	Dec. 25, 2021
Equity [Abstract]
Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings per Share	The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Fiscal Year 2021 2020 2019 (in thousands) Numerator: Net income $ 398,837 $ 365,306 $ 254,061 Less: Net income attributable to noncontrolling interests 7,855 1,002 2,042 Net income attributable to common shareholders $ 390,982 $ 364,304 $ 252,019 Denominator: Weighted-average shares outstanding—Basic 50,293 49,550 48,730 Effect of dilutive securities: Stock options, restricted stock units and performance share units 1,132 1,061 963 Weighted-average shares outstanding—Diluted 51,425 50,611 49,693
Changes to Each Component of Accumulated Other Comprehensive Income (Loss), Net of Income Taxes	Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment and Other Pension and Other Post-Retirement Benefit Plans Total (in thousands) December 28, 2019 $ (87,578) $ (90,441) $ (178,019) Other comprehensive income before reclassifications (1) 20,909 15,747 36,656 Amounts reclassified from accumulated other comprehensive income — 17,861 17,861 Net current period other comprehensive income 20,909 33,608 54,517 Income tax expense 7,215 8,157 15,372 December 26, 2020 (73,884) (64,990) (138,874) Other comprehensive loss before reclassifications (1) (30,316) (1,193) (31,509) Amounts reclassified from accumulated other comprehensive income — 1,678 1,678 Net current period other comprehensive loss (30,316) 485 (29,831) Income tax (benefit) expense (6,027) 2,062 (3,965) December 25, 2021 $ (98,173) $ (66,567) $ (164,740) (1) The impact of the foreign currency translation adjustment to other comprehensive income (loss) before reclassifications was primarily due to the effect of changes in foreign currency exchange rates of the Japanese Yen, Euro, British Pound, Canadian Dollar, Chinese Yuan Renminbi, and Hungarian Forint and to a lesser extent due to the impact of changes in the Brazilian Real.
Rollforward of Redeemable Noncontrolling Interest	The following table provi des a rollforward of the activity related to the Company’s redeemable noncontrolling interests: Fiscal Year 2021 2020 (in thousands) Beginning balance $ 25,499 $ 28,647 Adjustment of noncontrolling interests to redemption value 21,312 — Purchase of a 10% redeemable noncontrolling interest — (3,732) Net income (loss) attributable to noncontrolling interests 5,375 (852) Foreign currency translation 824 1,436 Ending balance $ 53,010 $ 25,499

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 25, 2021
Income Tax Disclosure [Abstract]
Components of Income from Continuing Operations Before Income Taxes and the Related Provision for Income Taxes	The components of income from continuing operations before income taxes and the related provision for income taxes are presented below: Fiscal Year 2021 2020 2019 (in thousands) Income before income taxes: U.S. $ 129,598 $ 226,935 $ 108,326 Non-U.S. 351,112 220,179 195,758 Total income before income taxes $ 480,710 $ 447,114 $ 304,084 Income tax provision (benefit): Current: Federal $ 32,728 $ 38,192 $ 18,101 Foreign 60,197 35,410 43,489 State 9,257 6,623 9,915 Total current 102,182 80,225 71,505 Deferred: Federal (27,486) 386 (3,226) Foreign 13,891 5,583 (17,111) State (6,714) (4,386) (1,145) Total deferred (20,309) 1,583 (21,482) Total provision for income taxes $ 81,873 $ 81,808 $ 50,023
Reconciliations of the Statutory U.S. Federal Income Tax Rate to Effective Tax Rates	Reconciliations of the statutory U.S. federal income tax rate to effective tax rates are as follows: Fiscal Year 2021 2020 2019 U.S. statutory income tax rate 21.0 % 21.0 % 21.0 % Foreign tax rate differences 0.1 1.2 2.7 State income taxes, net of federal tax benefit 0.8 0.4 2.6 Non-deductible compensation 1.2 1.0 1.7 Research tax credits and enhanced deductions (5.0) (3.4) (4.4) Stock-based compensation (4.3) (2.7) (2.2) Enacted tax rate changes 3.0 0.7 (0.4) Tax on unremitted earnings 1.8 1.3 1.7 Impact of tax uncertainties 0.7 (0.2) (2.6) Impact of acquisitions and restructuring (1.6) 0.5 2.7 Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA) — (0.1) (6.8) Other (0.7) (1.4) 0.5 Effective income tax rate 17.0 % 18.3 % 16.5 %
Components of Deferred Tax Assets and Liabilities	The components of deferred tax assets and liabilities are as follows: December 25, 2021 December 26, 2020 (in thousands) Deferred tax assets: Compensation $ 28,900 $ 32,118 Accruals and reserves 23,760 17,970 Net operating loss and credit carryforwards 410,156 406,085 Operating lease liability 65,592 43,646 Other 8,323 4,253 Valuation allowance (315,645) (334,845) Total deferred tax assets 221,086 169,227 Deferred tax liabilities: Goodwill and other intangibles (280,081) (202,430) Depreciation related (35,514) (33,277) Venture capital investments (16,018) (32,848) Tax on unremitted earnings (21,060) (27,707) Right-of-use assets (64,257) (43,557) Other (3,650) (8,710) Total deferred tax liabilities (420,580) (348,529) Net deferred taxes $ (199,494) $ (179,302)
Reconciliation of Valuation Allowance	A reconciliation of the Company’s beginning and ending valuation allowance are as follows: Fiscal Year 2021 2020 2019 Beginning balance $ 334,845 $ 309,962 $ 9,788 Additions (reductions) charged to income tax provision, net 1,023 (2,707) 299,197 Additions due to acquisitions 7,747 — 924 Reductions due to divestitures, restructuring (4,706) — — Currency translation and other (23,264) 27,590 53 Ending balance $ 315,645 $ 334,845 $ 309,962
Reconciliation of the Company's Beginning and Ending Unrecognized Income Tax Benefits	A reconciliation of the Company’s beginning and ending unrecognized income tax benefits is as follows: Fiscal Year 2021 2020 2019 (in thousands) Beginning balance $ 24,970 $ 19,665 $ 18,827 Additions to tax positions for current year 9,544 7,044 3,691 Additions to tax positions for prior years 2,476 4,589 5,234 Reductions to tax positions for prior years (1,330) (127) (1,033) Settlements (1,870) (5,859) (274) Expiration of statute of limitations (1,198) (342) (6,780) Ending balance $ 32,592 $ 24,970 $ 19,665

EMPLOYEE BENEFIT PLANS (Tables)

EMPLOYEE BENEFIT PLANS (Tables)	12 Months Ended
	Dec. 25, 2021
Retirement Benefits [Abstract]
Reconciliation of Benefit Obligations and Plans Assets of the Company's Pension Plans	The following table provides a reconciliation of benefit obligations and plan assets of the Company’s pension, DCP and ESLIRP plans: December 25, 2021 December 26, 2020 (in thousands) Change in projected benefit obligations: Benefit obligation at beginning of year $ 367,468 $ 447,409 Service cost 3,455 3,609 Interest cost 5,492 8,849 Other — 429 Benefit payments (7,564) (8,913) Settlements (82) (101,979) Transfer out due to divestiture (11,956) — Actuarial loss 18,107 9,816 Administrative expenses paid — (808) Effect of foreign exchange (2,321) 9,056 Benefit obligation at end of year $ 372,599 $ 367,468 Change in fair value of plan assets: Fair value of plan assets at beginning of year $ 324,752 $ 357,181 Actual return on plan assets 24,151 36,551 Employer contributions 11,221 34,092 Settlements (82) (101,979) Transfer out due to divestiture (15,918) — Benefit payments (7,564) (8,913) Administrative expenses paid — (808) Effect of foreign exchange (929) 8,628 Fair value of plan assets at end of year $ 335,631 $ 324,752 Net balance sheet liability $ 36,968 $ 42,716 Amounts recognized in balance sheet: Noncurrent assets $ 39,621 $ 31,916 Current liabilities 1,876 1,713 Noncurrent liabilities 74,713 72,919
Amounts Recognized in Accumulated Other Comprehensive Loss Related to the Company's Pensions Plans	Amounts recognized in accumulated other comprehensive loss related to the Company’s pension, DCP and ESLIRP plans are as follows: Fiscal Year 2021 2020 (in thousands) Net actuarial loss $ 82,746 $ 82,914 Net prior service cost (credit) (1,091) (1,593) Net amount recognized $ 81,655 $ 81,321
Accumulated Benefit Obligation and Fair of Plan Assets	The accumulated benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with accumulated benefit obligations in excess of plan assets are as follows: December 25, 2021 December 26, 2020 (in thousands) Accumulated benefit obligation $ 75,133 $ 72,940 Fair value of plan assets 12,663 11,543
Projected Benefit Obligation and Fair Value of Plan Assets	The projected benefit obligation and fair value of plan assets for the Company’s pension, DCP and ESLIRP plans with projected benefit obligations in excess of plan assets are as follows: December 25, 2021 December 26, 2020 (in thousands) Projected benefit obligation $ 96,089 $ 93,192 Fair value of plan assets 19,500 18,560
Components of Net Periodic Benefit Costs for the Company's Pension Plans	Components of total benefit cost for the Company’s pension, DCP and ESLIRP plans are as follows: Fiscal Year 2021 2020 2019 (in thousands) Service cost $ 3,455 $ 3,609 $ 2,833 Interest cost 5,492 8,849 11,583 Expected return on plan assets (8,058) (11,348) (13,005) Amortization of prior service credit (531) (489) (489) Amortization of net loss 4,528 6,239 2,250 Other — 417 850 Net periodic benefit cost 4,886 7,277 4,022 Settlement (2,320) 12,385 — Total benefit cost $ 2,566 $ 19,662 $ 4,022
Weighted-average Assumptions	Weighted-average assumptions used to determine projected benefit obligations are as follows: December 25, 2021 December 26, 2020 Discount rate 1.8 % 1.5 % Rate of compensation increase 3.7 % 3.0 % The discount rate reflects the rate the Company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current pension obligations. A 25- basis point change across all discount rates changes the projected benefit obligation by approximately $17 million for all Company plans. Weighted-average assumptions used to determine net periodic benefit cost are as follows: December 25, 2021 December 26, 2020 December 28, 2019 Discount rate 1.5 % 2.1 % 3.2 % Expected long-term return on plan assets 2.5 % 3.4 % 4.3 % Rate of compensation increase 3.0 % 3.0 % 3.2 %
Fair Value of the Company's Pension Plan Assets by Asset Category	The fair value of the Company’s pension plan assets by asset category are as follows: December 25, 2021 December 26, 2020 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total (in thousands) Cash and cash equivalents $ 8,142 $ 4,549 $ — $ 12,691 $ 20,163 $ 1,466 $ — $ 21,629 Equity securities (1) — 60,872 — 60,872 8,633 54,832 — 63,465 Debt securities (2) — 140,082 — 140,082 — 99,188 — 99,188 Mutual funds (3) 7,071 69,269 — 76,340 7,018 65,189 — 72,207 Other (4) — 44,568 1,078 45,646 508 66,439 1,316 68,263 Total $ 15,213 $ 319,340 $ 1,078 $ 335,631 $ 36,322 $ 287,114 $ 1,316 $ 324,752 (1) This category comprises equity investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end. (2) This category comprises debt investments and securities held by non-U.S. pension plans valued at the quoted closing price and translated into U.S. dollars using a foreign currency exchange rate at year end. Holdings primarily include investment-grade corporate bonds and treasuries at various durations. (3) This category comprises mutual funds valued at the net asset value of shares held by non-U.S. pension plans at year end and translated into U.S. dollars using a foreign currency exchange rate at year end. (4) This category mainly comprises fixed income securities tied to various U.K. government bond yields held by non-US pension plans valued at the net asset value of shares held at year-end and translated into U.S. dollars using a foreign currency exchange rate at year end.
Estimated Future Benefit Payments Over the Next Five Years	Fiscal Year Pension Plans (in thousands) 2022 $ 7,317 2023 6,865 2024 7,475 2025 7,870 2026 53,330 2027-2031 45,604

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 25, 2021
Share-based Payment Arrangement [Abstract]
Financial Statement Line Items in Which Stock-based Compensation is Reflected	The following table provides stock-based compensation by the financial statement line item in which it is reflected: Fiscal Year 2021 2020 2019 (in thousands) Cost of revenue $ 13,087 $ 10,636 $ 9,038 Selling, general and administrative 58,387 45,705 48,233 Stock-based compensation, before income taxes 71,474 56,341 57,271 Provision for income taxes (10,299) (8,130) (9,465) Stock-based compensation, net of income taxes $ 61,175 $ 48,211 $ 47,806
Summary of Stock Option Activity	The following table summarizes stock option activity under the Company’s stock-based compensation plans: Number of shares Weighted Average Weighted Average Aggregate (in thousands) (in years) (in thousands) Options outstanding as of December 26, 2020 1,216 $ 129.34 Options granted 160 $ 337.13 Options exercised (431) $ 105.80 Options canceled (28) $ 177.46 Options outstanding as of December 25, 2021 917 $ 175.24 4.7 $ 177,834 Options exercisable as of December 25, 2021 286 $ 127.69 2.6 $ 69,111 Options expected to vest as of December 25, 2021 631 $ 196.81 5.6 $ 108,723
Weighted-average Assumptions	The fair value of stock options granted was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: Fiscal Year 2021 2020 2019 Expected life (in years) 6.0 6.0 3.6 Expected volatility 32 % 30 % 27 % Risk-free interest rate 1.0 % 0.4 % 2.4 % Expected dividend yield 0 % 0 % 0 %
Summary of Restricted Stock and Restricted Stock Unit Activity	The following table summarizes the restricted stock units activity for fiscal year 2021: Restricted Stock Units Weighted Average Grant Date Fair Value (in thousands) December 26, 2020 466 $ 144.03 Granted 103 $ 340.42 Vested (173) $ 131.93 Canceled (23) $ 194.61 December 25, 2021 373 $ 197.45
Information about PSUs and Related Weighted-Average Assumptions	The Company utilizes a Monte Carlo simulation valuation model to value these awards. Information pertaining to the Company’s PSUs and the related estimated weighted-average assumptions used to calculate their fair value were as follows: Fiscal Year 2021 2020 2019 (shares in thousands) PSUs granted 64 98 160 Weighted average grant date fair value $ 407.76 $ 209.67 $ 164.47 Key assumptions: Expected volatility 37 % 35 % 25 % Risk-free interest rate 0.2 % 0.2 % 2.4 % Expected dividend yield 0 % 0 % 0 % Total shareholder return of 20-trading day average stock price on grant date 39.9 % 21.7 % 17.7 %

FOREIGN CURRENCY CONTRACTS (Tab

FOREIGN CURRENCY CONTRACTS (Tables)	12 Months Ended
	Dec. 25, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments on Statements of Income	The following table summarizes the effect of the foreign exchange forward contracts entered into to limit the Company’s foreign currency exposure related to U.S. dollar denominated loans borrowed by a non-U.S. Euro functional currency entity under the Credit Facility on the Company’s consolidated statements of income: Fiscal Year 2021 2020 2019 Location of gain (loss) Financial statement caption amount Amount of gain (loss) Financial statement caption amount Amount of gain (loss) Financial statement caption amount Amount of gain (loss) (in thousands) Interest expense $ 73,910 $ 34,131 $ 86,433 $ (9,325) $ 60,882 $ 18,672 The following table summarizes the effect of the foreign exchange forward contracts in connection with certain intercompany loans on the Company’s consolidated statements of income: Fiscal Year 2021 2020 2019 Location of gain (loss) Financial statement caption amount Amount of gain (loss) Financial statement caption amount Amount of gain (loss) Financial statement caption amount Amount of gain (loss) (in thousands) Other (expense) income, net $ (35,894) $ (1,599) $ 99,984 $ (892) $ 12,293 $ (121)
Schedule of Notional Amounts and Fair Value of Derivatives	The notional amount and fair value of the open contract is summarized as follows: December 25, 2021 Notional Amount Fair Value Balance Sheet Location (in thousands) $ 39,211 $ (141) Other current liabilities

RESTRUCTURING AND ASSET IMPAI_2

RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)	12 Months Ended
	Dec. 25, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Costs	The following table presents a summary of restructuring costs related to these initiatives within the consolidated statements of income: Severance and Transition Costs Asset Impairments and Other Costs Total (in thousands) December 25, 2021 Cost of services provided and products sold (excluding amortization of intangible assets) $ 1,898 $ 934 $ 2,832 Selling, general and administrative 2,819 1,205 4,024 Total $ 4,717 $ 2,139 $ 6,856 December 26, 2020 Cost of services provided and products sold (excluding amortization of intangible assets) $ 4,453 $ 920 $ 5,373 Selling, general and administrative 3,137 4,084 7,221 Total $ 7,590 $ 5,004 $ 12,594 December 28, 2019 Cost of services provided and products sold (excluding amortization of intangible assets) $ 4,348 $ 2,367 $ 6,715 Selling, general and administrative 7,106 18 7,124 Total $ 11,454 $ 2,385 $ 13,839 The following table presents restructuring costs by reportable segment for these productivity improvement initiatives: Fiscal Year 2021 2020 2019 (in thousands) RMS $ 7 $ 845 $ 3,110 DSA 3,114 8,605 7,307 Manufacturing 3,663 2,733 3,032 Unallocated corporate 72 411 390 Total $ 6,856 $ 12,594 $ 13,839
Rollforward of Company's Severance and Retention Costs Liability	The following table provides a rollforward for all of the Company’s severance and transition costs and certain lease related costs related to all restructuring activities: Fiscal Year 2021 2020 2019 (in thousands) Beginning balance $ 5,818 $ 6,406 $ 2,921 Expense (excluding non-cash charges) 5,695 9,284 12,674 Payments / utilization (5,604) (9,918) (9,206) Other non-cash adjustments (1,831) — — Foreign currency adjustments (67) 46 17 Ending balance $ 4,011 $ 5,818 $ 6,406

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 25, 2021
Leases [Abstract]
Schedule of Right-of-Use Lease Assets and Lease Liabilities in Condensed Financial Statements	Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows: Fiscal Year December 25, 2021 December 26, 2020 (in thousands) Operating leases Operating lease right-of-use assets, net $ 292,941 $ 178,220 Other current liabilities $ 33,267 $ 24,674 Operating lease right-of-use liabilities 252,972 155,595 Total operating lease liabilities $ 286,239 $ 180,269 Finance leases Property, plant and equipment, net $ 29,437 $ 31,614 Current portion of long-term debt and finance leases $ 2,694 $ 3,018 Long-term debt, net and finance leases 24,529 26,029 Total finance lease liabilities $ 27,223 $ 29,047
Schedule of Operating and Finance Lease Costs and Supplemental Cash Flow Information	The components of operating and finance lease costs were as follows: Fiscal Year December 25, 2021 December 26, 2020 December 28, 2019 (in thousands) Operating lease costs $ 45,728 $ 32,965 $ 30,885 Finance lease costs: Amortization of right-of-use assets 3,337 3,723 4,007 Interest on lease liabilities 1,280 1,306 1,349 Short-term lease costs 2,441 2,349 1,056 Variable lease costs 4,623 5,122 3,161 Sublease income (2,008) (1,673) (994) Total lease costs $ 55,401 $ 43,792 $ 39,464 Other information related to leases was as follows: Supplemental Cash Flow Information Fiscal Year December 25, 2021 December 26, 2020 December 28, 2019 (in thousands) Cash flows included in the measurement of lease liabilities: Operating cash flows from operating leases $ 42,576 $ 29,961 $ 27,153 Operating cash flows from finance leases 1,282 1,306 1,406 Finance cash flows from finance leases 3,202 4,350 3,766 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 142,764 $ 63,499 $ 24,382 Right-of-use lease assets obtained in exchange for new finance lease liabilities 1,567 1,571 4,819 Lease Term and Discount Rate As of As of As of December 25, 2021 December 26, 2020 December 28, 2019 Weighted-average remaining lease term (in years) Operating lease 9.0 8.5 8.2 Finance lease 11.7 12.4 13.0 Weighted-average discount rate Operating lease 3.6 % 4.5 % 4.4 % Finance lease 4.4 % 4.1 % 4.6 %
Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases After Adoption	As of December 25, 2021, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows: Operating Leases Finance Leases (in thousands) 2022 $ 43,420 $ 3,865 2023 40,959 3,524 2024 39,080 3,288 2025 37,177 2,955 2026 32,072 2,460 Thereafter 146,151 19,157 Total minimum future lease payments 338,859 35,249 Less: Imputed interest 52,620 8,026 Total lease liabilities $ 286,239 $ 27,223
Schedule of Future Minimum Lease Payments Under Non-Cancellable Finance Leases After Adoption	As of December 25, 2021, maturities of operating and finance lease liabilities for each of the following five years and a total thereafter were as follows: Operating Leases Finance Leases (in thousands) 2022 $ 43,420 $ 3,865 2023 40,959 3,524 2024 39,080 3,288 2025 37,177 2,955 2026 32,072 2,460 Thereafter 146,151 19,157 Total minimum future lease payments 338,859 35,249 Less: Imputed interest 52,620 8,026 Total lease liabilities $ 286,239 $ 27,223

DESCRIPTION OF BUSINESS AND S_4

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 25, 2021USD ($)segmentcontract	Dec. 26, 2020USD ($)contract
Debt Instrument [Line Items]
Number of reportable segments | segment	3
Number of life insurance contracts | contract	45	44
Face value of life insurance contracts | $	$ 89.8	$ 79.1
Minimum
Debt Instrument [Line Items]
Company's ownership percentage	1.00%
Renewal term for leases	1 year
Maximum
Debt Instrument [Line Items]
Company's ownership percentage	12.00%
Renewal term for leases	5 years

DESCRIPTION OF BUSINESS AND S_5

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment, Net (Details)	12 Months Ended
	Dec. 25, 2021
Minimum | Buildings and building improvements
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	10 years
Minimum | Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	3 years
Minimum | Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	5 years
Minimum | Computer hardware and software
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	3 years
Minimum | Vehicles
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	3 years
Maximum | Buildings and building improvements
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	40 years
Maximum | Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	20 years
Maximum | Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	10 years
Maximum | Computer hardware and software
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	8 years
Maximum | Vehicles
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	5 years

ACQUISITIONS AND DIVESTITURES -

ACQUISITIONS AND DIVESTITURES - Additional Information (Details) - USD ($) $ in Thousands

Oct. 12, 2021

Jun. 28, 2021

Mar. 30, 2021

Mar. 29, 2021

Mar. 03, 2021

Dec. 31, 2020

Aug. 06, 2020

Jan. 03, 2020

Aug. 28, 2019

Apr. 29, 2019

Dec. 25, 2021

Dec. 25, 2021

Dec. 25, 2021

Dec. 25, 2021

Dec. 26, 2020

Dec. 26, 2020

Dec. 28, 2019

Feb. 29, 2020

Business Acquisition [Line Items]

Goodwill

$ 2,711,881

$ 2,711,881

$ 2,711,881

$ 2,711,881

$ 1,809,168

$ 1,809,168

$ 1,540,565

Disposal Group, Disposed of by Sale, Not Discontinued Operations | RMS Japan Operations

Business Acquisition [Line Items]

Consideration received from divestiture

$ 73,500

Cash proceeds from divestiture

8,200

Pension over funding and other post-closing adjustments

3,600

Gain on divestiture

$ 22,700

Disposal Group, Disposed of by Sale, Not Discontinued Operations | CDMO Site

Business Acquisition [Line Items]

Consideration received from divestiture

59,600

Cash proceeds from divestiture

200

Contingent consideration

15,300

Disposal Group, Disposed of by Sale, Not Discontinued Operations | Maximum | CDMO Site

Business Acquisition [Line Items]

Contingent consideration

25,000

Purchase obligation

$ 10,000

Supplier

Business Acquisition [Line Items]

Ownership percentage

80.00%

Remaining ownership interest

20.00%

Vigene Biosciences, Inc.

Business Acquisition [Line Items]

Purchase price

$ 323,900

Cash acquired

2,700

Contingent consideration

34,500

Consideration contingent upon future performance

$ 57,500

Transaction and integration costs

5,300

Revenue since acquisition

109,900

Operating income (loss) since acquisition

$ 2,500

Weighted average life

11 years

Definite-lived intangible assets

$ 93,900

Property, plant and equipment

7,649

Goodwill

239,681

Other long-term assets

$ 694

Vigene Biosciences, Inc. | Customer Relationships

Business Acquisition [Line Items]

Weighted average life

12 years

Retrogenix Limited

Business Acquisition [Line Items]

Purchase price

$ 53,900

Cash acquired

8,500

Consideration contingent upon future performance

$ 6,900

Transaction and integration costs

1,800

Weighted average life

11 years

Definite-lived intangible assets

$ 22,126

Property, plant and equipment

400

Goodwill

34,489

Other long-term assets

$ 1,385

Retrogenix Limited | Customer Relationships

Business Acquisition [Line Items]

Weighted average life

13 years

Cognate BioServices, Inc.

Business Acquisition [Line Items]

Cash acquired

$ 70,500

Transaction and integration costs

27,100

Revenue since acquisition

109,900

Operating income (loss) since acquisition

$ 2,500

Value of consideration not acquired

$ 15,700

Ownership percentage not acquired

2.00%

Weighted average life

13 years

Definite-lived intangible assets

$ 270,900

Property, plant and equipment

52,082

Goodwill

612,147

Other long-term assets

$ 6,098

Cognate BioServices, Inc. | Customer Relationships

Business Acquisition [Line Items]

Weighted average life

13 years

Distributed Bio, Inc.

Business Acquisition [Line Items]

Purchase price

$ 97,000

Cash acquired

800

Contingent consideration

14,000

Consideration contingent upon future performance

21,000

Transaction and integration costs

1,200

1,200

Cash portion of consideration transferred

80,800

Payments to settle promissory note

$ 3,000

Weighted average life

7 years

Definite-lived intangible assets

$ 24,540

Property, plant and equipment

2,382

Goodwill

71,585

Other long-term assets

$ 2,055

Distributed Bio, Inc. | Customer Relationships

Business Acquisition [Line Items]

Weighted average life

9 years

Other Acquisitions

Business Acquisition [Line Items]

Purchase price

$ 35,400

$ 23,000

Contingent consideration

15,900

Consideration contingent upon future performance

17,500

Cash portion of consideration transferred

$ 19,500

5,500

Future performance period

3 years

Definite-lived intangible assets

$ 15,200

Property, plant and equipment

3,000

Amount of pre-existing relationship for supply agreement

4,000

Goodwill

$ 17,300

13,000

Other long-term assets

12,000

Redeemable noncontrolling interest

$ 9,000

Other Acquisitions | Supplier Relationships

Business Acquisition [Line Items]

Weighted average life

4 years

Other Acquisitions | Supplier

Business Acquisition [Line Items]

Ownership percentage

80.00%

Remaining ownership interest

20.00%

Cognate BioServices, Inc. and Viegene Biosciences, Inc. | Depreciation and Amortization Expense

Business Acquisition [Line Items]

Adjustments to purchase price

24,500

24,200

Cognate BioServices, Inc. and Viegene Biosciences, Inc. | Interest Expense

Business Acquisition [Line Items]

Adjustments to purchase price

5,600

10,400

Cellero, LLC

Business Acquisition [Line Items]

Purchase price

$ 36,900

Cash acquired

$ 500

Transaction and integration costs

700

2,700

Weighted average life

12 years

Definite-lived intangible assets

$ 16,230

Property, plant and equipment

1,648

Goodwill resulting from transaction

10,800

Goodwill

19,457

Other long-term assets

$ 849

Cellero, LLC | Customer Relationships

Business Acquisition [Line Items]

Weighted average life

13 years

HemaCare Corporation

Business Acquisition [Line Items]

Purchase price

$ 376,700

Cash acquired

$ 3,100

Transaction and integration costs

700

6,100

$ 3,300

Revenue since acquisition

43,000

Operating income (loss) since acquisition

$ (8,100)

Weighted average life

18 years

Definite-lived intangible assets

$ 183,540

Property, plant and equipment

10,033

Goodwill

210,196

Other long-term assets

$ 5,920

HemaCare Corporation | Customer Relationships

Business Acquisition [Line Items]

Weighted average life

19 years

Citoxlab

Business Acquisition [Line Items]

Purchase price

$ 490,400

Cash acquired

$ 36,700

Contingent consideration

$ 2,000

Transaction and integration costs

$ 2,300

$ 4,100

$ 20,700

Weighted average life

12 years

Definite-lived intangible assets

$ 162,400

Property, plant and equipment

88,605

Goodwill resulting from transaction

7,200

Goodwill

280,161

Other long-term assets

20,063

Redeemable noncontrolling interest

$ 4,035

Citoxlab | Customer Relationships

Business Acquisition [Line Items]

Weighted average life

13 years

ACQUISITIONS AND DIVESTITURES_2

ACQUISITIONS AND DIVESTITURES - Purchase Price Allocations (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Jun. 28, 2021	Mar. 30, 2021	Mar. 29, 2021	Dec. 31, 2020	Dec. 26, 2020	Aug. 06, 2020	Jan. 03, 2020	Dec. 28, 2019	Apr. 29, 2019
Business Acquisition [Line Items]
Goodwill	$ 2,711,881					$ 1,809,168			$ 1,540,565
Vigene Biosciences, Inc.
Business Acquisition [Line Items]
Trade receivables		$ 3,548
Other current assets (excluding cash)		1,657
Property, plant and equipment		7,649
Operating lease right-of-use asset, net		22,507
Goodwill		239,681
Definite-lived intangible assets		93,900
Other long-term assets		694
Deferred revenue		(4,260)
Current liabilities		(6,319)
Operating lease right-of-use liabilities		(21,220)
Deferred tax liabilities		(13,958)
Total purchase price allocation		$ 323,879
Retrogenix Limited
Business Acquisition [Line Items]
Trade receivables			$ 2,266
Other current assets (excluding cash)			209
Property, plant and equipment			400
Goodwill			34,489
Definite-lived intangible assets			22,126
Other long-term assets			1,385
Current liabilities			(1,575)
Deferred tax liabilities			(4,174)
Other long-term liabilities			(1,205)
Total purchase price allocation			$ 53,921
Cognate BioServices, Inc.
Business Acquisition [Line Items]
Trade receivables				$ 18,566
Inventories				4,231
Other current assets (excluding cash)				9,816
Property, plant and equipment				52,082
Operating lease right-of-use asset, net				34,349
Goodwill				612,147
Definite-lived intangible assets				270,900
Other long-term assets				6,098
Deferred revenue				(20,539)
Current liabilities				(44,974)
Operating lease right-of-use liabilities				(31,383)
Deferred tax liabilities				(31,847)
Other long-term liabilities				(414)
Total purchase price allocation				$ 879,032
Distributed Bio, Inc.
Business Acquisition [Line Items]
Trade receivables					$ 2,722
Other current assets (excluding cash)					221
Property, plant and equipment					2,382
Goodwill					71,585
Definite-lived intangible assets					24,540
Other long-term assets					2,055
Current liabilities					(2,823)
Deferred tax liabilities					(2,529)
Other long-term liabilities					(1,123)
Total purchase price allocation					$ 97,030
Cellero, LLC
Business Acquisition [Line Items]
Trade receivables							$ 1,500
Inventories							551
Other current assets (excluding cash)							182
Property, plant and equipment							1,648
Goodwill							19,457
Definite-lived intangible assets							16,230
Other long-term assets							849
Current liabilities							(1,360)
Deferred tax liabilities							(1,467)
Other long-term liabilities							(740)
Total purchase price allocation							$ 36,850
HemaCare Corporation
Business Acquisition [Line Items]
Trade receivables								$ 6,451
Inventories								8,468
Other current assets (excluding cash)								3,494
Property, plant and equipment								10,033
Goodwill								210,196
Definite-lived intangible assets								183,540
Other long-term assets								5,920
Current liabilities								(5,188)
Deferred tax liabilities								(38,529)
Other long-term liabilities								(7,664)
Total purchase price allocation								$ 376,721
Citoxlab
Business Acquisition [Line Items]
Trade receivables										$ 35,405
Inventories										5,282
Other current assets (excluding cash)										13,917
Property, plant and equipment										88,605
Goodwill										280,161
Definite-lived intangible assets										162,400
Other long-term assets										20,063
Deferred revenue										(15,278)
Current liabilities										(46,081)
Deferred tax liabilities										(27,458)
Other long-term liabilities										(22,624)
Redeemable noncontrolling interest										(4,035)
Total purchase price allocation										$ 490,357

ACQUISITIONS AND DIVESTITURES_3

ACQUISITIONS AND DIVESTITURES - Definite Lived Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 28, 2021	Mar. 30, 2021	Mar. 29, 2021	Dec. 31, 2020	Aug. 06, 2020	Jan. 03, 2020	Apr. 29, 2019
Vigene Biosciences, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 93,900
Weighted average amortization life of intangible assets acquired	11 years
Retrogenix Limited
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 22,126
Weighted average amortization life of intangible assets acquired		11 years
Cognate BioServices, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired			$ 270,900
Weighted average amortization life of intangible assets acquired			13 years
Distributed Bio, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired				$ 24,540
Weighted average amortization life of intangible assets acquired				7 years
Cellero, LLC
Business Acquisition [Line Items]
Definite-lived intangible assets acquired					$ 16,230
Weighted average amortization life of intangible assets acquired					12 years
HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired						$ 183,540
Weighted average amortization life of intangible assets acquired						18 years
Citoxlab
Business Acquisition [Line Items]
Definite-lived intangible assets acquired							$ 162,400
Weighted average amortization life of intangible assets acquired							12 years
Client relationships | Vigene Biosciences, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 87,500
Weighted average amortization life of intangible assets acquired	12 years
Client relationships | Retrogenix Limited
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 17,340
Weighted average amortization life of intangible assets acquired		13 years
Client relationships | Cognate BioServices, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired			$ 257,200
Weighted average amortization life of intangible assets acquired			13 years
Client relationships | Distributed Bio, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired				$ 16,080
Weighted average amortization life of intangible assets acquired				9 years
Client relationships | Cellero, LLC
Business Acquisition [Line Items]
Definite-lived intangible assets acquired					$ 14,740
Weighted average amortization life of intangible assets acquired					13 years
Client relationships | HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired						$ 170,390
Weighted average amortization life of intangible assets acquired						19 years
Client relationships | Citoxlab
Business Acquisition [Line Items]
Definite-lived intangible assets acquired							$ 134,600
Weighted average amortization life of intangible assets acquired							13 years
Trade name | HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired						$ 7,330
Weighted average amortization life of intangible assets acquired						10 years
Other intangible assets | Vigene Biosciences, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 3,500
Weighted average amortization life of intangible assets acquired	4 years
Other intangible assets | Retrogenix Limited
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 1,101
Weighted average amortization life of intangible assets acquired		2 years
Other intangible assets | Cognate BioServices, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired			$ 4,800
Weighted average amortization life of intangible assets acquired			2 years
Other intangible assets | Distributed Bio, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired				$ 4,520
Weighted average amortization life of intangible assets acquired				4 years
Other intangible assets | Cellero, LLC
Business Acquisition [Line Items]
Definite-lived intangible assets acquired					$ 1,490
Weighted average amortization life of intangible assets acquired					3 years
Other intangible assets | HemaCare Corporation
Business Acquisition [Line Items]
Definite-lived intangible assets acquired						$ 5,820
Weighted average amortization life of intangible assets acquired						3 years
Developed technology | Retrogenix Limited
Business Acquisition [Line Items]
Definite-lived intangible assets acquired		$ 3,685
Weighted average amortization life of intangible assets acquired		3 years
Developed technology | Distributed Bio, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired				$ 3,940
Weighted average amortization life of intangible assets acquired				5 years
Developed technology | Citoxlab
Business Acquisition [Line Items]
Definite-lived intangible assets acquired							$ 19,900
Weighted average amortization life of intangible assets acquired							3 years
Backlog | Vigene Biosciences, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired	$ 2,900
Weighted average amortization life of intangible assets acquired	1 year
Backlog | Cognate BioServices, Inc.
Business Acquisition [Line Items]
Definite-lived intangible assets acquired			$ 8,900
Weighted average amortization life of intangible assets acquired			1 year
Backlog | Citoxlab
Business Acquisition [Line Items]
Definite-lived intangible assets acquired							$ 7,900
Weighted average amortization life of intangible assets acquired							1 year

ACQUISITIONS AND DIVESTITURES_4

ACQUISITIONS AND DIVESTITURES - Pro Forma Financial Information (Details) - Cognate BioServices, Inc. and Viegene Biosciences, Inc. - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020
Business Acquisition [Line Items]
Revenue	$ 3,583,646	$ 3,068,161
Net income attributable to common shareholders	$ 376,152	$ 347,873

ACQUISITIONS AND DIVESTITURES_5

ACQUISITIONS AND DIVESTITURES - Schedule of Divestitures (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations $ in Thousands	Oct. 12, 2021USD ($)
RMS Japan Operations
Assets
Current assets	$ 26,524
Property, plant, and equipment, net	17,379
Goodwill	4,129
Other assets	3,695
Total assets	51,727
Liabilities
Current liabilities	8,705
Long-term liabilities	94
Total liabilities	8,799
CDMO Site
Assets
Current assets	8,187
Property, plant, and equipment, net	14,339
Operating lease right-of-use assets, net	19,733
Goodwill	27,764
Other assets	14,089
Total assets	84,112
Liabilities
Current liabilities	6,386
Operating lease right-of-use liabilities	18,221
Total liabilities	$ 24,607

REVENUE FROM CONTRACTS WITH C_3

REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 3,540,160	$ 2,923,933	$ 2,621,226
RMS
Disaggregation of Revenue [Line Items]
Revenue	690,437	571,152	537,089
RMS | Services and products transferred over time
Disaggregation of Revenue [Line Items]
Revenue	263,659	240,480	227,872
RMS | Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue	426,778	330,672	309,217
DSA
Disaggregation of Revenue [Line Items]
Revenue	2,107,231	1,837,428	1,618,995
DSA | Services and products transferred over time
Disaggregation of Revenue [Line Items]
Revenue	2,103,415	1,836,519	1,618,281
DSA | Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue	3,816	909	714
Manufacturing
Disaggregation of Revenue [Line Items]
Revenue	742,492	515,353	465,142
Manufacturing | Services and products transferred over time
Disaggregation of Revenue [Line Items]
Revenue	335,745	174,254	142,896
Manufacturing | Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Revenue	$ 406,747	$ 341,099	$ 322,246

REVENUE FROM CONTRACTS WITH C_4

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Estimated Revenue Related to Performance Obligations (Details) $ in Thousands	Dec. 25, 2021USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 716,473
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-12-26
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 357,855
Performance obligations expected to be satisfied, expected timing	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 338,685
Performance obligations expected to be satisfied, expected timing	2 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 18,250
Performance obligations expected to be satisfied, expected timing	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 1,683
Performance obligations expected to be satisfied, expected timing
DSA
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 713,745
DSA | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-12-26
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	355,127
DSA | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	338,685
DSA | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	18,250
DSA | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	1,683
Manufacturing
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	2,728
Manufacturing | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-12-26
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	2,728
Manufacturing | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	0
Manufacturing | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	0
Manufacturing | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 0

REVENUE FROM CONTRACTS WITH C_5

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Revenue from Contract with Customer [Abstract]
Client receivables	$ 489,452	$ 489,042
Contract assets (unbilled revenue)	160,609	135,400
Contract liabilities (current and long-term deferred revenue)	240,281	227,417
Contract liabilities (customer contract deposits)	$ 59,512	$ 42,244

REVENUE FROM CONTRACTS WITH C_6

REVENUE FROM CONTRACTS WITH CUSTOMERS - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020
Revenue from Contract with Customer [Abstract]
Payment terms	30 days
Unpaid advanced client billings	$ 36,000	$ 16,000
Contract liabilities (customer contract deposits)	$ 59,512	$ 42,244
Percentage of unbilled revenue billed during period	90.00%	90.00%
Amount of unbilled revenue billed during period	$ 135,000	$ 122,000
Percentage of contract liabilities recognized as revenue during period	90.00%	90.00%
Amount of contract liabilities recognized as revenue	$ 227,000	$ 193,000
Lease revenue	$ 18,100

SEGMENT AND GEOGRAPHIC INFORM_3

SEGMENT AND GEOGRAPHIC INFORMATION - Financial Information by Reportable Business Segment (Details) $ in Thousands	12 Months Ended
	Dec. 25, 2021USD ($)segment	Dec. 26, 2020USD ($)	Dec. 28, 2019USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment	3
Segment Reporting Information [Line Items]
Revenue	$ 3,540,160	$ 2,923,933	$ 2,621,226
Operating income	589,862	432,729	351,151
Depreciation and amortization	265,540	234,924	198,095
Capital expenditures	228,772	166,560	140,514
RMS
Segment Reporting Information [Line Items]
Revenue	690,437	571,152	537,089
Operating income	166,814	102,706	133,912
Depreciation and amortization	39,123	37,080	19,197
Capital expenditures	61,188	29,487	26,989
DSA
Segment Reporting Information [Line Items]
Revenue	2,107,231	1,837,428	1,618,995
Operating income	406,978	325,959	258,903
Depreciation and amortization	177,254	168,922	151,139
Capital expenditures	101,477	105,653	86,843
Manufacturing
Segment Reporting Information [Line Items]
Revenue	742,492	515,353	465,142
Operating income	246,390	181,494	145,420
Depreciation and amortization	46,195	25,904	23,584
Capital expenditures	$ 58,877	$ 26,287	$ 23,617

SEGMENT AND GEOGRAPHIC INFORM_4

SEGMENT AND GEOGRAPHIC INFORMATION - Reconciliation of Segment Operating Income, Depreciation, Amortization and Capital Expenditures (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Segment Reporting Information [Line Items]
Operating income	$ 589,862	$ 432,729	$ 351,151
Depreciation and Amortization	265,540	234,924	198,095
Capital Expenditures	228,772	166,560	140,514
Total reportable segments
Segment Reporting Information [Line Items]
Operating income	820,182	610,159	538,235
Depreciation and Amortization	262,572	231,906	193,920
Capital Expenditures	221,542	161,427	137,449
Unallocated corporate
Segment Reporting Information [Line Items]
Operating income	(230,320)	(177,430)	(187,084)
Depreciation and Amortization	2,968	3,018	4,175
Capital Expenditures	$ 7,230	$ 5,133	$ 3,065

SEGMENT AND GEOGRAPHIC INFORM_5

SEGMENT AND GEOGRAPHIC INFORMATION - Revenue by Product and Service Offering (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Segment Reporting Information [Line Items]
Revenue	$ 3,540,160	$ 2,923,933	$ 2,621,226
RMS
Segment Reporting Information [Line Items]
Revenue	690,437	571,152	537,089
DSA
Segment Reporting Information [Line Items]
Revenue	2,107,231	1,837,428	1,618,995
Manufacturing
Segment Reporting Information [Line Items]
Revenue	$ 742,492	$ 515,353	$ 465,142

SEGMENT AND GEOGRAPHIC INFORM_6

SEGMENT AND GEOGRAPHIC INFORMATION - Unallocated Corporate Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Segment Reporting Information [Line Items]
Stock-based compensation	$ 71,474	$ 56,341	$ 57,271
Depreciation	140,700	123,000	108,600
Unallocated corporate
Segment Reporting Information [Line Items]
Stock-based compensation	43,018	34,111	37,855
Compensation, benefits, and other employee-related expenses	92,459	73,814	73,893
External consulting and other service expenses	25,374	26,561	16,639
Information technology	18,450	18,912	16,080
Depreciation	2,968	3,018	4,175
Acquisition and integration	30,370	13,995	26,877
Other general unallocated corporate	17,681	7,019	11,565
Total unallocated corporate expense	$ 230,320	$ 177,430	$ 187,084

SEGMENT AND GEOGRAPHIC INFORM_7

SEGMENT AND GEOGRAPHIC INFORMATION - Revenue and Long-Lived Assets by Geographic Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Segment Reporting Information [Line Items]
Revenue	$ 3,540,160	$ 2,923,933	$ 2,621,226
Long-lived assets	1,291,068	1,124,358	1,044,128
U.S.
Segment Reporting Information [Line Items]
Revenue	1,934,404	1,627,149	1,471,097
Long-lived assets	755,400	627,871	602,654
Europe
Segment Reporting Information [Line Items]
Revenue	1,036,465	829,312	726,421
Long-lived assets	323,405	286,229	253,665
Canada
Segment Reporting Information [Line Items]
Revenue	339,098	306,259	271,987
Long-lived assets	145,274	145,410	127,495
Asia Pacific
Segment Reporting Information [Line Items]
Revenue	222,902	155,086	146,218
Long-lived assets	64,864	62,931	60,213
Other
Segment Reporting Information [Line Items]
Revenue	7,291	6,127	5,503
Long-lived assets	$ 2,125	$ 1,917	$ 101

SUPPLEMENTAL BALANCE SHEET IN_3

SUPPLEMENTAL BALANCE SHEET INFORMATION - Composition of Trade Receivables and Contract Assets, Net (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Supplemental Balance Sheet Information [Abstract]
Client receivables	$ 489,452	$ 489,042
Unbilled revenue	160,609	135,400
Total	650,061	624,442
Less: Allowance for credit losses	(7,180)	(6,702)
Trade receivables and contract assets, net	$ 642,881	$ 617,740

SUPPLEMENTAL BALANCE SHEET IN_4

SUPPLEMENTAL BALANCE SHEET INFORMATION - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Provisions to allowance for credit losses	$ 1.7	$ 6.4	$ 3
Depreciation	$ 140.7	$ 123	$ 108.6

SUPPLEMENTAL BALANCE SHEET IN_5

SUPPLEMENTAL BALANCE SHEET INFORMATION - Composition of Inventories (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Supplemental Balance Sheet Information [Abstract]
Raw materials and supplies	$ 33,118	$ 28,317
Work in process	40,268	36,755
Finished products	125,760	120,623
Inventories	$ 199,146	$ 185,695

SUPPLEMENTAL BALANCE SHEET IN_6

SUPPLEMENTAL BALANCE SHEET INFORMATION - Composition of Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Supplemental Balance Sheet Information [Abstract]
Prepaid income tax	$ 84,725	$ 68,462
Short-term investments	1,063	1,024
Restricted cash	4,023	3,074	$ 431
Other receivables	7,500	0
Other current assets	$ 97,311	$ 72,560

SUPPLEMENTAL BALANCE SHEET IN_7

SUPPLEMENTAL BALANCE SHEET INFORMATION - Composition of Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 2,394,048	$ 2,210,351
Less: Accumulated depreciation	(1,102,980)	(1,085,993)
Property, plant and equipment, net	1,291,068	1,124,358
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	59,486	61,031
Buildings and building improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	987,544	1,059,641
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	760,353	661,124
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	141,525	104,967
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	22,520	31,489
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	210,582	193,622
Vehicles
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	6,897	6,152
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 205,141	$ 92,325

SUPPLEMENTAL BALANCE SHEET IN_8

SUPPLEMENTAL BALANCE SHEET INFORMATION - Composition of Other Assets (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Supplemental Balance Sheet Information [Abstract]
Venture capital investments	$ 149,640	$ 197,100
Strategic equity investments	51,712	24,704
Cash surrender value of life insurance policies	51,048	43,827
Other long-term income tax assets	18,690	23,485
Restricted cash	1,077	1,621	$ 1,601
Long-term pension assets	39,582	31,915
Other	41,140	29,974
Other assets	$ 352,889	$ 352,626

SUPPLEMENTAL BALANCE SHEET IN_9

SUPPLEMENTAL BALANCE SHEET INFORMATION - Composition of Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Supplemental Balance Sheet Information [Abstract]
Current portion of operating lease right-of-use liabilities	$ 33,267	$ 24,674
Accrued income taxes	26,161	24,884
Customer contract deposits	59,512	42,244
Other	18,701	10,675
Other current liabilities	$ 137,641	$ 102,477

SUPPLEMENTAL BALANCE SHEET I_10

SUPPLEMENTAL BALANCE SHEET INFORMATION - Composition of Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Supplemental Balance Sheet Information [Abstract]
U.S. Transition Tax	$ 43,057	$ 48,781
Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plans	104,944	96,492
Long-term deferred revenue	20,578	19,475
Other	74,280	40,467
Other long-term liabilities	$ 242,859	$ 205,215

VENTURE CAPITAL INVESTMENTS A_2

VENTURE CAPITAL INVESTMENTS AND STRATEGIC EQUITY INVESTMENTS - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Feb. 16, 2022
Schedule of Equity Method Investments [Line Items]
Venture capital investments	$ 149,640	$ 197,100
Total commitment	165,300
Amount funded for venture capital investments	113,300
Dividends received	40,200	27,600	$ 11,400
Gains (losses) related to venture capital investments	(24,200)	100,400	20,700
Consolidated retained earnings	27,100	76,800
Strategic equity investments	51,712	24,704
Loss related to strategic equity investments	$ 6,200
Gains related to strategic equity investments		$ 500	$ 100
Subsequent Event
Schedule of Equity Method Investments [Line Items]
Total commitment				$ 25,000

FAIR VALUE - Assets and Liabili

FAIR VALUE - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Current assets measured at fair value:
Cash equivalents	$ 893	$ 2,273
Other assets:
Life insurance policies	42,918	35,770
Total assets measured at fair value	43,811	38,043
Other current liabilities measured at fair value:
Contingent consideration	11,794	2,328
Other long-term liabilities measured at fair value:
Contingent consideration	25,450
Total liabilities measured at fair value	37,244	2,328
Level 1
Current assets measured at fair value:
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities measured at fair value:
Contingent consideration	0	0
Other long-term liabilities measured at fair value:
Contingent consideration	0
Total liabilities measured at fair value	0	0
Level 2
Current assets measured at fair value:
Cash equivalents	893	2,273
Other assets:
Life insurance policies	42,918	35,770
Total assets measured at fair value	43,811	38,043
Other current liabilities measured at fair value:
Contingent consideration	0	0
Other long-term liabilities measured at fair value:
Contingent consideration	0
Total liabilities measured at fair value	0	0
Level 3
Current assets measured at fair value:
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities measured at fair value:
Contingent consideration	11,794	2,328
Other long-term liabilities measured at fair value:
Contingent consideration	25,450
Total liabilities measured at fair value	$ 37,244	$ 2,328

FAIR VALUE - Rollforward of Con

FAIR VALUE - Rollforward of Contingent Consideration (Details) - Contingent Consideration - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 2,328	$ 712
Additions	71,559	2,131
Payments	(2,889)	(230)
Total gains or losses (realized/unrealized):
Foreign currency translation	(368)	183
Adjustment of previously recorded contingent liability	(33,386)	(468)
Ending balance	$ 37,244	$ 2,328

FAIR VALUE - Additional Informa

FAIR VALUE - Additional Information (Details) - Contingent Consideration - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration	$ 37,244	$ 2,328	$ 712
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration	$ 37,200
Weighted average probability percentage of achieving maximum target	34.00%
Level 3 | Average Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, measurement input	0.36
Level 3 | Weighted Average Cost of Capital
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, measurement input	0.14
Level 3 | Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration	$ 110,000

FAIR VALUE - Debt Instruments (

FAIR VALUE - Debt Instruments (Details) - Senior Notes - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
5.5% Senior Notes due 2026
Debt Instrument [Line Items]
Stated interest rate	5.50%			5.50%
5.5% Senior Notes due 2026 | Book Value
Debt Instrument [Line Items]
Value of debt instruments	$ 0	$ 500,000
5.5% Senior Notes due 2026 | Fair Value
Debt Instrument [Line Items]
Value of debt instruments	$ 0	523,100
4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Stated interest rate	4.25%		4.25%
4.25% Senior Notes due 2028 | Book Value
Debt Instrument [Line Items]
Value of debt instruments	$ 500,000	500,000
4.25% Senior Notes due 2028 | Fair Value
Debt Instrument [Line Items]
Value of debt instruments	$ 521,250	523,750
3.75% Senior Notes due 2029
Debt Instrument [Line Items]
Stated interest rate	3.75%
3.75% Senior Notes due 2029 | Book Value
Debt Instrument [Line Items]
Value of debt instruments	$ 500,000	0
3.75% Senior Notes due 2029 | Fair Value
Debt Instrument [Line Items]
Value of debt instruments	$ 506,700	0
4.0% Senior Notes due 2031
Debt Instrument [Line Items]
Stated interest rate	4.00%
4.0% Senior Notes due 2031 | Book Value
Debt Instrument [Line Items]
Value of debt instruments	$ 500,000	0
4.0% Senior Notes due 2031 | Fair Value
Debt Instrument [Line Items]
Value of debt instruments	$ 507,500	$ 0

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Rollforward of Company's Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Goodwill [Roll Forward]
Gross carrying amount, beginning balance	$ 2,814,168	$ 2,545,565
Adjustments to goodwill, acquisitions	974,919	229,025
Adjustments to goodwill, foreign exchange	(40,313)	39,578
Adjustments to goodwill, divestitures	(31,893)
Gross carrying amount, ending balance	3,716,881	2,814,168
Accumulated impairment loss - DSA	(1,005,000)	(1,005,000)	$ (1,005,000)
Goodwill	2,711,881	1,809,168	$ 1,540,565
RMS
Goodwill [Roll Forward]
Gross carrying amount, beginning balance	287,759	56,586
Adjustments to goodwill, acquisitions	0	229,654
Adjustments to goodwill, foreign exchange	(106)	1,519
Adjustments to goodwill, divestitures	(4,129)
Gross carrying amount, ending balance	283,524	287,759
DSA
Goodwill [Roll Forward]
Gross carrying amount, beginning balance	2,383,130	2,350,223
Adjustments to goodwill, acquisitions	123,091	(629)
Adjustments to goodwill, foreign exchange	(28,715)	33,536
Adjustments to goodwill, divestitures	0
Gross carrying amount, ending balance	2,477,506	2,383,130
Manufacturing
Goodwill [Roll Forward]
Gross carrying amount, beginning balance	143,279	138,756
Adjustments to goodwill, acquisitions	851,828	0
Adjustments to goodwill, foreign exchange	(11,492)	4,523
Adjustments to goodwill, divestitures	(27,764)
Gross carrying amount, ending balance	$ 955,851	$ 143,279

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0	$ 0	$ 0
Amortization of intangible assets	$ 124,857,000	$ 111,877,000	$ 89,538,000

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Intangible Assets, Net by Major Class (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Finite-lived intangible assets
Gross	$ 1,672,415	$ 1,334,244
Accumulated Amortization	(611,223)	(546,645)
Net	1,061,192	787,599
Backlog
Finite-lived intangible assets
Gross	12,577	29,233
Accumulated Amortization	(9,517)	(29,233)
Net	3,060	0
Technology
Finite-lived intangible assets
Gross	135,764	130,907
Accumulated Amortization	(95,454)	(81,305)
Net	40,310	49,602
Trademarks and trade names
Finite-lived intangible assets
Gross	13,086	15,870
Accumulated Amortization	(3,448)	(5,648)
Net	9,638	10,222
Other
Finite-lived intangible assets
Gross	35,231	20,903
Accumulated Amortization	(8,445)	(14,633)
Net	26,786	6,270
Other intangible assets
Finite-lived intangible assets
Gross	196,658	196,913
Accumulated Amortization	(116,864)	(130,819)
Net	79,794	66,094
Client relationships
Finite-lived intangible assets
Gross	1,475,757	1,137,331
Accumulated Amortization	(494,359)	(415,826)
Net	$ 981,398	$ 721,505

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS - Estimated Amortization Expense for Intangible Assets for Next Five Fiscal Years (Details) $ in Thousands	Dec. 25, 2021USD ($)
Estimated amortization expense for each of the next five fiscal years
2022	$ 143,202
2023	131,385
2024	118,295
2025	110,830
2026	$ 103,485

LONG-TERM DEBT AND FINANCE LE_3

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS - Long-term Debt, Net (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,661,799
Finance leases (Note 16)	27,223	$ 29,047
Total debt and finance leases	2,689,022	1,994,131
Current portion of long-term debt	101	47,196
Current portion of finance leases (Note 16)	2,694	3,018
Current portion of long-term debt and finance leases	2,795	50,214
Long-term debt and finance leases	2,686,227	1,943,917
Debt discount and debt issuance costs	(22,663)	(14,346)
Long-term debt, net and finance leases	2,663,564	1,929,571
Term loans
Debt Instrument [Line Items]
Long-term debt, gross	0	146,875
Revolving facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,161,431	814,752
5.5% Senior Notes due 2026 | Senior Notes
Debt Instrument [Line Items]
Stated interest rate	5.50%			5.50%
Long-term debt, gross	$ 0	500,000
4.25% Senior Notes due 2028 | Senior Notes
Debt Instrument [Line Items]
Stated interest rate	4.25%		4.25%
Long-term debt, gross	$ 500,000	500,000
3.75% Senior Notes due 2029 | Senior Notes
Debt Instrument [Line Items]
Stated interest rate	3.75%
Long-term debt, gross	$ 500,000	0
4.0% Senior Notes due 2031 | Senior Notes
Debt Instrument [Line Items]
Stated interest rate	4.00%
Long-term debt, gross	$ 500,000	0
Other debt
Debt Instrument [Line Items]
Long-term debt, gross	$ 368	$ 3,457

LONG-TERM DEBT AND FINANCE LE_4

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS - Additional Information (Details)	Jun. 26, 2021USD ($)	Mar. 27, 2021USD ($)payment	Dec. 25, 2021USD ($)	Dec. 26, 2020USD ($)	Dec. 28, 2019USD ($)	Dec. 29, 2018USD ($)
Debt Instrument [Line Items]
Weighted average interest rate			2.78%	3.11%
Deferred financing costs expensed			$ 38,255,000	$ 0	$ 6,593,000
Debt extinguishment costs			29,964,000	3,661,000	4,943,000
Letter of Credit
Debt Instrument [Line Items]
Amount outstanding under letters of credit			17,700,000	16,000,000
Multi-currency Revolving Facility
Debt Instrument [Line Items]
Payments of long-term debt			$ 135,000,000
Multi-currency Revolving Facility | $2.05 Billion Credit Facility
Debt Instrument [Line Items]
Amount of credit facility		$ 2,050,000,000
Minimum EBITDA less capital expenditures to consolidated cash interest expense	3.50
Maximum consolidated indebtedness to consolidated EBITDA, with step downs			4.25
Multi-currency Revolving Facility | $2.05 Billion Credit Facility | Federal Funds Rate
Debt Instrument [Line Items]
Interest rate	0.50%
Multi-currency Revolving Facility | $2.05 Billion Credit Facility | LIBOR
Debt Instrument [Line Items]
Interest rate	1.00%
Multi-currency Revolving Facility | $3.0 Billion Credit Facility
Debt Instrument [Line Items]
Amount of credit facility	$ 3,000,000,000
Term Loan
Debt Instrument [Line Items]
Payments of long-term debt			$ 146,900,000
Term Loan | $750 Million Credit Facility
Debt Instrument [Line Items]
Amount of credit facility		$ 750,000,000
Number of quarterly installment payments | payment		19
Payments of long-term debt		$ 146,900,000
Deferred financing costs expensed		200,000
Senior Notes | 5.5% Senior Notes due 2026
Debt Instrument [Line Items]
Payments of long-term debt		500,000,000
Deferred financing costs expensed		5,000,000
Aggregate principal amount						$ 500,000,000
Stated interest rate			5.50%			5.50%
Debt extinguishment costs		21,000,000
Payments for accrued interest		$ 13,000,000
Senior Notes | 4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Aggregate principal amount					$ 500,000,000
Stated interest rate			4.25%		4.25%
Senior Notes | Senior Notes Due 2029 And 2031
Debt Instrument [Line Items]
Deferred financing costs expensed			$ 10,000,000
Aggregate principal amount			1,000,000,000
Debt extinguishment costs			21,000,000
Payments for accrued interest			13,000,000
Senior Notes | 3.75% Senior Notes due 2029
Debt Instrument [Line Items]
Aggregate principal amount			$ 500,000,000
Stated interest rate			3.75%
Senior Notes | 4.0% Senior Notes due 2031
Debt Instrument [Line Items]
Aggregate principal amount			$ 500,000,000
Stated interest rate			4.00%
Foreign Exchange Forward
Debt Instrument [Line Items]
Foreign exchange forward contract amount			$ 400,000,000	400,000,000
Other (Expense) Income, Net | Foreign Exchange Forward
Debt Instrument [Line Items]
Foreign currency translation gain (loss) recognized			(31,800,000)	11,900,000
Amount of gain (loss)			(1,599,000)	(892,000)	$ (121,000)
Interest Expense | Foreign Exchange Forward
Debt Instrument [Line Items]
Amount of gain (loss)			$ 34,131,000	$ (9,325,000)	$ 18,672,000

LONG-TERM DEBT AND FINANCE LE_5

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS - Principal Maturities of Long Term Debt (Details) $ in Thousands	Dec. 25, 2021USD ($)
Debt Disclosure [Abstract]
2022	$ 101
2023	0
2024	268
2025	0
2026	1,161,430
Thereafter	1,500,000
Total debt	$ 2,661,799

EQUITY AND NONCONTROLLING INT_3

EQUITY AND NONCONTROLLING INTERESTS - Reconciliation of Numerator and Denominator in the Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Numerator:
Net income	$ 398,837	$ 365,306	$ 254,061
Less: Net income attributable to noncontrolling interests	7,855	1,002	2,042
Net income attributable to common shareholders	$ 390,982	$ 364,304	$ 252,019
Denominator:
Weighted-average shares outstanding—Basic (in shares)	50,293	49,550	48,730
Effect of dilutive securities:
Stock options, restricted stock, restricted stock units and performance share units (in shares)	1,132	1,061	963
Weighted-average shares outstanding—Diluted (in shares)	51,425	50,611	49,693

EQUITY AND NONCONTROLLING INT_4

EQUITY AND NONCONTROLLING INTERESTS - Earnings Per Share, Additional Information (Details) - shares shares in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average shares outstanding—Diluted (in shares)	51,425	50,611	49,693
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	200	200	400
Restricted Stock, Restricted Stock Units, and PSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average shares outstanding—Diluted (in shares)	700	900	1,000

EQUITY AND NONCONTROLLING INT_5

EQUITY AND NONCONTROLLING INTERESTS - Treasury Shares, Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Shares acquired for individual minimum statutory tax withholding (in shares)	100,000	100,000	100,000
Value of shares acquired for individual minimum statutory tax withholding	$ 40,700,000	$ 24,000,000	$ 18,100,000
Treasury shares retired (in shares)	100,000	100,000	100,000
2010 Share Repurchase Program
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Aggregate authorization of share repurchase program	$ 1,300,000,000
Number of shares repurchased (in shares)	0	0	0
Amount remaining on the authorized share repurchase program	$ 129,100,000
Treasury Stock
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Number of shares repurchased (in shares)	148,000	146,000	139,000
Treasury shares retired (in shares)	148,000	146,000	140,000
Retirement of treasury shares	$ 40,700,000	$ 24,000,000	$ 18,100,000
Retained Earnings
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Retirement of treasury shares	35,600,000	19,200,000	13,800,000
Additional Paid-In Capital
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Retirement of treasury shares	$ 5,100,000	$ 4,800,000	$ 4,300,000

EQUITY AND NONCONTROLLING INT_6

EQUITY AND NONCONTROLLING INTERESTS - Changes to Accumulated Other Comprehensive Income (Loss), Net of Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Increase (Decrease) in Stockholders' Equity
Beginning balance	$ 2,118,169	$ 1,637,828	$ 1,319,778
Other comprehensive income (loss) before reclassifications	(31,509)	36,656
Amounts reclassified from accumulated other comprehensive income	1,678	17,861
Net current period other comprehensive income	(29,831)	54,517
Income tax (benefit) expense	(3,965)	15,372	(3,633)
Ending balance	2,538,982	2,118,169	1,637,828
Foreign Currency Translation Adjustment and Other
Increase (Decrease) in Stockholders' Equity
Beginning balance	(73,884)	(87,578)
Other comprehensive income (loss) before reclassifications	(30,316)	20,909
Amounts reclassified from accumulated other comprehensive income	0	0
Net current period other comprehensive income	(30,316)	20,909
Income tax (benefit) expense	(6,027)	7,215
Ending balance	(98,173)	(73,884)	(87,578)
Pension and Other Post-Retirement Benefit Plans
Increase (Decrease) in Stockholders' Equity
Beginning balance	(64,990)	(90,441)
Other comprehensive income (loss) before reclassifications	(1,193)	15,747
Amounts reclassified from accumulated other comprehensive income	1,678	17,861
Net current period other comprehensive income	485	33,608
Income tax (benefit) expense	2,062	8,157
Ending balance	(66,567)	(64,990)	(90,441)
Accumulated Other Comprehensive Income (Loss)
Increase (Decrease) in Stockholders' Equity
Beginning balance	(138,874)	(178,019)	(172,703)
Ending balance	$ (164,740)	$ (138,874)	$ (178,019)

EQUITY AND NONCONTROLLING INT_7

EQUITY AND NONCONTROLLING INTERESTS - Nonredeemable and Redeemable Noncontrolling Interest, Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 28, 2019	Dec. 25, 2021	Dec. 26, 2020	Feb. 29, 2020
Schedule of Investments [Line Items]
Redeemable noncontrolling interests	$ 28,647	$ 53,010	$ 25,499
Vital River
Schedule of Investments [Line Items]
Purchase price of additional equity interest	7,900
Gain in equity equal to the excess fair value of additional equity interest purchased	800
Charge in other income, net equal to the excess fair value of the hybrid equity instrument	$ 2,200
Redeemable noncontrolling interests		23,000
Citoxlab
Schedule of Investments [Line Items]
Redeemable noncontrolling interest, contractually defined redemption value				$ 4,000
Contingent consideration				$ 2,000
Supplier
Schedule of Investments [Line Items]
Redeemable noncontrolling interests		$ 30,000
Vital River
Schedule of Investments [Line Items]
Ownership percentage		92.00%
Additional equity interest percentage purchased	5.00%
Remaining ownership interest	8.00%
Citoxlab
Schedule of Investments [Line Items]
Ownership percentage	90.00%
Remaining ownership interest	10.00%		10.00%
Redeemable Noncontrolling Interest
Schedule of Investments [Line Items]
Remaining ownership interest				10.00%
Supplier
Schedule of Investments [Line Items]
Ownership percentage	80.00%
Remaining ownership interest	20.00%

EQUITY AND NONCONTROLLING INT_8

EQUITY AND NONCONTROLLING INTERESTS - Rollforward of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	$ 25,499	$ 28,647
Adjustment of noncontrolling interests to redemption value	21,312	0
Purchase of a 10% redeemable noncontrolling interest	0	(3,732)
Net income (loss) attributable to noncontrolling interests	5,375	(852)
Foreign currency translation	824	1,436
Ending balance	$ 53,010	$ 25,499
Citoxlab
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interest percentage acquired		10.00%	10.00%

INCOME TAXES - Components of In

INCOME TAXES - Components of Income from Continuing Operations Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Income before income taxes:
U.S.	$ 129,598	$ 226,935	$ 108,326
Non-U.S.	351,112	220,179	195,758
Income before income taxes	480,710	447,114	304,084
Current:
Federal	32,728	38,192	18,101
Foreign	60,197	35,410	43,489
State	9,257	6,623	9,915
Total current	102,182	80,225	71,505
Deferred:
Federal	(27,486)	386	(3,226)
Foreign	13,891	5,583	(17,111)
State	(6,714)	(4,386)	(1,145)
Total deferred	(20,309)	1,583	(21,482)
Total provision for income taxes	$ 81,873	$ 81,808	$ 50,023

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Income Tax Contingency [Line Items]
Tax expense	$ 81,873,000	$ 81,808,000	$ 50,023,000
Tax benefit recognized for operating loss carryforwards previously not likely to be utilized			20,600,000
Operating loss carryforwards			315,500,000
Amount of operating loss carryforward, valuation allowance unlikely to be utilized			$ 294,900,000
Increase in unrecognized income tax benefits	7,600,000
Unrecognized tax benefits that would impact effective tax rate	30,000,000	22,600,000
Increase in unrecognized income tax benefits that would impact tax rate	7,400,000
Decrease in unrecognized tax benefits that is reasonably possible	10,000,000
Accrued interest related to unrecognized income tax benefits	1,700,000	2,400,000
Accrued penalties related to unrecognized income tax benefits	0	0
Foreign Tax Authority
Income Tax Contingency [Line Items]
Operating loss carryforwards	368,500,000	$ 369,000,000
Tax credit carryforward	41,700,000
Foreign Tax Authority | Tax Credit Carryforwards, Expiring after 2038
Income Tax Contingency [Line Items]
Tax credit carryforward	40,400,000
Foreign Tax Authority | Tax Credit Carryforwards, Carried Forward Indefinitely
Income Tax Contingency [Line Items]
Tax credit carryforward	1,300,000
Foreign Tax Authority | Net Operating Loss Carryforward, Expiring after Next Year
Income Tax Contingency [Line Items]
Operating loss carryforwards	24,900,000
Foreign Tax Authority | Net Operating Loss Carryforward, Carried Forward Indefinitely
Income Tax Contingency [Line Items]
Operating loss carryforwards	$ 343,600,000

INCOME TAXES - Reconciliation o

INCOME TAXES - Reconciliation of US Statutory Tax Rate and Effective Tax Rate (Details)	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate	21.00%	21.00%	21.00%
Foreign tax rate differences	0.10%	1.20%	2.70%
State income taxes, net of federal tax benefit	0.80%	0.40%	2.60%
Non-deductible compensation	1.20%	1.00%	1.70%
Research tax credits and enhanced deductions	(5.00%)	(3.40%)	(4.40%)
Stock-based compensation	(4.30%)	(2.70%)	(2.20%)
Enacted tax rate changes	3.00%	0.70%	(0.40%)
Tax on unremitted earnings	1.80%	1.30%	1.70%
Impact of tax uncertainties	0.70%	(0.20%)	(2.60%)
Impact of acquisitions and restructuring	(1.60%)	0.50%	2.70%
Net operating loss deferred tax asset recognition, net of valuation allowance (NOL DTA)	0.00%	(0.10%)	(6.80%)
Other	(0.70%)	(1.40%)	0.50%
Effective income tax rate	17.00%	18.30%	16.50%

INCOME TAXES - Deferred Taxes (

INCOME TAXES - Deferred Taxes (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Deferred tax assets:
Compensation	$ 28,900	$ 32,118
Accruals and reserves	23,760	17,970
Net operating loss and credit carryforwards	410,156	406,085
Operating lease liability	65,592	43,646
Other	8,323	4,253
Valuation allowance	(315,645)	(334,845)	$ (309,962)	$ (9,788)
Total deferred tax assets	221,086	169,227
Deferred tax liabilities:
Goodwill and other intangibles	(280,081)	(202,430)
Depreciation related	(35,514)	(33,277)
Venture capital investments	(16,018)	(32,848)
Tax on unremitted earnings	(21,060)	(27,707)
Right-of-use assets	(64,257)	(43,557)
Other	(3,650)	(8,710)
Total deferred tax liabilities	(420,580)	(348,529)
Net deferred taxes	$ (199,494)	$ (179,302)

INCOME TAXES - Valuation Allowa

INCOME TAXES - Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Deferred Tax Asset, Valuation Allowance [Roll Forward]
Beginning balance	$ 334,845	$ 309,962	$ 9,788
Additions (reductions) charged to income tax provision, net	1,023	(2,707)	299,197
Additions due to acquisitions	7,747	0	924
Reductions due to divestitures, restructuring	(4,706)	0	0
Currency translation and other	(23,264)	27,590	53
Ending balance	$ 315,645	$ 334,845	$ 309,962

INCOME TAXES - Change in Tax Po

INCOME TAXES - Change in Tax Positions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Reconciliation of Unrecognized Tax Benefits
Beginning balance	$ 24,970	$ 19,665	$ 18,827
Additions to tax positions for current year	9,544	7,044	3,691
Additions to tax positions for prior years	2,476	4,589	5,234
Reductions to tax positions for prior years	(1,330)	(127)	(1,033)
Settlements	(1,870)	(5,859)	(274)
Expiration of statute of limitations	(1,198)	(342)	(6,780)
Ending balance	$ 32,592	$ 24,970	$ 19,665

EMPLOYEE BENEFIT PLANS - Additi

EMPLOYEE BENEFIT PLANS - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 26, 2020	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Sep. 30, 2020
Defined Benefit Plan Disclosure [Line Items]
Benefit obligations	$ 367,468	$ 372,599	$ 367,468	$ 447,409
Fair value of plan assets	324,752	335,631	324,752	357,181
Employer contributions to participants within plan assets		11,221	34,092
Net periodic benefit cost (income)		$ 4,886	7,277	4,022
Deferral period		3 years
Maximum annual contributions per employee, percent		10.00%
Period of highest consecutive years of compensation		5 years
Costs associated with deferred compensation plan and executive supplemental life insurance retirement plans		$ 4,300	5,700	2,500
Cash surrender value of life insurance policies	43,827	51,048	43,827
Change in projected benefit obligation based on sensitivity		$ 17,000
Sensitivity of expected rate of return on plan assets, percent change		0.50%
Sensitivity of change in expected rate of return, annual pension expense amount		$ 1,700
Decrease in benefit obligations from new morality improvement scales		500	7,800
Expected employer contributions in next fiscal year		200
Accumulated benefit obligation	1,300	1,000	1,300
Costs associated with employee savings plan		24,000	14,600	19,100
Executive Officer
Defined Benefit Plan Disclosure [Line Items]
Costs associated with deferred compensation plan and executive supplemental life insurance retirement plans			8,100
Settlement charges related to pension losses			2,100
U.K. Plan
Defined Benefit Plan Disclosure [Line Items]
Employer contributions to participants within plan assets		8,300
U.K. Plan | Defined Benefit Plan, Funding Status
Defined Benefit Plan Disclosure [Line Items]
Employer contributions to participants within plan assets		39,600
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Benefit obligations					$ 93,800
Fair value of plan assets					$ 93,000
Employer contributions to participants within plan assets	800	9,100
Non-cash settlement charge related to pension losses, reclassified from AOCI to other expense			10,300
Net periodic benefit cost (income)		500	1,600	$ 1,500
Employer contributions to participants outside of plan assets		2,100
Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	63,465	$ 60,872	63,465
Target asset allocation percentage		20.70%
Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	99,188	$ 140,082	99,188
Target asset allocation percentage		13.80%
Other Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 68,263	$ 45,646	$ 68,263
Target asset allocation percentage		65.50%

EMPLOYEE BENEFIT PLANS - Reconc

EMPLOYEE BENEFIT PLANS - Reconciliation of Benefit Obligations and Plan Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Change in projected benefit obligations:
Benefit obligation at beginning of year	$ 367,468	$ 447,409
Service cost	3,455	3,609	$ 2,833
Interest cost	5,492	8,849	11,583
Other	0	429
Benefit payments	(7,564)	(8,913)
Settlements	(82)	(101,979)
Transfer out due to divestiture	(11,956)	0
Actuarial loss	18,107	9,816
Administrative expenses paid	0	(808)
Effect of foreign exchange	(2,321)	9,056
Benefit obligation at end of year	372,599	367,468	447,409
Change in fair value of plan assets:
Fair value of plan assets at beginning of year	324,752	357,181
Actual return on plan assets	24,151	36,551
Employer contributions	11,221	34,092
Settlements	(82)	(101,979)
Transfer out due to divestiture	(15,918)	0
Benefit payments	(7,564)	(8,913)
Administrative expenses paid	0	(808)
Effect of foreign exchange	(929)	8,628
Fair value of plan assets at end of year	335,631	324,752	$ 357,181
Net balance sheet liability	36,968	42,716
Amounts recognized in balance sheet:
Noncurrent assets	39,621	31,916
Current liabilities	1,876	1,713
Noncurrent liabilities	$ 74,713	$ 72,919

EMPLOYEE BENEFIT PLANS - Amount

EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Amounts recognized in accumulated other comprehensive income (loss)
Net actuarial loss	$ 82,746	$ 82,914
Net prior service cost (credit)	(1,091)	(1,593)
Net amount recognized	$ 81,655	$ 81,321

EMPLOYEE BENEFIT PLANS - Accumu

EMPLOYEE BENEFIT PLANS - Accumulated Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Plans with Accumulated Benefit Obligations in Excess of Plan Assets
Accumulated benefit obligation	$ 75,133	$ 72,940
Fair value of plan assets	$ 12,663	$ 11,543

EMPLOYEE BENEFIT PLANS - Projec

EMPLOYEE BENEFIT PLANS - Projected Benefit Obligation and Fair Value of Plan Assets for Pension Plans with Projected Benefit Obligations in Excess of Plan Assets (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Retirement Benefits [Abstract]
Projected benefit obligation	$ 96,089	$ 93,192
Fair value of plan assets	$ 19,500	$ 18,560

EMPLOYEE BENEFIT PLANS - Compon

EMPLOYEE BENEFIT PLANS - Components of Net Period Benefit Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Retirement Benefits [Abstract]
Service cost	$ 3,455	$ 3,609	$ 2,833
Interest cost	5,492	8,849	11,583
Expected return on plan assets	(8,058)	(11,348)	(13,005)
Amortization of prior service credit	(531)	(489)	(489)
Amortization of net loss	4,528	6,239	2,250
Other	0	417	850
Net periodic benefit cost	4,886	7,277	4,022
Settlement	(2,320)	12,385	0
Total benefit cost	$ 2,566	$ 19,662	$ 4,022

EMPLOYEE BENEFIT PLANS - Weight

EMPLOYEE BENEFIT PLANS - Weighted-average Assumptions (Details)	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Weighted-average assumptions used to determine projected benefit obligations
Discount rate	1.80%	1.50%
Rate of compensation increase	3.70%	3.00%
Weighted-average assumptions used to determine net periodic benefit cost
Discount rate	1.50%	2.10%	3.20%
Expected long-term return on plan assets	2.50%	3.40%	4.30%
Rate of compensation increase	3.00%	3.00%	3.20%

EMPLOYEE BENEFIT PLANS - Fair V

EMPLOYEE BENEFIT PLANS - Fair Value of Company's Pension Plan Assets by Asset Category (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 335,631	$ 324,752	$ 357,181
Cash and Cash Equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	12,691	21,629
Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	60,872	63,465
Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	140,082	99,188
Mutual Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	76,340	72,207
Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	45,646	68,263
Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	15,213	36,322
Level 1 | Cash and Cash Equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8,142	20,163
Level 1 | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	8,633
Level 1 | Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | Mutual Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,071	7,018
Level 1 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	508
Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	319,340	287,114
Level 2 | Cash and Cash Equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,549	1,466
Level 2 | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	60,872	54,832
Level 2 | Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	140,082	99,188
Level 2 | Mutual Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	69,269	65,189
Level 2 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	44,568	66,439
Level 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,078	1,316
Level 3 | Cash and Cash Equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Mutual Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 1,078	$ 1,316

EMPLOYEE BENEFIT PLANS - Estima

EMPLOYEE BENEFIT PLANS - Estimated Future Benefit Payments (Details) - Pension Plans $ in Thousands	Dec. 25, 2021USD ($)
Defined Benefit Plan Disclosure [Line Items]
2022	$ 7,317
2023	6,865
2024	7,475
2025	7,870
2026	53,330
2027-2031	$ 45,604

STOCK-BASED COMPENSATION - Addi

STOCK-BASED COMPENSATION - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	May 31, 2018	May 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares to be awarded (in shares)	6,200,000
Capitalized stock-based compensation related costs	$ 0	$ 0	$ 0
Weighted-average grant date fair value of stock options granted (in dollars per share)	$ 108.61	$ 53.37	$ 33.97
Stock-based compensation	$ 71,474,000	$ 56,341,000	$ 57,271,000
2016 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equivalent shares (in shares)					1
2018 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equivalent shares (in shares)				1
Maximum | 2016 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares to be awarded (in shares)					6,100,000
Maximum | 2018 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares to be awarded (in shares)				8,900,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years	4 years	4 years
Unrecognized compensation cost related to unvested stock options expected to vest	$ 21,400,000
Weighted average vesting period of unvested stock options expected to vest	2 years 2 months 12 days
Intrinsic value of options exercised	$ 94,400,000	$ 48,600,000	$ 27,000,000
Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expiration period	5 years	5 years	5 years
Stock Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expiration period	10 years	10 years	10 years
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average vesting period of unvested stock options expected to vest	2 years 4 months 24 days
Unrecognized compensation cost related to unvested restricted stock units expected to vest	$ 46,000,000
Fair value of awards vested	$ 22,800,000	$ 20,000,000	$ 16,500,000
Restricted Stock Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years	2 years	2 years
Restricted Stock Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years	4 years	4 years
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Fair value of awards vested	$ 26,000,000	$ 20,900,000	$ 20,200,000
Maximum number of common shares to be issued upon vesting of PSUs (in shares)	100,000
Stock-based compensation	$ 31,800,000	$ 22,700,000	$ 25,300,000
PSUs | Performance Shares Grantee Group Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
PSUs granted (in shares)	5,000	9,000	15,000
Weighted average per share fair value (in dollars per share)	$ 477.52	$ 179.66	$ 144.67
PSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years	3 years	3 years
Number of shares employee is entitled to receive at no cost (in shares)	0	0	0
Restricted Stock, Restricted Stock Units, and PSUs | 2016 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equivalent shares (in shares)					2.3
Restricted Stock, Restricted Stock Units, and PSUs | 2018 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equivalent shares (in shares)				2.3

STOCK-BASED COMPENSATION - Fina

STOCK-BASED COMPENSATION - Financial Statement Line Items in Which Stock-Based Compensation is Located (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, before income taxes	$ 71,474	$ 56,341	$ 57,271
Provision for income taxes	(10,299)	(8,130)	(9,465)
Stock-based compensation, net of income taxes	61,175	48,211	47,806
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, before income taxes	13,087	10,636	9,038
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation, before income taxes	$ 58,387	$ 45,705	$ 48,233

STOCK-BASED COMPENSATION - Stoc

STOCK-BASED COMPENSATION - Stock Option Activities (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 25, 2021USD ($)$ / sharesshares
Number of shares
Options outstanding, balance at the beginning of the period (in shares) | shares	1,216
Options granted (in shares) | shares	160
Options exercised (in shares) | shares	(431)
Options canceled (in shares) | shares	(28)
Options outstanding, balance at the end of the period (in shares) | shares	917
Weighted Average Exercise Price
Options outstanding, balance at the beginning of the period (in dollars per share) | $ / shares	$ 129.34
Options granted (in dollars per share) | $ / shares	337.13
Options exercised (in dollars per share) | $ / shares	105.80
Options canceled (in dollars per share) | $ / shares	177.46
Options outstanding, balance at the end of the period (in dollars per share) | $ / shares	$ 175.24
Other Disclosures
Options outstanding weighted average remaining contractual life	4 years 8 months 12 days
Options outstanding, aggregate intrinsic value | $	$ 177,834
Options exercisable (in shares) | shares	286
Options exercisable (in dollars per share) | $ / shares	$ 127.69
Options exercisable, weighted average remaining contractual life	2 years 7 months 6 days
Options exercisable, aggregate intrinsic value | $	$ 69,111
Options expected to vest (in shares) | shares	631
Options expected to vest (in dollars per share) | $ / shares	$ 196.81
Options expected to vest, weighted average remaining contractual life	5 years 7 months 6 days
Options expected to vest, aggregate intrinsic value | $	$ 108,723

STOCK-BASED COMPENSATION - St_2

STOCK-BASED COMPENSATION - Stock Options, Weighted Average Assumptions (Details)	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Share-based Payment Arrangement [Abstract]
Expected life (in years)	6 years	6 years	3 years 7 months 6 days
Expected volatility	32.00%	30.00%	27.00%
Risk-free interest rate	1.00%	0.40%	2.40%
Expected dividend yield	0.00%	0.00%	0.00%

STOCK-BASED COMPENSATION - Rest

STOCK-BASED COMPENSATION - Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units shares in Thousands	12 Months Ended
	Dec. 25, 2021$ / sharesshares
Restricted Stock Units
Balance at the beginning of the period (in shares) | shares	466
Granted (in shares) | shares	103
Vested (in shares) | shares	(173)
Canceled (in shares) | shares	(23)
Balance at the end of the period (in shares) | shares	373
Weighted Average Grant Date Fair Value
Balance at the beginning of the period (in dollars per share) | $ / shares	$ 144.03
Granted (in dollars per share) | $ / shares	340.42
Vested (in dollars per share) | $ / shares	131.93
Canceled (in dollars per share) | $ / shares	194.61
Balance at the end of the period (in dollars per share) | $ / shares	$ 197.45

STOCK-BASED COMPENSATION - Perf

STOCK-BASED COMPENSATION - Performance Based Stock Award Program (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Key assumptions:
Expected volatility	32.00%	30.00%	27.00%
Risk-free interest rate	1.00%	0.40%	2.40%
Expected dividend yield	0.00%	0.00%	0.00%
Trading day average stock price on grant date	20 days
PSUs
Key assumptions:
Expected volatility	37.00%	35.00%	25.00%
Risk-free interest rate	0.20%	0.20%	2.40%
Expected dividend yield	0.00%	0.00%	0.00%
Total shareholder return of 20-trading day average stock price on grant date	39.90%	21.70%	17.70%
PSUs | PSU Grantee Group One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
PSUs granted (in shares)	64	98	160
Weighted average per share fair value (in dollars per share)	$ 407.76	$ 209.67	$ 164.47

FOREIGN CURRENCY CONTRACTS - Sc

FOREIGN CURRENCY CONTRACTS - Schedule of Derivative Instruments on Statements of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Derivatives, Fair Value [Line Items]
Interest expense	$ 73,910	$ 86,433	$ 60,882
Other (expense) income, net	(35,894)	99,984	12,293
Interest expense | Foreign Exchange Forward
Derivatives, Fair Value [Line Items]
Amount of gain (loss)	34,131	(9,325)	18,672
Other (expense) income, net | Foreign Exchange Forward
Derivatives, Fair Value [Line Items]
Amount of gain (loss)	$ (1,599)	$ (892)	$ (121)

FOREIGN CURRENCY CONTRACTS - _2

FOREIGN CURRENCY CONTRACTS - Schedule of Notional and Fair Value of Foreign Currency Contracts (Details) - Foreign Exchange Forward - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Derivatives, Fair Value [Line Items]
Notional amount	$ 400,000	$ 400,000
Other Current Liabilities | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount	39,211
Fair value	$ (141)

RESTRUCTURING AND ASSET IMPAI_3

RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs By Classification on the Consolidated Statements of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 6,856	$ 12,594	$ 13,839
Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2,832	5,373	6,715
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	4,024	7,221	7,124
Severance and Transition Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	4,717	7,590	11,454
Severance and Transition Costs | Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,898	4,453	4,348
Severance and Transition Costs | Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2,819	3,137	7,106
Asset Impairments and Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2,139	5,004	2,385
Asset Impairments and Other Costs | Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	934	920	2,367
Asset Impairments and Other Costs | Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,205	$ 4,084	$ 18

RESTRUCTURING AND ASSET IMPAI_4

RESTRUCTURING AND ASSET IMPAIRMENTS - Severance and Retention Costs by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Segment Reporting Information [Line Items]
Restructuring costs	$ 6,856	$ 12,594	$ 13,839
Total reportable segments | RMS
Segment Reporting Information [Line Items]
Restructuring costs	7	845	3,110
Total reportable segments | DSA
Segment Reporting Information [Line Items]
Restructuring costs	3,114	8,605	7,307
Total reportable segments | Manufacturing
Segment Reporting Information [Line Items]
Restructuring costs	3,663	2,733	3,032
Unallocated corporate
Segment Reporting Information [Line Items]
Restructuring costs	$ 72	$ 411	$ 390

RESTRUCTURING AND ASSET IMPAI_5

RESTRUCTURING AND ASSET IMPAIRMENTS - Additional Information (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019	Dec. 29, 2018
Restructuring Cost and Reserve [Line Items]
Severance and retention costs liability	$ 4,011	$ 5,818	$ 6,406	$ 2,921
Severance and Transition Costs | Accrued Compensation
Restructuring Cost and Reserve [Line Items]
Severance and retention costs liability	$ 4,000	$ 5,800

RESTRUCTURING AND ASSET IMPAI_6

RESTRUCTURING AND ASSET IMPAIRMENTS - Rollforward of Severance and Transition and Lease Obligation Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Restructuring Reserve [Roll Forward]
Beginning balance	$ 5,818	$ 6,406	$ 2,921
Expense	5,695	9,284	12,674
Payments / utilization	(5,604)	(9,918)	(9,206)
Other non-cash adjustments	(1,831)	0	0
Foreign currency adjustments	(67)	46	17
Ending balance	$ 4,011	$ 5,818	$ 6,406

LEASES - Right-of-Use Lease Ass

LEASES - Right-of-Use Lease Assets and Lease Liabilities in Condensed Consolidated Financial Statements (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Leases [Abstract]
Operating lease right-of-use assets, net	$ 292,941	$ 178,220
Other current liabilities	33,267	24,674
Operating lease right-of-use liabilities	252,972	155,595
Total operating lease liabilities	286,239	180,269
Property, plant and equipment, net	29,437	31,614
Current portion of long-term debt and finance leases	2,694	3,018
Long-term debt, net and finance leases	24,529	26,029
Total finance lease liabilities	$ 27,223	$ 29,047
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Current portion of long-term debt and finance leases	Current portion of long-term debt and finance leases
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term debt, net and finance leases	Long-term debt, net and finance leases

LEASES - Components of Operatin

LEASES - Components of Operating and Finance Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Leases [Abstract]
Operating lease costs	$ 45,728	$ 32,965	$ 30,885
Amortization of right-of-use assets	3,337	3,723	4,007
Interest on lease liabilities	1,280	1,306	1,349
Short-term lease costs	2,441	2,349	1,056
Variable lease costs	4,623	5,122	3,161
Sublease income	(2,008)	(1,673)	(994)
Total lease costs	$ 55,401	$ 43,792	$ 39,464

LEASES - Supplemental Cash Flow

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 42,576	$ 29,961	$ 27,153
Operating cash flows from finance leases	1,282	1,306	1,406
Finance cash flows from finance leases	3,202	4,350	3,766
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	142,764	63,499	24,382
Right-of-use lease assets obtained in exchange for new finance lease liabilities	$ 1,567	$ 1,571	$ 4,819

LEASES - Weighted Average Remai

LEASES - Weighted Average Remaining Lease Term and Discount Rates (Details)	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Weighted-average remaining lease term (in years)
Operating lease	9 years	8 years 6 months	8 years 2 months 12 days
Finance lease	11 years 8 months 12 days	12 years 4 months 24 days	13 years
Weighted-average discount rate
Operating lease	3.60%	4.50%	4.40%
Finance lease	4.40%	4.10%	4.60%

LEASES - Schedule of Future Min

LEASES - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases After Adoption (Details) - USD ($) $ in Thousands	Dec. 25, 2021	Dec. 26, 2020
Operating Leases
2022	$ 43,420
2023	40,959
2024	39,080
2025	37,177
2026	32,072
Thereafter	146,151
Total minimum future lease payments	338,859
Less: Imputed interest	52,620
Total lease liabilities	286,239	$ 180,269
Finance Leases
2022	3,865
2023	3,524
2024	3,288
2025	2,955
2026	2,460
Thereafter	19,157
Total minimum future lease payments	35,249
Less: Imputed interest	8,026
Total lease liabilities	$ 27,223	$ 29,047

LEASES - Additional Information

LEASES - Additional Information (Details) $ in Millions	Dec. 25, 2021USD ($)
Lessor, Lease, Description [Line Items]
Future minimum lease payments for leases that have not yet commenced	$ 111
Minimum
Lessor, Lease, Description [Line Items]
Terms for leases that have not yet commenced	6 years
Maximum
Lessor, Lease, Description [Line Items]
Terms for leases that have not yet commenced	15 years

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 25, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Deductible amount under insurance policies	$ 2
Certain property insurance, deductibles	15
Representation and warranty insurance, maximum deductible	6.6
Unconditional purchase obligations	$ 260